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Abstract
The successful treatment of childhood cancer with chemotherapy and radiotherapy
may be associated with testicular damage resulting in impaired spermatogenesis and
temporary or permanent infertility in adulthood. In this study testicular function and
semen quality was investigated in 33 survivors of childhood cancer. Treatment of
childhood cancer was associated with a significant risk of impaired spermatogenesis,
with 30.3% of this population being azoospermic and 18.2% being oligozoospermic.
Moreover, in those men who do have surviving spermatogenesis after treatment, it is
commonly compromised, with reductions being observed in ejaculate volume, sperm
concentration, sperm motility and the proportion of morphologically normal sperm.
Only 33.3% of this group of 33 male childhood cancer survivors had completely
normal semen quality by conventional criteria. However, the sperm produced do not
appear to carry a greater burden of damaged DNA compared with the healthy
population, suggesting that assisted conception treatment is a safe option for these
men.
Detection of gonadal damage in the prepubertal male is hampered by lack of a
sensitive marker. The role of inhibin B as a marker of early gonadotoxic effects of
chemotherapy in prepubertal children treated for cancer was investigated. In
prepubertal boys, chemotherapy had little immediate effect on Sertoli cell production
of inhibin B during and immediately after treatment stopped, although one boy
showed a delayed deleterious effect. Inhibin B changed earlier and appeared to be a
more sensitive marker of gonadal damage than FSH or LH. Prospective studies are
ix
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underway combining inhibin B with FSH, LH and sex hormone measurements, to
assess the impact of cancer therapy on gonadal function in children, particularly as
they approach and progress through puberty.
For prepubertal boys fertility preservation through semen cryopreservation is not an
option and consequently, attention is focusing on the development of techniques that
might preserve or restore fertility potential in boys being subjected to gonadotoxic
cancer therapy. In rats, it has been shown that some germ cells survive cytotoxic
therapy and that the resulting azoospermia is a consequence of the inability of those
spermatogonia that are present to proliferate and differentiate. Suppression of the
hypothalamic-pituitary-gonadal (H-P-G) axis facilitates recovery of spermatogenesis
following such cytotoxic treatment. Investigation of whether suppression of the H-P-
G axis in men rendered azoospermic by treatment for childhood cancer might restore
spermatogenesis was undertaken, using both semen analysis and testicular biopsy as
end points. In men treated with sterilising radiotherapy and chemotherapy for
childhood cancer, effective gonadotrophin suppression with medroxyprogesterone
acetate for at least 3 months did not result in restoration of spermatogenesis. The
absence of histological evidence of spermatogonial stem cells in testicular biopsies
from these men before and after suppression suggests complete ablation of the
germinal epithelium and irreversible infertility.
Understanding the vulnerability of the prepubertal human testis to cytotoxic damage
is compounded by the dearth of data describing normal testicular development in the
x
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prepubertal human. Based on immunohistochemical studies in marmosets, a primate
that exhibits a similar developmental profile to the human male, it has been shown
that significant testicular development occurs during childhood long before the
clinical onset of puberty. If we can establish that cell activity does occur in the
'quiescent' testis in boys and is comparable to changes shown in the marmoset, it
will validate use of the marmoset as a model for the human in this instance and give
encouragement to the possibility of using this primate model to develop a method of
protecting spermatogenesis in boys undergoing cancer therapy prior to puberty.
Preliminary studies to investigate the development of the prepubertal human testis
confirmed testicular cell activity in the foetal and neonatal periods and infancy
comparable to that shown in the marmoset. However, to date development during
mid childhood and early puberty has proved to be somewhat discordant with the
marmoset studies. It is too premature to definitively conclude that marmoset and
human testicular development are dissimilar, as a number of explanations have been
proffered to explain the discrepancies, including suboptimal tissue fixation and
antigen preservation in the human tissues.
xi
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1. Introduction
Tremendous advances in the management of childhood malignancies over the last 30
years mean that the majority of children can realistically hope for long-term survival
(Figure l.l)1"2. With survival rates in excess of 70% it is estimated that by the year
2010 one in 250 of the young adult population will be a long-term survivor of
childhood cancer3. However, the successful treatment of childhood cancer with
multi-agent chemotherapy, in combination with surgery and or radiotherapy, is
associated with significant morbidity in later life4. The major challenge faced by
paediatric oncologists today is to sustain the excellent survival rates whilst striving to
improve the quality of life of the survivors.
1962- 1965- 1968- 1971- 1974- 1977- 1980- 1983-
1964 1967 1970 1973 1976 1979 1982 1985
year of diagnosis
Figure 1.1. Trends in 5 year survival rates'
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Testicular dysfunction is well recognized after chemotherapy and radiotherapy
treatment for childhood cancer. Cytotoxic agents may cause irreparable damage to
the testes with both infertility and hypogonadism reported5"16. In contrast to the
testicular germinal epithelium, Leydig cells are more resistant to the deleterious
effects of chemotherapy and radiotherapy. However, direct irradiation of the testes
may cause hypogonadism and testosterone replacement may be required to initiate
and sustain pubertal development and normal potency in adulthood8"18. After
chemotherapy, while overt testosterone deficiency is uncommon, mild Leydig cell
dysfunction is increasingly recognised and it is not yet clear whether these patients
may benefit from testosterone replacement therapy17"19.
While Leydig cell dysfunction is amenable to treatment, damage to the germinal
epithelium is usually irreversible and associated with long lasting or permanent
azoospermia10,11'15'16. Infertility is a recognised consequence of treatment for
childhood cancer. Advances in assisted reproduction techniques have focused
attention on preserving gonadal tissue for future use20"23. For prepubertal boys, for
whom fertility preservation through cryopreservation of semen is not possible,
testicular germ cell harvesting and cryopreservation may in the future preserve fertile
potential24"27. Harvesting, and the potential future use of gonadal tissue, is an exciting
area of gamete biology that opens up new and uncharted territory for paediatric
oncologists. However, many scientific, ethical and legal issues remain to be
addressed before techniques to preserve fertility are available28.
3
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An overview of normal testicular physiology and clinical assessment of testicular
function is presented in Chapter 2. Chapter 3 reviews the impact of childhood cancer
treatment on testicular function, explores the options for preserving fertile potential
and discusses the effects such interventions may have on the offspring. Chapter 4 is
devoted to assessment of testicular function in long-term survivors of childhood
cancer. This involved detailed study of sperm quality and spermatozoal DNA
integrity and we discuss the implications for these men when considering assisted
conception.
Although the extent of testicular damage and probability of infertility may be
predicted to some extent by the treatment the child has received, confirmation of this
is delayed until testicular function can be assessed in adulthood. At present, there are
no clinical tools available to assess testicular function in prepubertal children. In
Chapter 5, the results of a pilot study evaluating the role of inhibin B as a potential
marker of gonadotoxicity in children during treatment for childhood cancer are
presented.
There is tremendous impetus to develop techniques to preserve or restore fertility in
cancer patients as discussed in Chapter 6. For the group ofmen in our study rendered
infertile as a consequence of treatment for cancer during childhood, it was
investigated whether hormone manipulation might restore spermatogenesis in
azoospermic men and present our findings in Chapter 6. There is very little known
about the extent of the damage to the testes at histological level. The impact of
4
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cancer therapy on testicular tissue was assessed using immunohistochemical
techniques and the findings are also presented in Chapter 6.
There are no options currently available in clinical practice for preservation of
fertility in the prepubertal child. To establish why the testis in prepubertal boys is
susceptible to the damaging effects of certain cancer therapies, such that fertility is
compromised in adulthood we carried out detailed assessment of human testicular
tissue from prepubertal boys, presented in Chapter 7. Our objective was to prove that
the testis in boys is active before the onset of puberty, as opposed to being quiescent,
as was traditionally thought to be the case. With this knowledge, a strategy to
'quieten' the prepubertal testis, based on hormone manipulation could be devised and
this may be able to protect the testis from damage and thus help preserve fertility in
adulthood.
During this period of research it became abundantly clear that preservation of
fertility in children undergoing treatment for cancer raises many ethical and legal
issues that are the subject of much debate. Chapter 8 of this thesis addresses these
issues and discusses the implications for the medical profession, the child and his/her
family. Based upon the evidence available to date we propose a strategy for the best
clinical practice for preserving fertile potential in children undergoing treatment for
cancer.
5
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Chapter 2
Overview of normal testicular function
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2. Overview of normal testicular function
The major functions of the male reproductive tract are twofold: to manufacture
spermatozoa and deliver these to the female reproductive tract, and to produce male
sex steroid hormones, necessary for normal male sexual differentiation during foetal
life, puberty, adult male phenotype and behaviour, and reproduction29,30. The organs
responsible for these functions are (i) the testes (Figure 2.1); site of sperm and
androgen production: (ii) the duct system or transport system: and (iii) the accessory
glands; for secretion of seminal fluid necessary to support transport and facilitate
fertilization. Testicular function is regulated by the anterior pituitary hormones;
follicle stimulating hormone (FSH) and luteinizing hormone (LH), under the
controlling influence of hypothalamic gonadotrophin releasing hormone (GnRH). In
turn, the hypothalamic-pituitary-testicular axis is influenced by testicular hormones,
which completes the negative feedback loop.
2.1. Anatomy of the testis
The testes are composed of two structurally distinct but functionally related
compartments, the seminiferous tubules and intertubular space, site of
spermatogenesis and steroidogenesis respectively (Figure 2.2). The intertubular
compartment is subdivided into two compartments: the interstitial and intravascular
space. The seminiferous tubule, of which there are about 500 in each testis, is a
convoluted loop that converges and drains spermatozoa into the rete testis. The
tubules are lined by seminiferous epithelium consisting of various types of male
7
Male fertility in survivors of childhood cancer Chapter 2
germ cells (spermatogenic cells) and a single type of supporting cell, the Sertoli cell.
The seminiferous tubules are further subdivided into two compartments, the basal
and adluminal compartments, by formation of inter-Sertoli cell tight junctions, which
form the blood-testis barrier and segregate the epithelium into anatomical and
physiological compartments (Figure 2.2 insert). The two compartments support




Figure 2.1. Anatomy of the human testis
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Rough endoplasmic reticulum
Figure 2.2. Cross-section through part of a seminiferous tubule of an adult testis.
The testis is divided into two major compartments; the seminiferous tubule and intertubular
space. The intertubular space is subdivided into the interstitium, which includes the
lymphatic vessels and Leydig cells, and the vascular compartment (V). The seminiferous
tubule is further divided into basal (B) and adluminal (A) compartments. The blood vessels,
lymphatics and nerves are contained entirely within the intertubular space, separated from
the seminiferous tubules by the basement membrane. Within the tubule, the basal and
adluminal compartments are separated by rows of zonular tight and gap junction complexes
(see insert) which link adjacent Sertoli cells round the entire circumference of the tubule.
The spermatogonia are confined to the basal compartment, whilst spermatocytes, round and
elongating spermatids and spermatozoa are in the adluminal compartment, in intimate
contact with the Sertoli cells. (Support for illustrations provided by Ted Pinner, MRC
Reproductive Sciences Unit, Centre for Reproductive Biology, University ofEdinburgh).
9
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2.2. Spermatogenesis
Spermatogenesis is a complex process by which diploid germ cell spermatogonia
undergo proliferation and differentiation into mature haploid spermatozoa29. The
general organization of spermatogenesis is essentially the same in all mammals and
can be divided into phases of development through which all spermatogenic germ
cells pass sequentially over time. This highly co-ordinated process can be divided
into three phases: mitotic proliferation of spermatogonia to yield primary
spermatocytes; meiotic maturation of spermatocytes to yield round spermatids; and
differentiation of spermatids into mature spermatozoa, a process known as
spermiogenesis (Figure 2.3). The time taken from division of one stem cell
spermatogonium to production ofmature spermatozoa varies between species, and in
humans is determined to be approximately 74 days. Clearly, male reproduction does
not hinge upon an episodic pattern of fertility every six weeks or so, but rather, is
dependent upon continuous production ofmature spermatozoa. Consequently, sperm
production is organised spatially and temporally such that rounds of spermatogenesis
are initiated at time intervals that are constant and characteristic for each species.
There are six stages in humans. To ensure a continuous supply of spermatozoa, each
successive segment of the tubule will show a sequential stage of development. It is as
if adjacent tubule segments, each containing synchronized populations of
spermatogenic stem cells, have entered the cycle slightly out of phase with each
other, giving the tubule a helical appearance longitudinally (Figure 2.4). The
resulting appearance is known as the spermatogenic wave which is a description of a
spatial event, rather than the temporal cycle events29,30.
10
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Figure 2.3. Division of spermatogonial germ cells to mature spermatozoa
This process can is divided into three phases: mitotic proliferation of spermatogonia
to yield primary spermatocytes; meiotic maturation of spermatocytes to yield round
spermatids; and differentiation of spermatids into mature spermatozoa, known as
spermiogenesis. (Support for illustrations provided by Ted Pinner, MRC Reproductive
Sciences Unit, Centre for Reproductive Biology, University ofEdinburgh).
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Spatial arrangement of stages of the spermatogenic cycle
Rat Human
Segmental arrangement of stages Helical arrangement of stages
ii
Figure 2.5. Helical appearance of tubule.
Diagrammatic representation of the different spatial arrangement of the stages of
spermatogenic cycle along a short length of seminiferous tubule in the rat and
human29.
Organization of this highly complex process of spermatogenesis, both spatially and
temporally, is incompletely understood but there is compelling evidence to suggest
that it is attributable to the Sertoli cell, which provides a continuous cytoplasmic
12
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network around the tubule that may enable communication and synchronization to
occur. The Sertoli cell also spans across the tubule from membrane to lumen
facilitating communication between intratubular space, basal and adluminal
compartments. The functions of the Sertoli cell are numerous and include fluid
production, phagocytosis of degenerating germ cells, synthesis and secretion of
numerous proteins and enzymes, metabolic conversions, and production of known
and putative growth factors. The principal role of the Sertoli cell is to support
spermatogenesis in response to hormone regulation by FSH and testosterone29,30.
2.3. Hormone regulation
Testicular function, and ultimately spermatogenesis, is regulated by the anterior
pituitary hormones LH and FSH, which are released from the anterior pituitary gland
in response to hypothalamic gonadotrophin-releasing hormone (GnRH) and modified
by various regulatory factors from the testes namely testosterone and inhibin. FSH
binds exclusively to receptors on the Sertoli cell and stimulates synthesis of androgen
receptors, inhibin and activin, which play a mediatory role in spermatogenesis.
Testosterone, essential for spermatogenesis, is synthesized and secreted by the
Leydig cells in response to stimulation by LH, and passes through the cellular
barriers to the Sertoli cell, with a substantial proportion entering the blood and
lymphatic system. FSH and testosterone act synergistically on Sertoli cells to
promote Sertoli cell function and support spermatogenesis because germ cells per se
do not possess receptors for either hormone. The mechanism by which
spermatogenesis is initiated and sustained is poorly understood and is likely to
13
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involve a number of stimulatory and inhibitory mechanisms. Testosterone exerts a
negative feedback regulation on the hypothalamic and pituitary hormones. Another
such inhibitory mechanism is the regulatory role of inhibin B. Inhibins are
glycoprotein heterodimers composed of an alpha subunit and one of two types of
beta subunits, either pA (inhibin A) or pB (inhibin B). In males, inhibin B is the
major component and the Sertoli cell is the predominant site of its production,
although there is some speculation regarding subunit production by Leydig and germ
cells. Inhibin B, the secretion of which requires the presence of germ cells, mediates
non-steroidal negative feedback from the testes, reflecting the number of
spermatozoa produced and regulating FSH secretion31,32. Inhibin B secretion in the
adult requires the presence of intact germ cells31 and increasingly inhibin B is being
used as a predictor of seminiferous epithelial function.
In addition to its mandatory role in spermatogenesis, testosterone has a peripheral
role. Testosterone circulates in the plasma as a pro-hormone, bound largely to plasma
proteins (98%), and is converted to the metabolically active hormones, DHT and
oestradiol. DHT is thought to mediate male sexual differentiation and virilization.
Oestradiol appears to mediate bone maturation and mineralization, epiphyseal fusion,
and negative feedback inhibition of FSH29,30.
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2.4. Puberty
The prepubertal testis has classically been defined as a quiescent organ, however
evidence is emerging to the contrary33"35. The development of the testis from the time
of foetal differentiation to adulthood is characterised by dramatic morphological and
functional changes that lay the groundwork for the onset of spermatogenesis. From
birth to puberty the testis has been shown to triple its volume, largely attributable to
an increase in seminiferous tubule length35. Sertoli cells proliferate intensely and are
functionally active during childhood, producing large amounts of anti-Mullerian
hormone, throughout the prepubertal period, and inhibin B until the age of 2-4
years36. These hormones are believed to modulate the proliferation and differentiation
of Leydig cell precursors. Multiplication of early germ cells does occur but
progression beyond the mitotic stage is not supported by the immature Sertoli cells.
At puberty there is a sleep-entrained increase in the pulsatile secretion of LH and to a
lesser extent FSH, associated with increased nocturnal plasma testosterone
concentrations. With pubertal progression, the increased pulsatile release of
gonadotrophins is maintained throughout the day and night and high concentrations
of testosterone are sustained throughout the 24-hour cycle. Spermatogenesis is
initiated at puberty as a consequence of increased secretion of FSF1. Integral to this is
the changing role, and responsiveness of the Sertoli cell. FSH stimulated maturation
of the Sertoli cells to form two compartments and create the blood-testis barrier is
essential for the progression of germ cells through meiosis and spermatogenesis. As
15
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puberty progresses the responsiveness of the Sertoli cell, and ultimately control of
spermatogenesis, shifts from FSH to testosterone34'35-37.
2.5. Investigation of testicular function
Assessment of testicular maturation and function involves pubertal staging,
measurement of plasma hormones and semen analysis (Table 2.1). Pubertal staging
provides important clinical information about both Leydig cell function and
spermatogenesis38. The development of normal secondary sexual characteristics
would imply intact Leydig cell function with normal steroidogenesis. Reduced
testicular volume (<15ml), determined using the Prader Orchidometer (Figure 2.6), is
strongly suggestive of impaired spermatogenesis and azoospermia. Hormone analysis
requires measurement of basal plasma FSH, LH, testosterone and inhibin B if
available39. In prepubertal children hormone analysis is an unreliable predictor of
gonadal damage because the hypothalamic-pituitary-testicular axis is relatively
quiescent. In post pubertal boys elevated LH and diminished testosterone levels
would indicate Leydig cell dysfunction. Subtle Leydig cell damage may be manifest
by elevated LH with normal serum testosterone levels. Elevated FSH and diminished
inhibin B would be indicative of impaired spermatogenesis but semen analysis
remains the definitive measure of spermatogenesis.
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Table 2.1. Assessment of testicular function
Testicular dysfunction
Leydig cell dysfunction Reduced testosterone
Elevated LH




Figure 2.6. Prader Orchidometer.
This is used to clinically determine testicular volumes. Prepubertal testes, less than
4ml in volume are coloured blue on the beads.
17
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3. Testicular damage
Cytotoxic chemotherapy and radiotherapy may damage the testes at all ages and
result in hormone insufficiency and sterility. However, the full impact of
gonadotoxic treatment in prepubertal children is difficult to detect during childhood
and may be manifest during puberty as hypogonadism or in adulthood as infertility5"
16
There is convincing evidence that the prepubertal testis is susceptible to the toxic
effects of radiation and chemotherapy8"11,16. The seminiferous epithelium is very
susceptible to cytotoxic damage but the exact mechanism of cell damage remains to
be elucidated40. This is explored further in Chapter 7.
The mechanism of Leydig cell damage is equally uncertain. Chemotherapy may have
a direct cytotoxic effect upon the Leydig cells or an indirect impact by damaging
other cell populations and disrupting paracrine regulation. Radiotherapy may directly
destroy the slowly turning over Leydig cells at high doses or more likely, have an
indirect effect due to damage to the vasculature. Radiotherapy damage to the testes is
associated with decreased testicular blood flow41. Where this is marked,
compensatory mechanisms may be insufficient to increase intratesticular testosterone
concentrations, resulting in reduced testosterone output. Furthermore reduction in
arterial blood flow into the testes may be associated with a diminished stimulatory
effect of LH42.
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3.1. Chemotherapy
3.1.1. Seminiferous epithelial damage
Chemotherapy-induced damage to the testicular seminiferous epithelium has been
recognized for many years and was first described in humans by Spitz in 194843.
Post-mortem examination of testicular tissue from 30 men treated with nitrogen
mustard demonstrated complete absence of spermatogenesis and seminiferous
tubules lined with Sertoli cells only, in 90% of cases. Since then a number of agents
have been identified as causing testicular damage, including cis-platinum,
procarbazine and the alkylating agents, such as chlorambucil and cyclophosphamide
(Table 3.1)10'11'44"48. Cytotoxic chemotherapy agents may produce long-lasting or
permanent damage to the seminiferous epithelium resulting in oligozoospermia or
azoospermia'0,11,49_53.
The extent of the damage to the testis is dependent upon the agent administered and
dose received1011'44'47"54. However, as most treatments are delivered as multi-agent
regimens, often with synergistic toxicity, it can be difficult to determine the specific
contribution of each individual agent. The impact of chemotherapy on testicular
function has been widely investigated and most clinical studies have focused on
combination chemotherapy regimens used in the treatment of haematological
malignancies, particularly Hodgkin's disease10'11'48"52. Occasionally chemotherapeutic
agents are administered as monotherapy, enabling the direct gonadotoxic effects of
the agent to be studied, such as cyclophosphamide treatment of immunologically
mediated disease47.
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Combination chemotherapy treatment of Hodgkin's disease with established
regimens (mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) or
mechlorethamine, vincristine, procarbazine and prednisolone (MOPP) or
chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP) or
cyclophosphamide, vincristine, procarbazine and prednisolone (COPP)) have been
reported in a number of studies to result in permanent azoospermia in more than 85%
of adult males. The gonadotoxic agents in these regimens are mechlorethamine and
procarbazine in MVPP and MOPP respectively, chlorambucil and procarbazine in
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ChlVPP, and procarbazine and cyclophosphamide in COPP1011,48"51,55. The ABVD
combination (adriamycin, bleomycin, vinblastine and dacarbazine), which contains
neither an alkylating agent nor procarbazine, has been shown to be significantly less
gonadotoxic, resulting in temporary azoospermia in 33% of patients and
oligozoospermia in 21%, with 'full' recovery after 18 months reported in all patients
retested50. However, the advantage of reduced incidence of azoospermia is offset by
the increased potential of cardiac disease due to anthracycline exposure.
In view of the high chance of azoospermia associated with treatment for Hodgkin's
disease, alternating combination chemotherapy regimens, 'hybrid' regimens, have
been developed in an attempt to reduce the overall dosage of any one particular agent
and potentially reduce all drug related side effects. 'Hybrid' regimens (such as
alternate cycles ofABVD with cycles ofChlVPP or MOPP) appear to be as effective
as single regimen therapies with respect to cure rates and will hopefully be less
gonadotoxic and cardiotoxic. Fertility is preserved in approximately 50% of men
following three cycles of MOPP, in contrast to almost universal azoospermia
following six cycles of MOPP51. In direct comparison of MOPP treatment with
MOPP/ABVD, azoospermia was reported in 100% and 76% of patients,
respectively56.
A number of other combination chemotherapy regimens have also been studied
which do not include procarbazine or chlorambucil and have generally been shown
to be less gonadotoxic. Treatment of 51 men with non-Hogkin's lymphoma (NHL)
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with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)- based
chemotherapy rendered all men azoospermic during treatment but recovery to
normospermia occurred in 67% of patients and oligozoospermia in 5% by 5 years".
A number of other regimens have been used successfully to treat NHL and are also
associated with a more favourable outcome in terms of testicular function, including
MACOP-B or VACOP-B (mechlorethamine doxorubicin, prednisolone, vincristine,
cyclophosphamide and bleomycin or vinblastine replacing mechlorethamine in the
latter)58 VAPEC-B (vincristine, doxorubicin, prednisolone, etoposide,
cyclophosphamide and bleomycin)59, and VEEP (vincristine, etoposide, epirubicin
and prednisolone)52. The vast majority of men have normal fertility following
treatment with the above regimens, which, although containing cyclophosphamide,
emphasises the role of procarbazine in causing irreversible damage to the testicular
seminiferous epithelium.
Bone marrow transplant (BMT) or peripheral blood stem cell (PBSC) rescue
following marrow ablation are increasingly being used to successfully treat a number
of haematological and solid malignancies. Testicular dysfunction may follow
marrow ablation therapy with total body irradiation or high-dose chemotherapy,
including cyclophosphamide and busulphan. In a study of 155 patients, aged 13-56
years, undergoing BMT for haematological malignancies or aplastic leukaemia,
preparative chemotherapy regimens included cyclophosphamide (200mg/kg) in 109
patients, or busulphan (16mg/kg) and cyclophosphamide (200mg/kg) in the
remaining 46 patients. Recovery of testicular function, defined by normal FSH
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and/or sperm production, was assessed at 3 (1-19) years post treatment. In the group
treated with cyclophosphamide only, 42 of the 109 (39%) patients had evidence of
recovery, while amongst those who received both agents testicular dysfunction was
evident in 38 of 46 (83%)16. Busulphan was clearly associated with greater
gonadotoxicity at those doses. In another study semen analysis in long term survivors
of bone marrow transplantation receiving preconditioning with busulphan (16mg/kg)
and cyclophosphamide (120mg/kg) demonstrated sperm production in 21 out of 26
(81%) patients, 10 ofwhom were oligozoospermic60.
Follow up of 30 men for a mean of 12.8 years following treatment with
cyclophosphamide (total dose 560-840 mg/kg) for childhood nephrotic syndrome,
reported azoospermia in 13%, oligozoospermia in 30% and normal semen analysis in
the remaining 57% of the men47. The threshold for impaired spermatogenesis was a
total dose of lOg. However, when used for the treatment of solid tumours in
combination with doxorubicin and dacarbazine or vincristine, which have not been
shown to be gonadotoxic, azoospermia was permanent in 90% of men treated with
cyclophosphamide doses >7.5g/m261. Management of childhood leukaemia, which is
the commonest childhood malignancy, is continually evolving and often includes
cyclophosphamide or cytarabine. A study of testicular histology in 44 boys treated
for ALL demonstrated a 50% reduction in tubular fertility index (TFI) (percentage of
tubules containing identifiable spermatozoa), with severe impairment (TFI <40%) in
18 patients. The severity of the damage was influenced by previous chemotherapy
treatment with cyclophosphamide and cytarabine (>lg/m2), whereas the tubular
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fertility index improved with increasing time from treatment62. 'Full' recovery of
spermatogenesis was observed in 3 of 7 of the patients with severe depression of TFI
followed up for median (range), 10.8 (5.5-15.9) years off treatment45. Seminiferous
epithelial damage has also been described following successful treatment for
childhood ALL with a modified LSA2L2 protocol, which includes treatment with
cyclophosphamide and cytarabine63. In contrast, normal testicular function was
reported in 14 boys successfully treated for ALL, which did not include either
cyclophosphamide or cytarabine64. Current treatment of ALL in the UK includes
cytarabine (total dose: 2g/m2 or 4g/m2) and cyclophosphamide (total dose: 1.2g/m2 or
2.4g/m2). Although this is unlikely to be sterilising, long-term follow-up is necessary.
The value of serum inhibin B in detecting male gonadal dysfunction was studied in
27 postpubertal and 12 pubertal survivors of childhood cancer. Serum inhibin B
levels were found to correlate with testicular volume and gonadotrophin
concentrations. In the post pubertal group, small testicular volume was strongly
correlated with low inhibin B levels (<42pg/ml) and inversely related to FSH levels.
In all prepubertal survivors, inhibin B levels were greater than 90pg/ml, except in
one patient with testicular cancer, whose inhibin B was barely detectable and FSH
was elevated, indicative of testicular damage. Inhibin B appears to be a sensitive
marker of seminiferous epithelial function and may be a tool for evaluation of
testicular function in cancer survivors unable to produce semen for analysis65.
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3.1.2. Leydig cell damage
The Leydig cells are less vulnerable to the cytotoxic effects of chemotherapy than the
sensitive seminiferous epithelium"'44,47"49'54,55. Gonadotoxic chemotherapy agents
responsible for seminiferous epithelial damage may, however, also cause Leydig cell
dysfunction. In a study of 30 men treated with cyclophosphamide (2-3mg/kg body
weight/day for a mean of 280 days, range 42-556) for childhood nephrotic syndrome
all men had normal development of secondary sexual characteristics, normal libido
and sexual function. All patients demonstrated a significantly raised luteinizing
hormone response on stimulation with luteinizing hormone releasing hormone, in the
presence of normal testosterone concentrations, suggesting compensated Leydig cell
failure47.
Following treatment for Hodgkin's disease with the gonadotoxic regimens MVPP,
MOPP, ChlVPP, COPP, elevated LH (basal and stimulated) was reported in 24-88%
of patients10'1''46,48,49,55. In the majority (>85% of patients) testosterone levels were
within the normal range, indicating compensated Leydig cell dysfunction.
Young boys and adolescent males who receive standard dose cyclophosphamide
(200mg/kg) as conditioning therapy for bone marrow transplantation appear to retain
normal Leydig cell function, as evidenced by normal hormone profile and pubertal
development in the majority of males66. Although the data are limited, Leydig cell
function appears to be preserved in most males treated with the combination of
busulphan and cyclophosphamide, despite damage to the seminiferous epithelium67.
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3.2. Radiotherapy-induced damage
3.2.1. Seminiferous epithelial damage
The seminiferous epithelium is very sensitive to damage from both radiotherapy and
chemotherapy. The degree and permanency of radiotherapy-induced testicular
damage depends on the treatment field, total dose and fractionation schedule (Table
3.2)13"16-68. Doses as low as 0.1-1.2 Gy damage dividing spermatogonia and disrupt
cell morphology resulting in oligozoospermia68,69. Following low-dose, single
fraction irradiation, complete recovery of spermatogenesis was observed 9-18
months following irradiation with 1 Gy, by 30 months following doses of 2-3 Gy and
at 5 years or more in those treated with 4 Gy68'69. The seminiferous epithelium
appears to be more susceptible to fractionation of radiotherapy, with doses greater
than 1.2 Gy fractionated resulting in permanent azoospermia15.







>20 Gy - prepubertal
>30 Gy - post-pubertal
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In a large study, 463 males aged 26 (11-62) (mean (range)) years, received TBI, 10-
15.75 Gy, as preparative treatment before BMT for haematological malignancies or
aplastic anaemia16. Assessment of testicular function, at 3 (1-19) years post transplant
demonstrated impaired testicular function, with normal defined as normal FSH, LH
and testosterone concentrations with evidence of sperm production, in 83% (382 of
463) of subjects.
The effects of irradiation on testicular function were evaluated in 60 long-term
survivors of childhood ALL. All patients received 18 or 24 Gy cranial or
craniospinal irradiation, groups one and two, and the third group received 12 Gy
abdominal irradiation in addition to craniospinal irradiation. Primary germ cell
dysfunction, defined as elevated FSH and/or reduced testicular volume, was
significantly associated with the field of radiotherapy. Of the patients who received
additional abdominal irradiation, 55% demonstrated evidence of seminiferous
epithelial dysfunction, in contrast to none of the patients treated with cranial
irradiation alone. Interestingly, 17% of the group receiving craniospinal irradiation
demonstrated evidence of primary germ cell damage, indicating that scatter
irradiation exposure may also impair testicular function13.
Gonadal function was assessed in 15 boys following testicular irradiation for
childhood ALL. The dose to the testes was 12 Gy in 12 boys, 15 Gy in one boy and
24 Gy in the remaining two boys. Azoospennia was observed in all boys70.
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In a further study, testicular function was investigated in 21 boys, mean age 19.0
years, following total body irradiation and bone marrow transplantation for
haematological malignancies at a mean age of 11.3 years, 15 of whom were
prepubertal at time of treatment. All boys had reduced testicular volumes (mean
10.5ml) with elevated basal FSH concentrations, with normalisation in only one
patient, indicating severe impairment of reproductive function following TBI72.
3.2.2. Leydig cell damage
Leydig cells are more resistant to damage from radiotherapy than the seminiferous
epithelium and progression through puberty with normal potency is common despite
severe impairment of spermatogenesis. Susceptibility to radiation-induced Leydig
cell damage appears to be inversely related to age, or sexual maturation, with greater
damage following smaller doses in prepubertal boys1314'70"75.
Impact of radiotherapy on testicular function has been studied in children undergoing
BMT for leukaemia. Seventeen prepubertal boys, aged less than 12 years, received
hyperfractionated TBI (TD: 13.75-15 Gy) with a testicular boost of 4Gy in 16
patients and 12 Gy in the remaining patient. Before undergoing transplantation, all of
the boys had received multi-agent chemotherapy, and for nine of them this had
included cyclophosphamide. Of the 17 boys, median age 14 years (10.4-17.1), 14
(82%) entered puberty spontaneously, two were less than 12 years old and
prepubertal, and the remaining subject, who had received a 12 Gy testicular boost,
required androgen replacement therapy to induce puberty. Although overt Leydig
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cell failure was rare, 36% of the subjects demonstrated compensated Leydig cell
dysfunction. Furthermore, pubertal boys with raised plasma LH concentrations were
younger at the time of BMT than pubertal boys with normal levels of LH73. Similar
reports of increased vulnerability of the young Leydig cell to radiation-induced
damage are reported in a number of studies66,73"76. Leydig cell function was evaluated
in 41 men treated with total body irradiation (12 Gy fractionated or 10 Gy single
dose), 6 Gy single dose total lymphoid irradiation or chemotherapy alone at median
age 7.7 years (0.6-13.6). Leydig cell dysfunction was reported in 10 (24%) of the
men, of whom 3 had complete Leydig cell failure76. Testicular irradiation with doses
of greater than 20 Gy is associated with Leydig cell dysfunction in prepubertal boys
while Leydig cell function is usually preserved up to 30 Gy in sexually mature males
(Table 3.2)73"76.
Pubertal development after TBI was investigated in 21 boys treated with allogeneic
BMT for haematological malignancies at a mean age of 11.3 years. Fifteen of the
boys were prepubertal at BMT. Normal development of secondary sexual
characteristics was observed in 19 men. The remaining 2 men with hypogonadism
had received an additional boost of testicular irradiation and required androgen
supplementation. However, despite clinical evidence of intact Leydig cell function,
and normal testosterone levels in all 19 men, LH levels were elevated in the majority
of subjects indicating mild Leydig cell dysfunction72.
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3.3. Clinical impact of impaired testicular function
The clinical implications of frank Leydig cell failure and azoospermia are very clear.
The implications of mild/subclinical Leydig cell insufficiency are, however, unclear.
The clinical manifestations of Leydig cell dysfunction will inevitably depend upon
the age of the child at the time of treatment. Loss of Leydig cell function before the
onset of, or during puberty, will be associated with failure to enter puberty
spontaneously or arrest of pubertal development. Cytotoxic insult following the
development of normal secondary sexual characteristics will manifest clinically as
erectile dysfunction, reduced libido, fatigue and mood changes, and biochemically
will be associated with decreased bone mineral density, loss of muscle mass and
other metabolic disturbances'7"19.
Leydig cell failure in the prepubertal child will require androgen supplementation for
induction and progression of puberty and in the adult, testosterone replacement.
Increasing evidence is emerging that compensated Leydig cell impairment may play
an important role in bone mineral density and general well being. In the adult male,
overt testosterone deficiency is associated with decreased energy level, poor libido,
increased incidence of anxiety and depression, altered body composition and reduced
bone mineral density (BMD). These symptoms if found in males following
chemotherapy imply mild testosterone deficiency17"19. Limited data are available
exploring the role of testosterone supplementation in men with compensated Leydig
cell dysfunction. In a single blind randomised study, 35 men (mean age 40.9 years)
with mild Leydig cell dysfunction, as defined by raised LH and low or low normal
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testosterone level, were identified following treatment with cytotoxic chemotherapy
for malignancy. Patients were randomised to receive 12 months treatment with
transdermal testosterone or placebo patches. Testosterone levels increased
significantly in the testosterone treated group compared with the placebo group and
LH levels returned to normal values in 94% of subjects. However, there were no
significant changes in bone mineral density, body composition or lipid profile, apart
from a small reduction in LDL cholesterol. In terms of quality of life, the only
perceived benefit was a marginal reduction in physical fatigue with no effects on
mood or sexual function77. Testosterone supplementation for mild hypogonadism
appears to be of limited clinical benefit but further studies are required to further our
understanding and define the role of testosterone replacement therapy.
3.4. Progeny
Overall there are reassuring reports that there is no increased incidence of either
congenital abnormalities or childhood malignancy in children born to long-term
survivors of childhood cancer78-79. However these successful pregnancies mostly
result from normally achieved conception. We do not know the consequences of
circumventing the natural selection processes of normal sexual reproduction using
assisted reproduction techniques (ART), nor the effects of ART on the complex
cascade of precisely timed molecular interactions of early embryonic development.
Continued surveillance of the progeny of survivors of childhood cancer remains
essential80.
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3.4.1. Paternal risk to the offspring
The mutagenic potential of cancer therapy may confer a risk to the foetus conceived
using gametes produced after cancer therapy, although current epidemiological data
suggests that offspring of cancer survivors do not have an increased incidence of
congenital abnormalities or cancer relative to the general population78'79. There is at
least the hypothetical possibility of injection of abnormal spermatozoa or immature
spermatogenic cells carrying abnormal genomic DNA with the potential to increase
congenital and other abnormalities amongst offspring80'81. Studies in animals have
shown that exposure of the male germ line to chemotherapy agents may disrupt
spermatozoal DNA and result in deleterious effects on embryo development82"84.
Awareness of the importance of sperm DNA integrity for accurate transmission of
genetic material to the offspring has necessitated the development of new techniques
to assess sperm characteristics in more detail81. It has become clear that men from
subfertility clinic populations, with abnormalities of the conventional criteria of
semen quality, also demonstrate elevated levels of damage to the genomic DNA in
their gametes. Even amongst normal populations, sperm chromatin damage has been
linked with impaired fecundity85. It has been shown that sperm DNA damage does
not preclude pronucleus formation at ICSI, and that abnormal DNA within the male
gamete is detectable in the early embryo86. Thus far, evidence on the safety of ICSI
has been largely based upon its use in populations of men with deficits in
spermatogenesis unrelated to potentially mutagenic cancer treatment. This evidence
has been broadly reassuring concerning health risks to the offspring, although it is
limited by the restricted length of follow-up currently available87'88. The quality of
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spermatozoal DNA in long-term survivors of childhood cancer is investigated and
the results are discussed in Chapter 453.
Successful pregnancies have been achieved using immature spermatogenic cells,
which adds an unquantified risk to the foetus89. Fertilisation of oocytes with
immature spermatogenic cells, such as round and elongated spermatids, which have
not yet completed spermatogenesis, must be pursued with caution. The mechanism
by which sperm precursor cells activate the oocyte at fertilisation is uncertain but it is
speculated that suboptimal oocyte activation may confer poor fertilisation,
implantation and high early abortion rates89. Spermatid transition into spermatozoa is
characterised by salient changes in nuclear protein composition. The significance of
circumventing these changes is uncertain90. Genetic imprinting plays an important
role in embryogenesis and in processes leading to the development of paediatric
cancers, including Wilms' tumour and embryonal rhabdomyosarcoma, and other
human diseases90. Although the mechanism involved in genetic imprinting is
uncertain, it is likely to involve differences in DNA methylation and requires careful
consideration when embarking on germ cell maturation. Children born following
assisted conception using spermatozoa and immature spermatogenic cells require
long-term careful monitoring.
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Chapter 4
Semen quality and spermatozoal DNA
integrity in survivors of childhood cancer
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4. Semen quality and spermatozoal DNA integrity in survivors of
childhood cancer
4.1. Introduction
With continued improvement in survival from childhood cancer, such that 70% of
patients are now long-term survivors, attention has focused on the lasting morbidity
associated with radiation and chemotherapy treatment2. One of the most frequently
encountered and psychologically traumatic late complications following treatment is
infertility. Cytotoxic chemotherapy agents, particularly alkylating agents, may
produce long-lasting or permanent damage to the seminiferous epithelium, resulting
in oligozoospermia or azoospermia4"9. In addition, the seminiferous epithelium is
very sensitive to radiotherapy and doses as low as 1.2 Gy may result in permanent
sterility15. Recovery from surviving germ cells may occur but is unpredictable and
often prolonged10'11. Leydig cells, with their slower rate of turnover, are more
resistant to gonadotoxic therapy, resulting in preservation of androgen production
even when patients are infertile74.
Advances in techniques of assisted reproduction, and particularly intracytoplasmic
sperm injection (ICSI), have provided a treatment option to enable men with
oligozoospermia to achieve fatherhood22'91. Concerns have been raised about the
safety of ICSI92, particularly relating to the possibility that spermatozoa from men
with impaired spermatogenesis may carry abnormal genetic information80,86'93.
Although the best available data on the health of offspring following ICSI are
broadly reassuring87, there are no data on the health of offspring where the man's
36
Male fertility in survivors of childhood cancer Chapter 4
deficit in semen quality is a consequence of potentially mutagenic treatment94.
Studies in animals have shown that exposure of the male germ line to chemotherapy
agents may disrupt spermatozoal DNA and result in deleterious effects on embryo
development82. Awareness of the importance of sperm DNA integrity for accurate
transmission of genetic material to the offspring has necessitated the development of
new techniques to assess sperm characteristics in more detail81.
The aim of this study was to investigate testicular function and semen quality in
survivors of childhood cancer. The role of sexual maturation and endocrine
parameters were investigated as potential markers of testicular function and
spermatogenesis. Amongst patients who were not azoospermia detailed assessment
of semen characteristics was made including assessment of sperm DNA integrity.
37
Male fertility in survivors of childhood cancer Chapter 4
4.2. Patients and Methods
The study was approved by the Lothian Paediatric and Reproductive Medicine
Research Ethics Sub-Committee and all patients gave written informed consent.
4.2.1. Patients
A review of the oncology database, at the Royal Hospital for Sick Children,
Edinburgh, for all male survivors of childhood cancer, over the age of 16 years,
identified 51 male survivors, median age of 22.2 years (range 16.5-35.2). Forty-five
men were invited to participate in the study. Of the remaining six men, five had
moved away from our region and one was on antidepressant medication and
therefore excluded. Six men declined and six did not reply to the invitation. The 18
men who did not participate in the study were comparable for age, diagnoses, age at
diagnosis, treatment regimens and disease free survival. Thirty-three men, aged 21.9
(16.5-35.2) years, participated in the study, a response rate of 73% of those invited,
and an inclusion rate of 65% for the group as a whole. Of the 33 participants, median
age (range) at diagnosis was 10.0 (2.2-16.9) years and disease free survival 11.6 (0.3-
24.4) years. The underlying malignancies included acute lymphoblastic leukaemia
(n=15), Hodgkin's disease (n=6), Ewing's sarcoma (n=5), non-Hodgkin's lymphoma
(n=2), brain tumours (n=2), Wilms' tumour (n=l), osteosarcoma (n=l) and
teratocarcinoma (n=l). A summary of the patients' diagnoses with details of the
potentially gonadotoxic chemotherapy and radiotherapy received are summarised in
Table 4.1. For each study patient, two age-matched controls (n=66) were recruited
from a parallel survey of the reproductive health of normal volunteers. Volunteers
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were recruited by means of advertisement in local media and through hospital
outpatient clinics, and selected on the basis of the absence of any clinical evidence,
on history or physical examination, of reproductive health problems.
4.2.2. Assessment of testicular function
Pubertal maturation was assessed according to the Tanner criteria and testicular
volume (ml) was measured using the Prader Orchidometer38. The mean value of the
two testes was taken to represent the subject's testicular volume. Venous blood
samples were collected (20ml), and LH, FSH and testosterone levels were measured
using automated immunoassay analyser (Bayer Immuno 1). A separate aliquot of the
sample was centrifuged at 2000 x g for 10 minutes and serum stored at -20°C until
assayed for inhibin B as previously described95. Semen samples were collected in a
room adjacent to the laboratory, by masturbation into sterile wide mouthed non-toxic
containers, following an abstinence period of at least 48 hours. These samples were
analysed for ejaculate volume (ml), sperm concentration (x 106/ml), motility (%) and
normal morphology (%) according to the protocols of the World Health Organisation
(1999)96. Throughout the period of the study, the laboratory was subject to external
quality control.
4.2.3. Assessment of sperm DNA integrity
DNA fragmentation in spermatozoa was measured using a modification of the
method of terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP-biotin
nick end-labelling (TUNEL) previously described by Sun et aP1. An unselected
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population of cells was obtained by mixing an aliquot of each sample with Biggers-
Whitten-Whittingham (BWW) medium97 containing 20nM N-(2-hydroxyethyl)
piperazine-N'-(2-ethan sulfonic acid) (HEPES); Gibco, UK) and 0.3% human serum
albumin solution (HAS) and centrifuged at 500 x g for 5 minutes. Following
decanting of the supernatant, the spermatozoa pellet was resuspended in 2mls of
phosphate buffered saline (PBS) (Sigma-Aldrich Co. Ltd Gillingham, UK) and
centrifuged at 500 x g for 5 minutes. This step was repeated and the spermatozoa
were subsequently fixed in 1% formaldehyde (Sigma-Aldrich Co. Ltd Gillingham,
UK) in PBS for 60 minutes at room temperature. The fixed sperm concentration was
adjusted to 20 x 106 cells/ml, using a Neubauer haemocytometer. The sample was
centrifuged at 500 x g for 5 minutes and washed in PBS. The fixed sperm were
resuspended in 100 pi prewash buffer (PWB) containing single strength One-Phor-
All buffer (Amersham Pharmacia Biotech, Bucks., UK) and 0.1% Triton X-100
(Sigma-Aldrich Co. Ltd Gillingham, UK) for 15 minutes at room temperature. The
sperm were spun out of the buffer at 500 x g for minutes and resuspended in 50 pi of
TdT buffer containing 3 pM biotin-16-dUTP (Roche Diagnostics Ltd. Lewes, UK), 6
pM dATP (Amersham Pharmacia Biotech, Bucks., UK) and llU/pl of TdT enzyme
(Amersham Pharmacia Biotech, Bucks., UK) and incubated at 37°C for 60 minutes.
After washing in PBS the fixed permeabilized sperm were resuspended in 100 pi of
staining buffer consisting of 0.1%
Triton X-100 (in distilled water) and 1% streptavidin/fluorescin conjugate
(Calbiochem-Novabiochem Ltd., Nottingham, UK) and incubated in the dark at 4°C
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for 30 minutes. The stained cells were spun at 500 x g for 5 minutes and resuspended
in 500 pi PBS to give a concentration of approximately 1 x 106 cells/ml.
For negative controls, the enzyme terminal transferase was omitted from the reaction
mixture. For positive controls, the samples were treated with 0.8IU/pl DNase I
(Roche Diagnostics Ltd., Lewes, UK) for 15 minutes at room temperature, prior to
the incubation with the TdT buffer.
4.2.4. Flow cytometry
The samples were analysed using a Epics XL flow cytometer (Beckman Coulter
Corporation, Bucks., UK) with a 15mW argon ion laser operating at 488nm. Using
the FL1 detector, green fluorescence was measured at 525nm. The flow rate during
analysis was controlled at 200 events/sec, and 10 000 events were analysed in each
sample. Light-scatter and fluorescence data were obtained at a fixed gain setting in
the logarithmic mode. Debris were gated out based on the Forward Scatter versus
Side Scatter dot plot by drawing a region enclosing the cell population of interest,
and 10 000 events were collected. The data were processed using an IBM compatible
computer installed with System II™ Version 1.0 software (Beckman Coulter
Corporation, Bucks., UK). The percentage of labelled sperm in each sample was
determined.
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4.2.5. Testicular biopsy
Seven of the 10 men identified by semen analysis as being azoospermic were
recruited into our study investigating suppression of the hypothalamic-pituitary-
gonadal axis to restore spermatogenesis, described in chapter 6. As part of this latter
study the seven men underwent testicular biopsy, under general anaesthetic, before
commencing hormone therapy, which also served to exclude the diagnosis of
obstructive azoospermia. The specimens were fixed in Bouins and stained with
haemotoxylin and eosin and evaluated for the presence of spermatogonia.
4.2.6. Statistical analysis
Statistical analysis was performed by the Statistical Package for Social Science
(SPSS Inc., Chicago, 111) version 10.0. Analysis of variance was performed on the
endocrine data and ejaculate volume, the data common to all three groups. This
involved Kruskal-Wallis tests for analysis of ejaculate volume (parametric) and one¬
way analysis of variance for the hormones (non-parametric). Where differences
existed between the three groups pair-wise tests were performed to study differences
between the groups. T-test and Mann-Whitney U-test were employed to compare the
differences between patient groups and controls with regard to endocrine data and
semen data respectively. For comparisons involving all three patient groups, three
pair-wise two-sample tests were carried out and Bonferroni corrections were applied
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4.3. Results
4.3.1. Patient characteristics
The childhood cancer survivor patient cohort and healthy volunteer control groups
were comparable for age, smoking, alcohol consumption and abstinence (Table 4.2).










Age: median (range) years 19.5 (16.5-25.3) 22.4(17.6-35.2) 20.8 (18.0-36.3)
Smoking habits (%) 40 22 38
Alcohol consumption (%)
0 (units/week) 10 26 8
<10 50 13 9
11-20 10 48 44
>21 30 13 39
Pubertal staging
Tanner 5 5 5
Testicular volume 10 (7.4-12)*** 17.5 (15-21.25) 20 (15-23)
(median, interquartile range)
*** —= P<0.001 for azoospermic group compared with other two groups
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4.3.2. Semen analysis
Of the 33 patients, 10 (30.3%) were azoospermic (Table 4.1). Five of the
azoospermic patients had received treatment for Hodgkin's disease with the
alkylating agent chlorambucil, total dose, >340mg, >504mg/nT, procarbazine >6.3g,
2 2
>8.4g/m and vinblastine >54mg, >72g/m , all of which are known to be
gonadotoxic. Two of the azoospermic patients had been treated with ifosfamide
2 2
(139.2, 84g/m ; 165.6g, 87g/m ) for Ewing's sarcoma, two had received total body
irradiation (14.4Gy) and one had received direct testicular irradiation (24Gy). Of the
10 azoospermic patients, seven were prepubertal at diagnosis, providing cogent
evidence that the prepubertal testis is not afforded protection from cytotoxic insult.
Six (18.2%) patients were oligoozospermia (sperm concentration <20 x 106/ml), with
severe oligozoospermia (<2 x 106/ml) in one patient, while in contrast
oligozoospermia was observed in only 4.5% of the control population (m=66). Only
one of the six patients treated for Hodgkin's disease with an alkylating agent-based
regimen showed preservation of spermatogenesis (sperm concentration: 4.55 x
106/ml). Three of the oligoozospermia patients had been treated with Medical
Research Council Protocols, UKALL II, III and X, which consisted of combination
chemotherapy, including, vincristine, prednisolone, 6-mercaptopurine methotrexate,
cytarabine and cyclophosphamide. Oligozoospermia was observed in one of the five
patients treated for Ewing's sarcoma, for whom treatment included both ifosfamide
2 2
132.6g, 102g/m", and cyclophosphamide 4.3g, 3.3g/m . The remaining
oligoozospermia patient (sperm concentration: 0.55 x 106/ml) did not receive
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treatment with agents expected to be gonadotoxic and the reason for impaired
spermatogenesis is unclear.
Sperm concentration in the non-azoospermic group was significantly lower than the
sperm concentration for the control population (95% CI: -67 to -15, p<0.01, Table
4.3, Figure 4.1). Nine (29%) of the subjects were asthenozoospermic (progressive
motility <50%) compared with ten (15.2%) for the control group. Median
progressive motility for the non-azoospermia group was significantly less than the
control group (95% CI: -15.1 to -0.6, p<0.05, Table 4.3). The percentage of sperm
with normal morphology was significantly less in the non-azoospermic group
compared with the control population (95% CI: -4.6 to -1.3, p<0.01, Table 4.3).
From our population of 33 male survivors of childhood cancer only 11 (33.3%) men
had a normal semen analysis as defined by the World Health Organisation (1999)
compared to 55 (83.3%) of the control group. There was no correlation between
either age at diagnosis or time out from treatment and sperm concentration in this
group of cancer survivors who were non-azoospermic (p=0.109 and p=0.516
respectively). Interestingly, there was a difference in ejaculate volume between the
three groups (p<0.001). Ejaculate volume was significantly reduced in both the
azoospermic and non-azoospermic groups, 1.9 (1.5-2.3) ml and 2.5 (2.1-3.5) ml,
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N = 66 23
Controls Non-azoospermia
Figure 4.1. Sperm concentration in non-azoospermic long-term survivors of
childhood cancer and in controls.
Median, IQR, and maximum and minimum values are shown.
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4.3.3. Sperm DNA integrity studies
The integrity of the spermatozoa DNA was assessed using the TUNEL assay and the
results are shown in Table 4.3. There was no statistically significant difference
between DNA fragmentation in the non-azoospermic group ^=23) and the control












Figure 4.2. Sperm DNA integrity in long-term survivors of childhood cancer
and in controls.
Median, IQR, and maximum and minimum values are shown.
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4.3.4. Testicular Biopsy
Testicular biopsies from the seven of the 10 men with azoospermia on semen
analysis demonstrated a Sertoli cell only picture in all cases thus excluding
obstructive azoospermia (Figure 4.3a). Examination of the testicular tissue also
demonstrated interstitial fibrosis, thickening of the basement membrane and atrophy
of the seminiferous tubules, in contrast to the healthy seminiferous epithelium of a
healthy adult man (Figure 4.3b).
4.3.5. Endocrine profile
Analysis of variance for the endocrine measurements, FSH, LH, testosterone and
inhibin B, demonstrated a significant difference for the FSF1, LF1 and inhibin B
values for the three groups (p<0.001) with no significant difference between the
groups for testosterone levels. Pair-wise tests were subsequently performed to
analyse the differences between the groups with Bonferroni corrections applied.
Basal serum FSH concentrations were significantly higher in the azoospermic group
(n=10), (mean, ± standard error ofmean (SEM)), 23.2 ±3.4 U/L compared with both
the non-azoospermic (n=23) and control groups (n=53), 6.6 ±0.9 U/L (95% CI: -22.0
to -11.3, p<0.001) and 3.2 ±0.2 U/L (95% CI: -23.1 to -17.1, p<0.001, Figure 4.4a).
Interestingly, the FSH concentrations were also significantly greater in the non-
azoospermic group than in the control population (95% CI: -4.8 to -2.1, p<0.001),
(Figure 4.4a). Inhibin B concentration was barely detectable in the azoospermic
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group (n=10), 24.0 ±12.3 ng/L, which was significantly lower than in both the non-
azoospermic (n=23) and control groups 153.3 ±17.8 ng/L (95% CI: 61.2-
190.5, p<0.001) and 222.9 ±8.7 ng/L (95% CI: 146.6 to 245.9, p<0.001) respectively
(Figure 4.4b). Inhibin B concentrations were also significantly lower in the non-
azoospermic group than the control group (95% CI: 34.6 to 106.3, p<0.001, Figure
4.4b).
Serum LH was significantly greater in both the non-azoospermic (n=23) and
azoospermic groups (n=10), 6.0 ±0.8 and 9.2 ±1.3 U/L respectively, compared with
the control group (n=52), 3.6 ±0.2 U/L (95% CI: -3.5 to -1.2 and -7.1 to - 4.2,
p<0.001 in both cases, Figure 4.4c). Testosterone concentrations were within normal
limits (10-30 nmol/L) in all 3 groups (azoospermic, non azoospermic and control
groups, n=10, 23 and 53 respectively) with no significant differences between the
groups (Figure 4.4d).
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Figure. 4.3 Human testicular tissue stained with haematoxylin and eosin. Panel
(a) shows testicular morphology from one of the study patients demonstrating
complete absence of all germ cell types. A healthy adult male with normal
seminiferous epithelium and abundant germ cell types is shown for comparison in
panel (b). Scale bar denotes 50pm.
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Figure 4.4. Comparison of values for follicle stimulating hormone (FSH) (A),
inhibin B (B), luteinizing hormone (LH) (C), and testosterone (D) in the control
group, and in the non-azoospermic and azoospermic cancer survivors.
Mean and SEM are shown. Reference ranges for FSH and LH are 1.5-9.0 U/L and
for testosterone 10-30 nmol/L. There is no established reference range for inhibin B.
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4.4. Discussion
We have shown that the treatment of childhood cancer is associated with a
significant risk of subsequently impaired spermatogenesis, with 30.3% of this
population being azoospermic and 18.2% being oligoozospermia. Moreover, in those
men who do have surviving spermatogenesis after treatment, it is commonly
compromised, with reductions being observed in ejaculate volume, sperm
concentration, sperm motility and the proportion of morphologically normal sperm.
Only 33.3% of this group ofmale childhood cancer survivors had completely normal
semen quality by conventional criteria96. Correspondingly, this group also had lower
inhibin B levels and higher FSH levels than the control population. Given that the
control group was comparable in other respects, it is likely that the reduction in
sperm number was directly attributable to the cytotoxic effects of cancer therapy.
Reassuringly, the integrity of the genomic DNA carried by their gametes appears
unaffected.
Fertility and sexual function are the principal life-style concerns in more than 80% of
men successfully treated for cancer, yet, a substantial proportion of our survivors
(27%) were reluctant to undergo an appraisal of their reproductive function, for
reasons that are unknown. In addition to treatment induced infertility, it is well
recognised that cancer survivors are less likely to have children for a number of
reasons, including their inability to form relationships, fear of relapse of their
disease, and the prospect of leaving their child parentless98.
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Cytotoxic treatment for childhood cancer should minimise unwanted side effects
without compromising survival. Where there is equal efficacy between regimens the
impact on reproductive function must be considered when devising the most
appropriate therapy50. The present data confirm the sterilising effects of treatment for
Hodgkin's disease with a standard regimen, ChlVPP (chlorambucil, vinblastine,
procarbazine and prednisolone)10,11. The ABVD (adriamycin, bleomycin, vinblastine
and dacarbazine) combination, which does not contain alkylating agents or
procarbazine, has been shown to be significantly less gonadotoxic, resulting in
temporary azoospermia in 33% of patients and oligozoospermia in 21%, with full
recovery after 18 months reported in all patients50. Consequently, with the
introduction of hybrid regimens, three cycles ofABVD with three cycles of ChlVPP
or MOPP, (mechlorethamine, vincristine, procarbazine and prednisolone)
gonadotoxicity may be significantly reduced.
Three of the sterile patients in our study had been treated with either 14.4 Gy
fractionated total body irradiation (n=2) or 24 Gy testicular irradiation. Although
recovery has been reported after a number of years, the high doses administered in
these treatments make recovery unlikely15. Furthermore, as a prerequisite of
recovery, some stem cells must survive, and for these three men, as indeed for all
seven men biopsied, all germ cells (and thus including stem cells) were absent on
testicular biopsy.
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Ifosfamide, an analogue of cyclophosphamide, is potentially gonadotoxic but no data
describing its effect on testicular function is available. Five of our cohort of patients
had received treatment that included ifosfamide for Ewing's sarcoma. Only two of
this group had a normal semen analysis (sperm concentrations: 53 and 125.25 x
106/ml), one was oligoozospermia (12.45 x 106/ml) and the remaining two patients
were azoospermic. The three patients with sperm present in their ejaculate were 11.3
(9.41-11.73) years out from treatment, compared to the azoospermic patients who
had completed treatment four and seven months previously. The two sterile patients
were sexually mature at the time of diagnosis and had provided semen samples for
cryopreservation before commencing cancer therapy, with sperm concentrations of
124 and 128 xl06/ml. This is the first report of azoospermia in young men who had
received ifosfamide containing regimens without any other potentially gonadotoxic
agent. Recovery of testicular function with increasing time since treatment is a
possible explanation. Continued, perhaps yearly, reassessment of semen analysis is
warranted in azoospermic patients.
Normal semen quality, as defined by the World Health Organisation, stipulates that
sperm concentration must be greater than 20 x 106/ml and progressive motility
greater than 50%96. Using these criteria, only 33.3% (11 out of 33) of the survivors of
childhood cancer had a normal semen analysis, compared with 83.3% (55 out of 66)
in the control group. Our results are similar to those reported by Lopez Andreu et
aP9.
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Oligozoospermia was observed in six (18.2%) of the long-term survivor patients,
compared with three (4.5%) in the control group. One of the patients, with
oligozoospermia, had been treated with alkylating agent chemotherapy for Hodgkin's
disease. Three of the oligozoospermia patients received treatment with standard
protocols for ALL, which included cytarabine (>lg/m ) and in one patient,
cyclophosphamide (5.67g, 4.2g/m2). The doses of cytarabine and cyclophosphamide
received by these three patients are significantly less than previously reported to be
gonadotoxic doses47 and may reflect individual susceptibility. Lendon et al studied
testicular histology in 44 boys treated for ALL and found a severely depressed
tubular fertility index (TFI), <40%, in 18 patients, indicative of seminiferous
epithelial damage62. In a follow-up study by Wallace et al''5, semen analysis in seven
of these patients with severe depression of TFI, 10.8 (5.5-15.9), (median, range)
years off treatment, reported azoospermia in 4 of the patients and 'full' recovery of
spermatogenesis in three patients (sperm concentration > 20 x 106/ml). From these
studies, previous chemotherapy treatment with cyclophosphamide and cytarabine
(>lg/m ) impaired gonadal function, which improved with increasing time after
treatment in some patients.
Inhibin B mediates non-steroidal negative feedback from the testes, reflecting the
number of spermatozoa produced and regulating FSH secretion31'32. Inhibin B
secretion in the adult requires the presence of germ cells31. Inhibin B concentrations
were barely detectable in the azoospermic patients, in whom the germ cells were
destroyed, despite preservation of Sertoli cells, as confirmed on testicular biopsy.
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This provides further evidence for the essential role of the germ cell-Sertoli cell
interaction for the production of inhibin B and confirms the value of inhibin B as a
non-invasive marker of spermatogenesis following cytotoxic therapy.
The sperm concentration in the non-azoospermic group was significantly less than
that of the control population, 37.1 (19.7-89.9) x 106/ml compared with 90.7 (50.5-
121.5) x 106/ml (p=0.002). Although azoospermia following gonadotoxic
chemotherapy has been widely investigated there are few data about sperm
concentrations in those patients in whom spermatogenesis is preserved. Rautonen et
al reported sperm concentrations of median (range), 67 (0.01-425) x 106/ml in 27
patients treated for a variety of childhood haematological and solid malignancies'02.
Sperm concentrations of 20.4 (3.2-43) x 106/ml were reported in a small study cohort
(n=4) treated for ALL (n=l) and non-Hodgkin's lymphoma (n=3) and 31 (4.5-100) x
106/ml in 8 long-term survivors of ALL, indicating a general trend towards a lower
sperm concentration102,103. Given that intact spermatogenesis requires the presence of
stem cells, which are capable of self-renewal in addition to differentiation, it is
difficult to reconcile the discrepancy in sperm concentrations between the non-
azoospermic and control groups. The non-azoospermic group clearly retains a
population of intact stem cells capable of undergoing normal spermatogenesis, yet
the surviving stem cells do not appear to repopulate the pool to produce sperm
concentrations comparable to the control population. This could reflect a more
complex picture highlighting the important role of Sertoli cells in supporting a finite
number of stem cells. If there has been subtle damage to the seminiferous epithelium,
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involving loss of Sertoli cells, the remaining Sertoli cells may already be functioning
to full capacity. This is reflected in the subnormal inhibin B concentrations and
corresponding elevation of serum FSH concentrations in the non-azoospermic group
compared with the control population. This is analogous to data showing a decline in
plasma inhibin B concentrations, directly in proportion to Sertoli cell numbers,
following unilateral orchidectomy in rhesus monkeys103. In a physiological setting,
where the negative feedback control system regulating the testes is operational,
Sertoli cell number is the primary determinant of circulating inhibin B levels103.
Ejaculate volume was significantly reduced in both the non-azoospermic and
azoospermic groups compared with the control group, a finding which is unlikely to
be attributable to retrograde ejaculation, obstruction, impaired autonomic innervation
or incomplete specimen collection. Testosterone levels were normal in both groups
of patients making testosterone deficiency an unlikely cause of decreased ejaculate
volume. Damage to the prostate is unlikely, as only three of the patients had
radiotherapy treatment involving the pelvis. Whether chemotherapy plays a role is
uncertain. There is one other report of this finding by Rautonen et alwo. In a study of
55 long-term survivors, treated with chemotherapy or radiotherapy for a variety of
childhood malignancies, 18 (33%) were reported to have a low ejaculate volume,
median (range), 2.0 (0.25-5.0)ml.
The mutagenic potential of cancer therapy may confer a risk to the foetus conceived
using gametes produced after cancer therapy, although current epidemiological data
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suggests that offspring of cancer survivors do not have an increased incidence of
congenital abnormalities or cancer relative to the general population78'79. However, an
important concern is that these results are largely based on offspring arising from
natural conception and the consequences of circumventing the natural selection
processes of fertilization involved by means of ICSI, are unknown80. There is at least
the hypothetical possibility of injection of abnormal spermatozoa carrying abnormal
genomic DNA with the potential to increase congenital and other abnormalities
amongst offspring81. Techniques to evaluate sperm DNA integrity have been
developed81'93 and it is has become clear that men from subfertility clinic populations,
with abnormalities of the conventional criteria of semen quality, also demonstrate
elevated levels of damage to the genomic DNA in their gametes. Even amongst
normal populations, sperm chromatin damage has been linked with impaired
fecundity85. It has been shown that sperm DNA damage does not preclude pronucleus
formation at ICSI86, and that abnormal DNA within the male gamete is detectable in
the early embryo104. Concern thus arises in the case of childhood cancer survivors,
given that the capacity of ionising radiation and some chemicals to induce
transmissible genetic damage in the germ cells of laboratory mammals has been
clearly demonstrated105. Thus far, evidence on the safety of ICSI has been largely
based upon its use in populations of men with deficits in spermatogenesis unrelated
to potentially mutagenic cancer treatment. This evidence has been broadly reassuring
concerning health risks to the offspring87'88, although it is limited by restricted length
of follow-up currently available. We have shown that although the conventional
criteria of semen quality are frequently abnormal in long-term survivors of childhood
62
Male fertility in survivors of childhood cancer Chapter 4
cancer, the sperm produced do not appear to carry a greater burden of damaged
DNA. This observation goes some way to providing reassurance about the use of
ICSI, which will circumvent the problems associated with severe oligozoospermia
and asthenozoospermia, and offer cancer survivors the possibility of paternity in
adulthood.
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Chapter 5
Inhibin B as a marker of gonadotoxicity in
prepubertal children treated for cancer
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5. Inhibin B as a marker of gonadotoxicity in prepubertal children
treated for cancer
5.1. Introduction
Traditionally, determining the impact of chemotherapy and radiotherapy on gonadal
function has involved clinical assessment of pubertal development and semen
analysis in males. Earlier detection of gonadal damage has been hampered by the
lack of a sensitive marker of gonadal function in prepubertal children. In these
children analysis of gonadotrophins is an unreliable predictor of gonadal damage
because the hypothalamic-pituitary-gonadal axis is relatively quiescent. Inhibin B is
a dimeric glycoprotein produced by the gonads, secreted from Sertoli cells in
males32,106. In the adult male inhibin B plays an important role in spermatogenesis,
mediated in part by inhibition of FSH secretion. There is increasing evidence
reporting that the prepubertal gonads are not quiescent and have a low level of
activity. The role of inhibin B as a marker of early gonadotoxic effects of
chemotherapy was investigated in prepubertal children treated for cancer.
5.2. Patients and methods
5.2.1. Patients
Stored plasma was analysed from blood samples collected for previous prospective,
longitudinal studies exploring the effects of chemotherapy on growth and bone
turnover107. The original studies and their extension to this study were approved by
the Lothian Paediatric and Reproductive Medicine Research Ethics Sub-Committee.
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The previous studies involved sequential recruitment of 29 boys, median age 4.5y
(range 1.2 - 15.3y), with a variety of haematological and solid malignancies over a
two year period. From this cohort were excluded patients for whom there was
insufficient plasma stored pre- or during treatment (n = 8) and post-pubertal patients
(n = 5). The study group consisted of 16 clinically prepubertal children with a
median age (range) at diagnosis of 4.5y (1.2 - 12.8y) and underlying malignancies
included acute lymphoblastic leukaemia (ALL, n = 6), neuroblastoma (n = 4), non-
Hodgkin's lymphoma (n = 3), rhabdomyosarcoma (n = 1), osteosarcoma (n = 1) and
Wilms' tumour (n = 1). Children with solid tumours (n = 10) were treated with
multiagent chemotherapy regimens in accordance with United Kingdom Children's
Cancer Study Group (UKCCSG) protocols. Children with ALL (n = 6) were treated
with the MRC UKALL XI protocol. Blood samples had been collected from patients
with solid malignancies (n = 10) before and during chemotherapy (median number of
cycles: 7, range 4 - 14) and from patients with ALL (n = 6) pre-treatment and at the
end of week 6 (after completion of induction and first intensification). In 7 of the 16
children treated for cancer, follow-up blood samples were also available between 1
and 6 months after completion of chemotherapy.
5.2.2. Methods
Following collection, blood samples were separated immediately and plasma was
stored at -70°C until analysis. Dimeric inhibin B was measured in duplicate by a
double antibody enzyme-linked immunosorbent assay, using a monoclonal antibody
raised against a synthetic peptide from the PB subunit, combined with an antibody to
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an inhibin a subunit sequence, as described95'108. The assay detection limit was 8
ng/L. Within and between assay coefficients of variation were 9.6% and 13.0% at 19
ng/L, 7.4% and 10.6% at 88 ng/L, and 8.4% and 10.2% at 233 ng/L respectively.
FSH and LH were measured in duplicate by Delfia time-resolved
immunofluorescence assays (Wallace, Milton Keynes, United Kingdom),
standardised against the second International Reference Preparation of pituitary
LH/FSH 78/549. Assay detection limits were 0.3 U/L for FSH and 0.2 U/L for LH.
Between-assay CVs for FSH were 6.5% at 5.2 U/L, 3.5% at 10.4 U/L and 3.6% at
35.3 U/L, and for LH were 5.9% at 6.4 U/L, 5.5% at 11.3 U/L and 4.4% at 18.7 U/L.
(These assays were carried as a service by the biochemistry department of the Royal
Hospital for Sick Children, Edinburgh, under the guidance ofDr P. Crofton).
5.2.3. Data analysis
Inhibin B levels in the blood vary with age and sex. Data are presented both as
absolute concentrations (ng/L) and as SD scores calculated for age and sex following
log-transformation, based on our own published data108. Group results are presented
as medians and ranges. Within-individual changes through time were evaluated by
Wilcoxon matched pairs.
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5.3. Results
Inhibin B levels were appropriate for age with no significant changes before, during
and after treatment in all but one boy (Table 5.1)108. FSH and LH levels remained
prepubertal in all patients pre-, during- and post- treatment (Table 5.1). Following
completion of treatment, six of the seven boys showed little change in inhibin B
(Figure 5.1). In one patient (aged 2yrs), inhibin B levels decreased to undetectable
levels following completion of treatment with alkylating-agent based gonadotoxic
2 2
chemotherapy (cyclophosphamide, 4.4 g/m", cis-platin 320 mg/mf and melphalan
200mg/m2) with no post-treatment increase in gonadotrophins (FSH 0.8 U/L, LH
<0.2 U/L).
Table 5.1. Median (range) of inhibin B, FSH and LH levels in boys before,
during and after chemotherapy
Before During After
N * 16 (10) 16(10) 7(6)
Inhibin B (ng/L) 93 (77, 244) 85 (58,261) 94 (<8, 170)
Inhibin B (SDS) -0.3 (-1.9,+1.8) -0.62 (-1.8,+1.8) -0.18 (<-7.0,+1.4)
FSH (U/L) <0.3 (<0.3, 1.2) <0.3 (<0.3, 0.8) 0.4 (<0.3, 2.6)
LH (U/L) <0.2 (<0.2, 0.3) <0.2 (<0.2, <0.2) <0.2 (<0.2, 0.3)
* Total number of children with cancer (number with solid tumours).
SDS, SD score according to age and sex.
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Stage of treatment
Figure 5.1 Inhibin B levels in individual boys with cancer before, during and
after treatment. Inhibin B is plotted on a log scale. The dotted line represents the
detection limit of the inhibin B assay.
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5.4. Discussion
Inhibin B, produced from Sertoli cells, mediates non-steroidal negative feedback
from the testes, reflecting the number of spermatozoa produced and regulating FSH
secretion109. Inhibin B secretion in the adult requires the presence of germ cells and in
the prepubertal boy may reflect continuous Sertoli cell proliferation and functional
activity together with maturation of early germ cells and spontaneous degradation.
Men with complete absence of germ cells (Sertoli cell only syndrome, SCOS), severe
hypospermatogenesis and spermatogonial and/or spermatocytic arrest have lower
inhibin B levels and higher FSH levels than normozoospermic controls"0"112.
Gonadotoxic chemotherapy in men is associated with a decrease in circulating
inhibin B during treatment113. A recent retrospective study of adult male survivors of
childhood brain tumours found lower inhibin B and higher FSH levels in those
treated with a combination of chemotherapy and radiotherapy compared with those
treated with radiotherapy alone114. Another retrospective study of male survivors of
childhood cancer found that previous treatment with alkylating agents was associated
with low inhibin B and high FSH levels in postpubertal patients but normal inhibin B
and variable FSH levels in pubertal patients65. Andersson and co-workers have
demonstrated that, although men with SCOS have generally undetectable levels of
inhibin B, prepubertal boys with acquired SCOS caused by irradiation/chemotherapy
for ALL have normal prepubertal levels of inhibin B"5. Follow-up post-pubertal
samples from the same SCOS boys had undetectable inhibin B.
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In this longitudinal study, boys with cancer had normal inhibin B levels before
treatment started and these changed little during and after chemotherapy except for
one boy with neuroblastoma treated with relatively high doses of known gonadotoxic
agents, cyclophosphamide, cisplatin and melphalan5'9,4447 in whom inhibin B became
undetectable following completion of treatment, suggestive of Sertoli cell damage.
This may reflect damage to the seminiferous epithelium and long-term follow-up and
monitoring of testicular function will be essential. The results show that inhibin B
levels were normal in boys with ALL throughout treatment, including year 2 of
continuing chemotherapy (data not shown), consistent with reports of normal
testicular function and normal spermatogenesis in most male survivors of childhood
ALL45'64. FSH and LH remained low or undetectable in all prepubertal boys with
cancer before, during and after treatment, illustrating their insensitivity as markers of
gonadal damage before the onset ofpuberty.
In prepubertal boys, chemotherapy had little immediate effect on Sertoli cell
production of inhibin B, although one boy showed a delayed deleterious effect.
Inhibin B changed earlier and appeared to be a more sensitive marker of gonadal
damage than FSH or LH. We conclude that inhibin B may be a useful addition to
sensitive measurements of FSH in the evaluation of early gonadotoxic effects of
chemotherapy in prepubertal children. This pilot study has not addressed the long-
term implications for future fertility. Further studies are planned, combining inhibin
B with FSH, LH and sex hormone measurements, to assess long-term reversibility
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and delayed effects, particularly as the children approach and progress through
puberty.
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Chapter 6
Investigation of suppression of the hypothalamic-
pituitary-gonadal axis to restore spermatogenesis in
azoospermic men treated for childhood cancer
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6. Investigation of suppression of the hypothalamic-pituitary-gonadal
axis to restore spermatogenesis in azoospermic men treated for
childhood cancer
6.1. Background to fertility preservation
Advances in assisted reproduction and increasing interest in gamete extraction and
maturation have focused attention on preserving gonadal tissue from children before
sterilising chemotherapy or radiotherapy, with the realistic expectation that future
technologies will be able to utilize their immature gametes. The impetus for preserving
gonadal tissue follows on the heels of pioneering experiments in ewes116, together with
media interest in the report of a successful autologous ovarian graft in a previously
oophorectomized female. In addition live human births have been reported resulting
from the transfer of embryos fertilized with immature spermatogenic cells116"122. Such
issues have inevitably raised questions from parents and oncologists about their possible
application in children undergoing cancer therapies28,123.
6.1.1. Established practice
6.1.1.1. Cryopreservation of gametes
Potential strategies for preservation of male fertility are dependent upon the sexual
maturity of the patient. The only established current clinical option for preservation of
male fertility is cryopreservation of spermatozoa (Table 6.1). Spermatozoa are usually
obtained from the ejaculate by masturbation but may be obtained using rectal
electrostimulation techniques under anaesthetic. When it is not possible to obtain an
ejaculate, sperm can be retrieved by epididymal aspiration or testicular biopsy in
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sexually mature men. The onset of spermatogenesis, or spermarche, is difficult to
determine. Spermarche is a mid-pubertal event, preceding the ability to produce an
ejaculate, which occurs at a median age (range) of 13.4 (11.7-15.2) years when median
testicular volume is 11.5 (4.7-19.6) mis124. Once spermarche is established, studies of
serial urine specimens have shown that spermaturia is a variable, intermittent process
throughout puberty125"131. Peripubertal males with spermaturia may identify a population
of males who are able to produce sperm but not yet mature enough to produce a sample
by masturbation. Surgical retrieval of spermatozoa may be considered for this group. In
view of the clinical application of this investigation we proposed to determine the
testicular volume at which spermaturia could reliably be expected to occur and to
establish the number of days lequired to analyse the urine to detect 90% of those cases
in whom spermarche had been achieved. Unfortunately, in a small pilot study the sperm
concentration in urine from men immediately following ejaculation was very low
making it highly unlikely that the detection rate in pubertal boys, where
spermatogenesis is only just beginning, would be significant. Therefore, this study was
not pursued.
Not infrequently, sperm produced by cancer patients at the time of diagnosis is of poor
quality. With advances in assisted reproduction techniques, in particular
intracytoplasmic sperm injection (ICSI), which involves the injection of a single
spermatozoan directly into an ooctye, the problems of low numbers and poor motility
may be cirvcumvented21"23. More recently a small number of pregnancies have been
achieved with ICSI using immature spermatids and secondary spermatocytes extracted
from testicular tissue in men with spermatogenic arrest116"122.
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6.1.2. Experimental strategies (Table 6.1)
Efforts to develop strategies to preserve fertile potential have focused largely on two
areas, namely hormone manipulation and cryopreservation of testicular tissue.
6.1.2.1. Hormone manipulation
Following the hypothesis that the relatively quiescent prepubertal testis was less
susceptible to the deleterious effects of chemotherapy and radiotherapy132 it was
postulated that inducing a prepubertal state by gonadal suppression would afford some
protection to the testis during cytotoxic therapy. Although it is clear that cytotoxic
Lheiapy is gonadotoxic at all ages13, the concept of manipulating the testiculai milieu by
gonadotrophin suppression has met with encouraging results in animal studies. We
explored this approach in humans and the results from our study are described in this
chapter.
6.1.2.2. Harvesting testicular tissue
For prepubertal boys, lacking in haploid gametes, there are no options currently
available to preserve fertility, and any potential strategies must be considered entirely
experimental. In theory testicular tissue could be removed before the start of treatment
and cryopreserved either as a segment of tissue or as isolated germ cells. Following cure
from his malignancy, the patient could have the frozen-thawed testicular tissue auto
grafted to the testes. Alternatively, isolated germ cells could be re-implanted into the
patient's own testes or these cells could be matured in vitro until they reached a stage
sufficiently mature to achieve fertilization with ICSI.
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The concept of testicular germ cell transplantation was pioneered by Brinster and
colleagues in 199425. Testicular germ cells isolated from mouse testis and transplanted
into the testis of genetically or experimentally sterile mice initiated and sustained
normal donor spermatogenesis, restoring fertility and producing healthy offspring133.
Successful transplantation has also been shown in mouse recipients rendered sterile with
the chemotherapeutic agent, busulphan. Interestingly these experiments also
demonstrated both endogenous and donor spermatogenesis simultaneously, indicating
that busulfan did not kill all the endogenous stem cells25. Subsequent studies have
shown that testicular germ cell transplantation can occur through autologous,
heterologous (mouse-to mouse, rat-to-rat) or xenologous (hamster, dog, rabbit or rat to
mouse) transfer of cells. The site can be heterotopic, as graft to a non-gonadal site in
the recipient, or homotopic when the cells are reintroduced into the testis25"27,134,135. In
order to develop autologous germ cell transplantation in humans, techniques have to be
developed by which human testicular germ cells can be isolated, stored and
reintroduced into the testis.
Testicular tissue obtained by testicular biopsy has been successfully cryopreserved with
subsequent isolation of spermatozoa from the thawed tissue and successfully used in
ICSI136,137. These studies have only utilised spermatozoa or immature spermatogenic
cells retrieved from tissue post thaw and it may be that survival of spermatogonial germ
cells post-thaw is poor. Furthermore as there is a more than theoretical risk of
transplanting tumour cells, it is likely that clinical practice will involve enzymatic
digestion and isolation of germ cells before cryopreservation rather than autografting
testicular tissue.
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Transplantation in rodent models has involved only semi-purified cell populations of
germ cells and somatic cells. For human application, purified stem cell populations
would be necessary to ensure that no malignant cells were transferred. The term 'stem
cell' is a functional description, given that there are no morphological, antigenic or
biochemical criteria by which to identify these cells in vivo or in vitro. Spermatogonial
transplantation is the only method at present by which stem cell presence can be
authenticated. In mice LacZ encodes for the enzyme B-galactosidase, which can be
demonstrated histochemically as an intracellular blue reaction product. Effective
purification will demand the development of specific antibody probes to differentiate
stem cells from other cells. Studies have shown that a number of cell surface antigens
are expressed on stem cells, including alpha-6, beta-1 integrin and c-kit, which may
enable enrichment using magnetic cell sorting138. The major limitation for human
application is that these antigens are shared with other progenitor cells including
haematopoietic cells, creating inherent problems in cancer patients.
The process of spermatogenesis begins in puberty although a number of immature
spermatogenic cells are described in the prepubertal testis. It is believed that 104 germ
cells contain as few as 2 stem cell spermatogonia capable of self-renewal. With the
average number of germ cells in the testis estimated to range between 13-83 x 106
during childhood, the relatively small numbers of stem cell spermatogonia available
poses a challenge for the process of stem cell isolation35. Consequently, there is a need
to develop an in vitro culture system to augment stem cell numbers following harvesting
and isolation. The feasibility of enrichment has been shown by Nagano et al who have
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maintained mouse stem cells in culture for up to 4 months and the cultured cells
initiated successful spermatogenesis following transplantation139.
Cryopreservation of spermatozoa and fertilisation following thawing are well
established. Application of this approach to stem cell spermatogonia will require
modification and optimisation of freezing procedures, taking into consideration the
inherent biological differences between the immature diploid stem cells and mature
gametes140. There is thus a need for studies to devise cryopreservation regimens that are
applicable to stem cells from the pre-pubertal testis.
6.1.2.2.1. Future use of cryopreserved testicular tissue
The future use of testicular germ cells is likely to involve either maturation of the germ
cells in vitro for use with ICSI or transplantation. Ideally transplantation would involve
injecting preparations of purified germ cells into the testis with restoration of natural
fertility. In vitro maturation techniques, although still very much in their infancy, would
have the advantage of eliminating any risk of transplanting harvested malignant cells
back into the patient. Creating an environment in vitro to stimulate germ cell maturation
and differentiation into spermatozoa may be the only option for a number of patients in
whom cancer therapy damage has been so extensive that the supporting Sertoli cells
would be unable to support spermatogenesis. Attempts to cultivate male germ cells in
vitro have shown that germ cells can survive several months in culture and are likely to
be undergoing cell division141. Tesarik reported in vitro spermatogenesis and healthy
offspring using ICSI. However, the maturation process involved in vitro maturation of
late stages of spermatogenesis rather than development from early germ cells141142.
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A number of studies have concentrated on developing the most efficient technique for
infusing the stem cells into the testis. The simplest and most effective method of filling
the seminiferous tubules in vitro has proved to be by injection into the rete testis of bull,
monkey and man, under ultrasound guidance143. These experiments involved injection
into partially involuted or prepubertal testes. This eliminates the problems associated
with backpressure of fluid in fully active testes, which would otherwise block the
infusion of the cell suspension into the tubules. Successful in vivo rete injections have
been performed on cynomologus monkeys treated with GnRH antagonist. Injecting the
cells into the rete allows a much larger volume to be infused in contrast to the micro¬
injections involved in re-infusing directly into the seminiferous tubules143. Further work
is required to perfect this technique for human application.
Immature testicular tissue has been shown to grow and differentiate when grafted into
another species26. This provides an additional strategy for conserving the male germ line
and circumvents the risk of reintroducing malignant cells. Clearly this technique is
unlikely to be ethically acceptable and is compromised by the risk of interspecies
transfer ofpotentially pathogenic micro-organisms.
80
Male fertility in survivors of childhood cancer Chapter 6
Table 6.1. Clinical and experimental strategies for preservation of male
reproductive function in children undergoing treatment for cancer
Clinical practice Experimental strategies
Sperm banking Cryopreservation of testicular tissue
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6.2. Introduction
A number of approaches to preserving fertility have been investigated based on the idea
that suppression of spermatogenesis might protect the normally rapidly dividing germ
cell population from damage. Suppression of the rat hypothalamic-pituitary-gonadal (H-
P-G) axis by administration of the gonadotrophin releasing hormone (GnRH) analogue,
goserelin, before and during chemotherapy with procarbazine, enhanced recovery of
spermatogenesis144. Similarly, protection of spermatogenesis in rats subjected to
treatment with procarbazine, cyclophosphamide and radiotherapy has been
demonstrated using a number of hormones including testosterone alone145 or in
combination with oestrogen146, GnRH analogues in combination with testosterone"17 01
the anti-androgen flutamide148'149.
Furthermore, recovery from spermatogenic damage in rats induced by radiotherapy or
procarbazine treatment has been shown to be enhanced by treatment with GnRH
analogues or testosterone even when administered after the gonadotoxic agent147150,151.
The mechanisms by which such hormonal manipulation offers protection or
enhancement of recovery of spermatogenesis are unclear. Hormonal analysis following
irradiation in rats has shown a dramatic increase in intratesticular testosterone levels and
it has been postulated that suppression of the H-P-G axis promotes multiplication and
differentiation of spermatogonia by lowering testosterone concentrations within the
testis150. While there is significant evidence for the success of protection/recovery
strategies in rats, clinical studies in man to date have been unsuccessful152"155 and there
have been no trials investigating the effects of post-gonadotoxic hormonal suppression.
The present study has investigated whether suppression of the H-P-G axis in men
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rendered azoospermic by treatment for childhood cancer might restore spermatogenesis,
using both semen analysis and testicular biopsy as end points156. There is little
information available on testicular histology in survivors of childhood cancer. To help
further our understanding of the impact of sterilizing cancer therapy on testicular
function we studied testicular histology in depth using immunohistochemical
techniques.
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6.3. Patients and Methods
The study was approved by the Lothian Paedialric and Reproductive Medicine Reseaieh
Ethics Sub-Committee and all patients gave written informed consent.
6.3.1. Patients
A review of the oncology database at the Royal Hospital for Sick Children, Edinburgh
for men rendered azoosperrnic secondary to treatment for childhood cancer, identified
seven men age 22.2 (18-25.3), median (range) years. These men formed part of the
group of ten men with azoospermia identified in our studies assessing semen analysis
and spermatozoal DNA integrity in survivors of childhood cancer (Chapter 4). The
remaining three men were not identified until after the commencement of the hormone
study. The men were invited to participate in the study regardless of the underlying
malignancy or cytotoxic therapy and all seven accepted. The three men not identified
early enough to be invited into the study, did not diffei in terms of underlying diagnosis
and severity of treatment. For the seven study patients, the median age at original
diagnosis was 10.4 (4.4-13.3) years with a disease free survival of 8.4 (3.3-14.7) years.
The underlying malignancies were acute lymphoblastic leukaemia (n=2), Hodgkin's
disease (n^M-) and non-Hodgkin's lymphoma (n=l). A summary of the patients'
diagnoses with details of the gonadotoxic chemotherapy and radiotherapy received is
given in Table 6.2. Clinical assessment and routine haematological and biochemical
assessment was performed on each patient to ensure that there was no evidence of
disease relapse or second primary malignancy, or other reason likely to impair
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6.3.2. Assessment of testicular function
Pubertal maturation was assessed according to the Tanner criteria and testicular
volume (ml) was measured using a Prader Orchidometer38. The mean value of the
two testes was taken to represent the subject's testicular volume. Venous blood
samples were collected (20ml), and LH, FSH and testosterone levels were measured
using an automated immunoassay analyser (Bayer Immuno 1). Inhibin B was
measured as previously described95, with the limit of assay sensitivity being
7.8pg/ml. Semen samples were collected in a room adjacent to the laboratory, by
masturbation into sterile wide mouthed non-toxic containers, following an abstinence
period of at least 48 hours. Samples were centrifuged at 3000 x g for 30 minutes and
the pellet examined to confirm azoospermia96. Seminal plasma was stored at -70°C
until assayed for inhibin B65. Testicular biopsy under general anaesthetic was
undertaken on all patients at the start of the study to exclude obstructive
azoospermia. The specimens were fixed in Bouins fixative and after routine
processing and paraffin embedding, sections were cut at 5|im and examined. A
second biopsy of the same testis was performed at the end of the study.
6.3.3. Hypothalamic-pituitary-gonadal axis suppression
All men underwent a period of suppression of the H-P-G axis, designed to induce
hypogonadotrophic hypogonadism with reduced intratesticular testosterone levels for
a period of approximately 24 weeks, followed by a recovery period of 24 weeks.
Following testicular biopsy, subjects were administered depot medroxyprogesterone
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acetate (DMPA, 300mg i.m.: Pharmacia and Upjohn, Milton Keynes, UK) and
testosterone pellets (4x 200mg s.c., NV Organon, Oss, The Netherlands).
Administration of DMPA was repeated 12 weeks later. Subjects were reviewed at 6
weekly intervals throughout the 48 weeks of the study for clinical assessment, blood
sampling and semen analysis.
6.3.4. Immunohistochemistry of testicular tissue
The objective of the immunohistochemical analysis was to investigate whether or not
any germ cells, in any developmental stage, were present in the testes of patients
before or after H-P-G suppressive treatment. This was achieved using
immunoexpression of the MAGE-57B antigen and androgen receptor (AR). The
MAGE-57B antigen is expressed in early germ cells, strongly in spermatogonia and
weakly in early spermatocytes157. Androgen receptor is expressed in the nuclei of all
Sertoli cells but not in the nuclei of any germ cells that might be present158. In
addition, detailed evaluation of the extent of testicular damage was assessed by
immunoexpression of androgen receptor (AR), specific for Sertoli, Leydig and
peritubular cells: inhibin a and (3B subunits, which localize to Sertoli and Leydig
cells, and Sertoli cells respectively: expression of steroidogenic enzymes 3|3-HSD
and 17a-hyroxylase as markers of Leydig cell function.
Unless otherwise stated, all incubations were undertaken at room temperature.
Sections were deparaffinized in xylene, rehydrated in graded ethanols and washed in
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water. A temperature-induced antigen retrieval step was required for androgen
receptor, inhibin a- and p-B and 3|3-HSD antigens. The sections were pressure
cooked in 0.01M citrate buffer for androgen receptor, inhibin a- and 3[3-HSD or
0.01M glycine buffer for inhibin [3-B, pH 6.0 for 5 minutes at full pressure, allowed
to stand for 20 minutes, cooled in running tap water and washed twice in (5 minutes
each wash) in Tris-buffered saline (TBS: 0.05 mol Tris-HCL, pH 7.4, 0.85% (w/v)
NaCl). Endogenous peroxidase activity was then blocked by immersing sections in
3% (v/v) H2O2 in methanol (both from BDH Laboratory Supplies, Poole) for 30
minutes, followed by two 5 minute washes in TBS. Sections were incubated for 30
minutes with the appropriate normal serum diluted 1:5 in TBS containing 5% bovine
serum albumin (BSA: Sigma) to block non-specific binding sites. Normal swine
serum (NSS) was used for androgen receptor and 3|3-HSD; normal goat serum
(NGS) for 17a-OH and normal rabbit serum (NRS) for inhibin a- and (3-B and
MAGE-57B (from Diagnostics Scotland, Carluke). Primary antibodies were added to
the sections at the appropriate dilution in either NSS-TBS-BSA (for androgen
receptor 1:2000: AR N-20, Santa Cruz Biotechnology SC0816; for 17 a-
hydroxylase 1:2000, from, for 3p-HSD 1:2000, gifted from Professor I Mason),
NRS-TBS-BSA (for inhibin a- 1:1000: 173.9K; inhibin (3-B 1:6000, 12/13, both
gifted from Professor N Groome, Oxford Brookes University; MAGE-57B: 1:50,
gifted from G Spagnoli) and incubated overnight at 4°C in a humidified chamber.
The sections were washed twice in TBS and then incubated for 30 minutes with anti-
rabbit or horseradish peroxidase-labelled polymer (EnVision: DAKO, Ely) for
88
Male fertility in survivors of childhood cancer Chapter 6
androgen receptor, 3P-HSD and 17a-OH or anti-mouse for inhibin a- and P-B and
MAGE-57B. Sections were washed twice (5 minutes each) in TBS and
immunostaining was developed using Liquid DAB (DAKO) until staining was
optimal, when the reaction was stopped by immersing sections in distilled water. The
sections were counter-stained with haematoxylin, dehydrated in graded ethanols,
cleared in xylene and cover-slipped using Pertex mounting medium (CellPath pic,
Hemel Hempstead, UK). As negative controls, slides were processed as above except
that the appropriate normal serum was substituted for the primary antibody.
Immunostained sections were examined and a mean of 132 (range 40-252) tubular
cross-sections were counted for each specimen. The sections were photographed
using an Olympus Provis microscope (Olympus Optical, Honduras Street, London,
UK) fitted with a digital camera (Kodak DCS330: Eastman Kodak, Rochester, NY,
USA). Captured images were stored on a computer (G4; Apple Computer Inc.,
Cupertino, CA) and compiled using Photoshop 5.0 before printing using an Epson
Stylus 870 colour printer (Seiko Epson Corp., Nagano, Japan).
6.3.5. Statistical analysis
Statistical analysis was performed by the Statistical Package for Social Science
(SPSS Inc., Chicago, III) version 10.0. For each individual patient hormone
concentrations at the beginning and end of the study were compared using t-tests and
a p < 0.05 was considered significant.
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6.4. Results
6.4.1. Clinical features
All seven men were Tanner stage V with reduced testicular volumes of 11 (5-12) ml,
mean (range) (Table 6.3). There were no changes in clinical features during the study
and no changes in testicular volume.
6.4.2. Hypothalamic-pituitary-gonadal axis suppression
MPA/testosterone treatment was well tolerated and there were no adverse effects.
One man reported increased libido during the first 12 weeks of the study. Pre-
treatment serum FSH levels were elevated, 22.4+4.4 U/L (mean+SEM, reference
range: 1.5-9 U/L), in keeping with damage to the seminiferous epithelium (Table
6.3). Serum LH concentrations pre-treatment were 9.0+1.8 U/L (reference range: 1.5-
9 U/L) and testosterone 17.9+1.5 nmol/L (reference range: 10-30 nmol/L), indicating
compensated Leydig cell dysfunction (Table 6.3). Serum and seminal plasma inhibin
B concentrations were barely detectable in all but one subject (subject no. 1: 35 ng/L
and 770 ng/L respectively; Table 6.3).
FSH was suppressed to undetectable concentrations during MPA/testosterone
treatment for 12 weeks, and remained partially suppressed during the subsequent 12
weeks (Figure 6.1). Thereafter, there was a gradual rise by weeks 42-48 to 19.5 +3.6
U/L, which was not significantly different from pre-treatment concentrations. LH
showed a similar pattern to FSH, with suppression to undetectable concentrations for
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12 weeks, followed by gradual recovery to 8.9 +1.6 U/L at 48 weeks (Figure 6.1b).
There was no statistically significant difference between LH concentrations pre-
treatment and at 48 weeks.
Conversely, testosterone concentrations rose initially following MPA/testosterone
administration to a peak of 29.7 +1.9 nmol/L at 6 weeks, close to the upper limit of
the normal range. This was followed by a gradual decline to a nadir of 10.2 ±0.2
nmol/L at 30 weeks, with a subsequent slight rise to 13.8 +1.9 nmol/L at weeks 42-
48. The latter was not significantly different from the pre-treatment concentration.
Serum inhibin B concentrations increased from 35 ng/L to 60.9 ng/L at 12 weeks in
the subject with the highest inhibin B pre-treatment, and rose from <15ng/L to low
but detectable concentrations (range 16- 35 ng/L) in the 5 other subjects (venous
serum reference range: mean 257, 95%CI 231-284ng/L). Serum inhibin B
concentrations fell toward the end of the study, becoming undetectable in all subjects
other than the individual with the highest pre-treatment concentration at weeks 42-
48. This same individual was the only subject with readily detectable seminal
plasma inhibin B concentration pre-treatment (770 ng/L, vs <20 ng/L in the others,
seminal plasma reference range: mean 2279, 95% CI 698-3864ng/L)32. Seminal
plasma inhibin B was not determined during MPA/testosterone treatment as the
volume of the ejaculate was insufficient. In all subjects seminal plasma inhibin B
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Weeks
Figure 6.1. Serum concentrations of FSH, LH and testosterone in the seven patients before (time
0) and during combined treatment with medroxyprogesterone acetate and testosterone.
Values are mean + SEM. Dashed lines show the limit of the assay sensitivity (FSH, LH) or the upper
and lower limits of the normal range (testosterone). Hormone levels at 42-48 weeks are not
significantly different from pre-treatment (time 0) values in each instance.
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6.4.3. Semen analysis
All men remained azoospermic throughout the study.
6.4.4. Testicular tissue
6.4.4.1. Light microscopy
Examination of testicular tissue pre- and post H-P-G axis suppression demonstrated
interstitial fibrosis, thickening of the basement membrane and atrophy of the
seminiferous tubules with complete absence of all germ cells, in contrast to the
abundant different germ cell types in the normal seminiferous epithelium of a healthy
adult man (Figure 6.2). This was representative of all seven cancer survivors.
6.4.4.2. Immunocytochemistry
Androgen receptor (AR)
The nuclei of all cells within the seminiferous epithelium of all patients
immunoexpressed AR (Figure 6.3(a) - brown staining), and this was comparable
before MPA/testosterone treatment and at the end of the study (Figure 6.3(b)), in
contrast to AR negative germ cells evident in the testis of a healthy adult man (Figure
6.3(c)). This finding suggested that only Sertoli cells were present within the tubules
of the cancer patients. Using the methodology applied in the current study, all
Sertoli cells in the human testis immunostained for AR with similar intensity'58,
although application of modified methods can reveal differences in staining intensity
between different Sertoli cells in the normal adult testis159.
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MAGE-57B antigen
Immunoexpression ofMAGE-57B was negative in all specimens, pre and post H-P-
G axis suppression, in contrast to the abundant immunopositive germ cells seen in
the healthy adult control (Figure 6.3(d)-(f)). This confirmed the absence of
spermatogonia in the cancer patients.
Inhibin a and J3B subunits
Testicular tissue from all seven cancer survivors expressed inhibin a and -pB
subunits in Sertoli and Leydig cells, and Leydig cells respectively and representative
examples are illustrated in Figure 6.4(a) and (c) comparable to controls, panels (b)
and (d).
3/3-HSD and 17a-OH
Leydig cell immunoexpression of the steroidogenic enzymes, 3P-FISD and 17a-OFI,
in the cancer patients (Figure 6.4 (e) and (g) respectively) was comparable to
expression in healthy adult controls (Figure 6.4 (f) and (h)).
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Figure 6.3.
Androgen receptor staining: Panels (a) and (b) show AR immunoexpression pre-
and post- H-P-G axis suppression, respectively, and demonstrate that all cell nuclei
within the seminiferous tubules are androgen receptor immunopositive (brown
staining), thus excluding the presence of AR negative germ cells, as evident in the
testis of a healthy adult man (c). Inset shows negative control in which the primary
antibody was omitted. Scale bars denote 50 pm.
MAGE-57B staining: Panels (d) and (e) shows no evidence of expression of the
MAGE-57B antigen (all cells stained blue), both pre-and post- H-P-G axis
suppression. In contrast to the abundant germ cells immunopositive (brown staining)
for MAGE-57B demonstrated in the healthy adult control (f). Insert shows negative
control in which the primary antibody was omitted. Scale bars denote 50 pm.
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Male fertility in survivors of childhood cancer Chapter 6
Figure 6.4.
Inhibin a and pB subunits. Panel (a) illustrates immunoexpression of inhibin a in
Sertoli and Leydig cells of the testicular tissue from the cancer survivor, comparable
to that of the healthy control sample shown in (b). Inhibin pB immunoexpression in
Leydig cells is similar in the cancer survivor and in the healthy adult control, shown
in panels (c) and (d) respectively.
3p-HSD and 17a-OH. Panels (e) and (g) illustrate immunoexpression of 3p-HSD
and 17a-OH in Leydig cells in the cancer patients comparable to expression in the
healthy adult controls, panels (f) and (h) respectively.
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6.5. Discussion
This study demonstrates that suppression of the H-P-G axis for at least 3 months, in
men rendered azoospermic by gonadotoxic chemotherapy or radiotherapy for
childhood cancer did not result in restoration of spermatogenesis, assessed by both
semen analysis and testicular biopsy. In rats, it has been shown that some germ cells
survive some types of cytotoxic therapy and that the resulting azoospermia is a
consequence of the inability of those spermatogonia that are present to proliferate
and differentiate40. Suppression of the H-P-G axis facilitates recovery of
spermatogenesis following such treatment, and it has been hypothesised that this is
the result of a reduction in intratesticular testosterone concentrations150. This can be
achieved by administration of steroid hormones, or GnRH agonists or antagonists
with or without testosterone before, during or after chemotherapy or radiotherapy
and such regimens have been demonstrated to enhance recovery of spermatogenesis
in rats144"149160. Application of this approach to humans makes the important
assumption that the mechanism of cytotoxic chemotherapy- or radiotherapy-induced
testicular damage is similar in both species, and it has been assumed that like the rat,
men might retain a population of spermatogonial stem cells from which
spermatogenesis could be regenerated. The mechanism and permanency of impaired
spermatogenesis induced by some forms of chemotherapy/radiotherapy in the human
may differ more substantially from the rat than was previously appreciated.
The success of hormonal treatment to aid recovery of spermatogenesis in rats
subjected to chemotherapy is believed to be based on lowering intratesticular
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testosterone levels. While the prepubertal testis is relatively quiescent there is a
steady turnover of early germ cells, which undergo spontaneous degeneration before
maturation is reached35. This relatively low activity, compared to the adult, does not
protect the prepubertal testis from the deleterious impact of cytotoxic therapy, as the
present data confirm. The slow turnover of germ cells and their subsequent
degeneration in the prepubertal testis may be partly due to low levels of
intratesticular testosterone, which is required to complete the end-stages of
spermatogenesis162. The lack of protection afforded to the prepubertal testis, at a time
when testosterone levels are low, would suggest additional environmental factors
play a role in the successful recovery of spermatogenesis in rats and the vulnerability
of the prepubertal human testis to cytotoxic therapy. In this regard, our studies with
the marmoset, a primate surrogate for man, have demonstrated that activation of
testicular cell function occurs well before puberty and is largely gonadotrophin-
dependent, but that spermatogonial replication appears to be independent of
gonadotrophin stimulation33.
In one study in which cyclophosphamide was administered as immunosuppressive
therapy for nephrotic syndrome in adult men, preservation of fertility was achieved
via supraphysiological testosterone therapy152. Of fifteen men treated with
cyclophosphamide, five received testosterone to suppress testicular function before
and during the eight-month cycle of chemotherapy. All men were azoospermic or
severely oligozoospermic within six months of commencing cyclophosphamide.
Nine of the ten men who received cyclophosphamide alone remained azoospermic
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six months after the end of immunosuppressive therapy, whereas sperm
concentrations returned to normal in all five of the men who received testosterone
therapy. High dose cyclophosphamide is known to be associated with impaired
spermatogenesis, which is often temporary and it is probable that in this study the
simultaneous administration of testosterone with cyclophosphamide provided some
protection or hastened the recovery of spermatogenesis. It would be interesting to
have long-term follow-up data on the ten patients who received cyclophosphamide
only treatment to enable a direct comparison with the natural history of recovery of
sperm production. In contrast, other studies have failed to show similar benefits in
humans. For example, suppression of testicular function with a GnRH agonist, alone
or in combination with testosterone during gonadotoxic chemotherapy treatment for
lymphoma did not confer any protective benefit or enhance recovery of
spermatogenesis153,154. A number of reasons may be considered for the lack of
successful outcome in the aforementioned studies. The number of patients and
controls studied was small and the cancer therapies variable, in contrast to
monotherapy with cyclophosphamide for a non-malignant condition. Treatment
regimens may not have been sufficiently gonadotoxic to cause sterility, so no
recovery effect could be seen or, conversely, the agents were so gonadotoxic that
permanent ablation of all germ cells was induced. Waxman and co-workers studied
the protective effects of a GnRH agonist during the treatment of 20 men with
cytotoxic chemotherapy for advanced Hodgkin's disease. Following administration
of the GnRH agonist, standard GnRH testing demonstrated adequate suppression of
LH, but not of FSH, throughout the chemotherapy treatment154. Follow-up
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assessment of the men after a three year interval showed that all remained severely
oligozoospermic154. In another study the effect of GnRH agonist administration
during combination chemotherapy for advanced lymphoma was evaluated in six
patients153. By six years post treatment, only one patient demonstrated any evidence
of spermatogenesis. Similar unsuccessful results were obtained using GnRH
analogues during cis-platinum chemotherapy for teratoma155. While the present study
explored the delayed suppression aspect of this hypothesis, no human studies have
combined pre-chemotherapy suppression with continued suppression for a significant
length of time following chemotherapy.
A number of steroid hormone combinations have been used to suppress the H-P-G
axis in rats and successfully restore spermatogenesis, including medroxyprogesterone
acetate in combination with testosterone40'162,163. Low dose testosterone,
medroxyprogesterone acetate or GnRH analogues alone have been shown to
stimulate recovery of spermatogenesis in rats following sterilization with
radiotherapy. However, the addition of testosterone to GnRH analogues may reduce
the effectiveness of GnRH analogues164. The combination of testosterone with MPA
may also have a reduced effect compared to either agent alone although this
combination results in a profound reduction in intratesticular testosterone
concentrations in men165. Although further study is warranted, the appropriate choice
of hormone suppression will require careful consideration. Long-acting
gonadotrophin analogues, such as goserelin have been shown to be ineffective at
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suppressing FSH long-term in normal men, with recovery of FSH and resumption of
spermatogenesis occurring within 2-3 months166,167.
Inhibin B mediates non-steroidal negative feedback from the testes, reflecting the
number of spermatozoa produced and regulating FSH secretion31,32,137'168. Inhibin B
secretion in the adult requires the presence of germ cells31. Inhibin B concentrations
were barely detectable in the azoospermic patients, despite the preservation of Sertoli
cells. Furthermore, the presence of the individual alpha and beta subunits were
present, as identified by immunohistochemisry. This provides further evidence for
an essential role of the germ cell-Sertoli cell interaction in the production of inhibin
B and confirms the value of inhibin B as a non-invasive marker of spermatogenesis
following cytotoxic therapy. Inhibin B was also undetectable in seminal plasma in
most subjects, as previously found in men with azoospermia of other aetiologies161.
All seven men had normal development of secondary sexual characteristics and
reported normal potency. However, despite having testosterone concentrations within
the normal range, hormone measurement demonstrated elevated LH levels,
suggesting that there had been subtle damage to the Leydig cells. It was not possible
to ascertain the degree of compensated Leydig cell function from
immunohistochemical studies, as steroidogenic activity in cancer survivors appeared
to be comparable to that of healthy controls, as assessed by intensity of
immunoexpression of 17a-OH and 3(3-HSD.
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Although the gonadotoxic effect of chemotherapy depends upon dosage and drugs
administered, and radiotherapy induced damage upon field of irradiation and dose
received, it is difficult to reliably predict the extent of testicular damage and which
azoospermic patients may show recovery of spermatogenesis. Our study population
comprised an unselected group of seven men rendered azoospermic secondary to
treatment for childhood cancer. Testicular biopsies from all seven patients
demonstrated complete absence of spermatogonia, yet survival of stem cells is a
prerequisite for endocrine restoration of spermatogenesis. It was felt to be unethical
to exclude men from the trial on the basis of Sertoli cell only biopsy specimens for
several reasons. Testicular volume in these men was markedly reduced and thus it
was justified to take only a small piece of testicular tissue, to eliminate any impact a
reduction in testicular tissue may have on Leydig cell numbers. Small islands of
spermatogonia may be present but were not present in the biopsied tissue. Survival of
germ cells following apparently sterilizing chemotherapy is evident from a number
of studies. Temporary azoospermia and late recovery of spermatogenesis following
chemotherapy have been reported, indicating the survival of stem cells,45,50'57 although
permanent azoospermia tends to follow procarbazine and alkylating agent-based
regimens, typical of treatment for Hodgkin's disease10,51'55. Similar histological
findings have been reported in other studies following treatment for Hodgkin's
disease with procarbazine-based regimens47'70. With advances in assisted
reproduction techniques, the development of testicular sperm extraction combined
with intracytoplasmic sperm injection (TESE-ICSI) offers potential for paternity in
these young men. Chan and co-workers report the use of TESE-ICSI to retrieve
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sperm from men with long-standing azoospermia and achieve a pregnancy171.
Seventeen men, median age (range), 37.4 (28-54) years had undergone sterilizing
chemotherapy treatment 16.3 (6-34) years previously. Of the 17 men, 13
demonstrated Sertoli cell only on biopsy and the remaining four were described as
having hypospermatogenesis. Using microdissection TESE techniques, sperm
retrieval was achieved in 7 subjects, 3 (43%) of whom demonstrated Sertoli cell only
on testicular histology and 4 (57%) hypospermatogenesis. The seven subjects
underwent nine TESE combined with ICSI procedures resulting in a clinical
pregnancy in 3 (33%) and a live birth in 2 (22%). These encouraging results suggest
that microscopic visualization of the seminiferous tubules may enable identification
of areas of continued spermatogenesis within the testis and sperm retrieval using
microdissection techniques. This reiterates the importance of not excluding men
from clinical trials of hormone restoration or from assisted reproduction techniques
on the basis of a Sertoli-cell only biopsy.
We report for the first time the extent of testicular damage following cytotoxic
chemotherapy and radiotherapy for childhood cancer and conclude that for these men
recovery of spermatogenesis is unlikely. Although it is possible that small islands of
germ cells exist in areas of tissues that were not biopsied, recovery of
spermatogenesis is unlikely given the extent of destruction to the general tissue
architecture. This does not exclude the possibility that earlier intervention and H-P-
G axis suppression might have been beneficial. However, it seems more probable
that H-P-G axis suppression to restore spermatogenesis may be more successful in
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patients in whom the testicular insult is less severe and in whom there is some
preservation of spermatogonia! stem cells.
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Chapter 7
Development of the prepubertal human testis:
an immunohistochemical study
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7. Development of the prepubertal human testis:
an immunohistochemical study
7.1. Introduction
Infertility is a well recognised late sequela for a number of patients following
treatment for childhood cancer. Consequently, there is tremendous impetus to
develop strategies to preserve fertile potential in children undergoing sterilizing
treatment for cancer.
The adult male reproductive system is highly susceptible to the toxic effects of
radiation and chemotherapy. Toxic insults may directly destroy proliferating germ
cells in the seminiferous epithelium, resulting in azoospermia, or, the effects may
result indirectly from impairment of Leydig cell function (reduced production of sex
steroids), or of Sertoli cell function. Sertoli cells are the key cell type regulating
sperm production and provide physical and nutritional support for germ cells. The
gonadotoxic effects of chemotherapy are well established, with the extent of
cytotoxic damage being dependent on the agent used and the dose administered. The
degree and permanency of testicular damage following radiotherapy depends on the
field of treatment, total and fractionated dose of radiotherapy administered, and is
inversely related to the age at time of treatment7"15.
It is understandable that the adult testis is susceptible to damage from chemotherapy
or radiotherapy because the process of sperm production involves the intense and
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continuous proliferation of germ cells, including germ stem cells, and proliferating
cells are targeted by either therapy. However, why radiation and chemotherapy
should exert gonadotoxic effects in the 'quiescent', prepubertal testis is uncertain.
This incongruity has been addressed via studies in a primate model, the marmoset
monkey. These animals exhibit a similar developmental profde to the human male, in
terms of having a neonatal period of testicular/hormonal activity, followed by a
'quiescent' period followed by puberty33. Using immunocytochemistry and cell
quantification on sections of the testes of animals during the 'quiescent' period, these
studies found that significant development/maturation of Sertoli, Leydig and germ
cells occurs during this period (probably equivalent to age six to eight years in boys),
which is long before the accepted time of onset of puberty in the marmoset33. From
this, it was a working hypothesis that comparable cell division and/or maturation in
the 'quiescent' testis of prepubertal boys is what renders the testis at this time
susceptible to damage by cancer therapy. There is already indirect evidence that
similar changes probably do occur in the 'quiescent' human testis as in the
marmoset. For example, based on autopsy material, testis volume trebles and germ
cell numbers increase steadily in the period from two years to prepuberty35. Other
evidence has shown that gonadotrophin secretion in boys, especially nocturnal
secretion, switches on many years prior to the time of clinically detectable puberty29.
Although these studies in the marmoset provide a logical potential explanation for
the susceptibility of the human prepubertal testis to damage by cancer therapy,
evidence is lacking to confirm that changes to Leydig, Sertoli and germ cells,
comparable to those that have been found in marmosets, also occur in the 'quiescent'
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testis of prepubertal boys. If such changes can be demonstrated to occur, it would
validate use of the marmoset as a model for the human in this instance and give
encouragement to the possibility of using this primate model to develop a method of
protecting spermatogenesis in boys undergoing cancer therapy prior to puberty.
The objective of this study was to establish the basis for why the testis in prepubertal
boys is susceptible to the damaging effects of certain cancer therapies, such that
fertility is compromised in adulthood. If it could be established that cell activity does
occur in the 'quiescent' testis in boys and is comparable to changes shown in the
marmoset, this will provide a rational basis for considering 'protective therapy' as
well as validating use of the marmoset as a model for establishing safety and efficacy
of such therapy. Testicular activity was assessed in testicular autopsy specimens
from boys by evaluating maturational and/or proliferative changes in the main
constituent cell types of the testis (Sertoli, Leydig and germ cells) using
immunocytochemical techniques.
113
Male fertility in survivors of childhood cancer Chapter 7
7.2. Methods
7.2.1. Tissue collection
7.2.1.1. Prepubertal testicular tissue
Prepubertal human testicular material was obtained from a tissue archive in the
Pathology Department at the Royal Hospital for Sick Children, Edinburgh. This
study was approved by the Lothian Paediatric and Reproductive Medicine Research
Ethics Sub-Committee. These specimens had been taken for diagnostic purposes at
post mortem and would otherwise have been discarded. The specimens were
supplied to us in an anonymised manner. Under these circumstances it is impossible
to obtain the consent of these patients (or their parents), however, it was felt that the
proposed studies using archived tissues would contribute in an important way
towards our understanding of the developing testis. It is unacceptable to (surgically)
sample testicular tissue from healthy boys during childhood in order to study
testicular development and it was considered ethical to further our knowledge by
studying the present supply of archive specimens, which would otherwise be
discarded. This understanding of testicular development is a prerequisite to
subsequent clinical studies in which a more informed assessment can be made of the
potential for developing approaches that might protect sperm production in boys
undergoing gonadotoxic cancer treatment.
The samples had been fixed in formalin and embedded in paraffin wax for storage at
the time of collection and sections were cut for further investigations.
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7.2.1.2. Control specimens
Adult human and marmoset testicular samples were obtained from an in-house tissue
archive (gifted from the pathology department, University of Edinburgh and owned
by Dr R. Sharpe and Dr P. Saunders); all had been fixed in Bouins.
7.2.1.3. Preparation of sections
Sections were cut to a depth of 5 microns, using a microtome (Leica, RM-2135) and
slides were made using TESPA (3-Triethoxysilylpropylamine, Sigma-Aldrich)
coated slides. The slides were dried in an oven at 37°C overnight.
7.2.2. Light microscopy assessment
In order to assess the overall architecture of the tissue the sections were stained with
haemotoxylin and eosin. Sections were deparaffinized in xylene, rehydrated in
graded ethanols and washed in water. The slides were immersed in haematoxylin for
5 minutes and then rinsed in water, followed by a brief immersion in alcohol (5-20
seconds) and a further washing in water. The slides were immersed in Scotts tap
water for 30 seconds and rinsed in water. The sections were counter-stained with
eosin, dehydrated in graded ethanols, cleared in xylene and cover-slipped using
Pertex mounting medium (CellPath pic, Hemel Hempstead, UK).
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7.2.3. Immunohistochemical markers of testicular cell development
To assess the maturational and proliferative status of the Leydig, Sertoli and germ
cells in the testes of boys of various ages, a variety of cell specific and non-cell
specific markers were used.
Cell specific markers:
Sulphated glycoprotein-2 (SGP-2): this is a protein marker expressed in Sertoli cell
cytoplasm and is a marker of Sertoli cell maturation/terminal differentiation in the
rat. In the marmoset it has been shown to be immunoexpressed in Sertoli cells from
mid childhood172.
3fi-hydroxysteroid dehydrogenase (3/3-HSD): a steroidogenic enzyme involved in
the biosynthesis of testosterone and is specific to Leydig cells or Leydig cell
precursors173. In the marmoset 3(3-HSD is immunoexpressed strongly during the
neonatal period, tailing off during mid childhood and increasing again from puberty
through to adulthood172.
17a-hydroxylase (17a-OH): a steroidogenic enzyme expressed in Leydig cells174.
C-kit: in the rat this is a plasma membrane marker for foetal germ cells (gonocytes).
In the marmoset it is not expressed beyond a few weeks of age, as one would not
expect to see gonocytes beyond this age175.
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MAGE-57B: the MAGE-57B antigen is expressed in gonocytes, equally strongly in
spermatogonia and weakly in early spermatocytes in rats and humans157.
Non-cell specific markers:
Androgen receptor (AR): is expressed in more than one cell type. In rat studies, AR
is immunoexpressed in the Sertoli cell nuclei just before the onset of puberty, and
also in peritubular cells and Leydig cells but never in germ cells176'177. Based upon
previous studies in the marmoset, AR is a nuclear protein marker expressed only in
Sertoli cells of seminiferous tubules of the prepubertal testis33.
Inhibin cc this is one of the subunits of the dimeric glycoprotein, inhibin-B, which is
secreted by the Sertoli cell and possibly by the Leydig cells in the testis, though
various forms of the free oc subunit may also be secreted32,178. It is a marker of Sertoli
cell maturation32'178.
Inhibin J3B: this combines with inhibin a to form the glycoprotein heterodimer
inhibin-B. It is secreted by Sertoli cells and is a marker of Sertoli cell maturation31,32.
It is also expressed in germ cells and in Leydig cells in some species.
Proliferating cell nuclear antigen (PCNA): this is expressed widely during the cell
cycle and is used as a marker of the rate of cell proliferation, or of 'non-quiescent'
cells. Though this will target all dividing cells, it is anticipated that it will label
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primarily germ cells at the ages relevant to the present investigation. PCNA has been
used for similar purposes in many previous studies, including in the rat179
marmoset33,176; rhesus monkey179 and human180.
Estrogen receptor oc Estrogens regulate germ cell function, mediated via high
affinity estrogen receptors: estrogen receptor a (ERa). and estrogen receptor (3
(ER(3)181,182. Only the results of our studies of ERa are presented in this thesis,
although studies are currently underway to explore immunoexpression of ER(3. ERa
immunoexpression localises to efferent duct epithelial cells in marmosets and rats
and may also target some interstitial cells, though only in the peripubertal period in
the marmoset33.
7.2.4. Antibodies
The first part of this study involved optimising conditions for human tissue for each
of the immunohistochemical assays. Immunolocalization of 17a-OH and 3(3-HSD
utilized rabbit polyclonal antibodies against the human proteins (both gifted from
Professor I Mason), both used at a dilution of 1:2000. C-kit was immunolocalized
using a rabbit polyclonal antibody, used at a dilution of 1:50. Immunolocalization of
inhibin (3B used a monoclonal mouse antibody against rabbit (3B (gift from Prof N
Groome, Oxford Brookes University), at a dilution of 1:6000. MAGE-57B was
immunolocalized using a mouse polyclonal antibody (Anti MAGE-A4 clone 57B;
gift from G. Spagnoli), used at a dilution of 1:50. Immunolocalization of SGP-2
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utilized a polyclonal antibody raised in sheep against human SGP-2 (gift from Dr J
MacRae, Australia), used at a dilution of 1:3000. Immunolocalization of AR utilized
a rabbit polyclonal antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA)
raised against an epitope at the N-terminus of human AR, at a dilution of 1:2000.
Immunolocalization of inhibin-a utilized a monoclonal antibody (173/9K) described
previously182, and used at a dilution of 1:1000. Proliferating cell nuclear antigen
(PCNA) was immunolocalized using a monoclonal antibody (PC 10; Dako), and was
used at a dilution of 1:500. ERa was immunolocalized utilizing a mouse monoclonal
antibody (NCL-ER-6F11, Novocaster), used at a dilution of 1:20.
7.2.5. Immunohistochemistry
Unless otherwise stated, all incubations were performed at room temperature.
Sections were deparaffinized in xylene, rehydrated in graded ethanols and washed in
water. A temperature-induced antigen retrieval step was required for androgen
receptor, inhibin a- and [3-B and 3(3-HSD, ERa antigens. The sections were pressure
cooked in 0.01M citrate buffer for androgen receptor, inhibin a- and 3[3-HSD and
ERa, or in 0.01M glycine buffer for inhibin (3-B antigen, pH 6.0 for 5 minutes at full
pressure, allowed to stand for 20 minutes, cooled in running tap water and washed
twice in (5 minutes each wash) in Tris-buffered saline (TBS: 0.05 mol Tris-HCL, pH
7.4, 0.85% (w/v) NaCl). Endogenous peroxidase activity was then blocked by
immersing sections in 3% (v/v) H2O2 in methanol (both from BDH Laboratory
Supplies, Poole) for 30 minutes, followed by two 5 minute washes in TBS. Sections
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were incubated for 30 minutes with the appropriate normal serum diluted 1:5 in TBS
containing 5% bovine serum albumin (BSA: Sigma) to block non-specific binding
sites. Normal swine serum (NSS) was used for androgen receptor, 3(3-HSD and C-
kit; normal goat serum (NGS) for 17a-OH and normal rabbit serum (NRS) for
inhibin a- and [3-B, MAGE-57B, ERa and SGP-2 (from Diagnostics Scotland,
Carluke). Primary antibodies were added to the sections at the appropriate dilution,
either in NSS-TBS-BSA, NRS-TBS-BSA, or NGS-TBS-BSA and incubated
overnight at 4°C in a humidified chamber. The sections were washed twice in TBS
and then incubated for 30 minutes with anti-rabbit or horseradish peroxidase-labelled
polymer (EnVision: DAKO, Ely) for androgen receptor, 3(3-HSD, 17a-OH and C-
kit, or anti-mouse for inhibin a- and (3-B, MAGE-57B and ERa, and anti-sheep for
SGP-2. Sections were washed twice (5 minutes each) in TBS and immunostaining
was developed using Liquid DAB (DAKO) until staining was optimal, when the
reaction was stopped by immersing sections in distilled water. The sections were
counter-stained with haematoxylin, dehydrated in graded ethanols, cleared in xylene
and cover-slipped using Pertex mounting medium (CellPath pic, Hemel Hempstead,
UK). As negative controls, slides were processed as above except that the
appropriate normal serum was substituted for the primary antibody.
Immunostained sections were examined and intensity was graded as weak
staining; moderate staining; '+++': intense staining. Relative numbers of cells
in a particular location staining positive was graded '1 to 5', with '1' representing
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only a few cells staining positive, to '5' reflecting all cells staining positive. The
sections were photographed using an Olympus Provis microscope (Olympus Optical,
Honduras Street, London, UK) fitted with a digital camera (Kodak DCS330:
Eastman Kodak, Rochester, NY, USA). Captured images were stored on a computer
(G4; Apple Computer Inc., Cupertino, CA) and compiled using Photoshop 5.0 before
printing using an Epson Stylus 870 colour printer (Seiko Epson Corp., Nagano,
Japan).
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7.3. Results
The objective of this study was to obtain post mortem testicular tissue samples from
preterm infants (from 23 weeks gestation onwards) through to puberty. It had been
hoped to identify at least six tissue samples from each age bracket in order to ensure
good representation and to enable conclusions to be reached about testicular
development during each time period. Age brackets were assigned as follows: 23-30
weeks gestation (n=13); 31-40 weeks gestation (n=22); 0-1 month (n=ll); 1-6
months (n=26); 7-12 months (n=6); 1-5 years (n=10); 6-10 years (n=7); 11-15 years
(n=l). Post mortem testicular tissue was abundantly available from premature babies
up to infants aged 12 months, but thereafter samples were fewer in numbers.
Unfortunately, due to the availability of testicular tissue it was not possible to include
as many tissue specimens from older patients as had been anticipated. As the study
continues it is hoped that the goal of six or more samples in each age group will
ultimately be achieved. In addition, at the time of collection of the original testicular
tissue the whole testes were taken and fixed in formalin for a variable time before
embedding in paraffin wax. The testes had not been weighed at the time of
collection, thus it was not possible to make an assessment about the volume of the
testes at different ages and therefore not possible to derive absolute numbers of
particular cell types per testis. Furthermore, as the precise fixation procedures were
not specified and may have been more optimal for some specimens than for others
(e.g. due to testis size) the quality of the tissue undoubtedly varied in quality between
specimens. Differences in timing between death and tissue fixation was also likely to
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have varied considerably and this may have differentially affected the preservation of
certain antigens. Such factors had to be taken into account in the studies described.
The immunohistochemical techniques had been established for rats and marmoset
tissues and a significant period of time was spent optimising the conditions for
human tissues. A compounding factor for the lack of success when applying the
procedures as determined for the marmoset, was that the marmoset testicular tissue
had been carefully dissected free of connective tissue, fixed in Bouin's fluid for a
defined period of time, after which the testis was dissected from the epididymis and
weighed, before processing the fixed testis overnight and embedding in paraffin.
7.3.1. Light microscopy
During infancy and early childhood, seminiferous cords were present with no
lumens. Sertoli cells were abundant with a few germ cells and the occasional
binucleated spermatogonium (Figure 7.1(a)-(h)). Seminiferous tubule lumens were
only evident in tissue from the 12yr old patient, which was the only specimen
available for the age bracket 11-15 years (Figure 7.1(h)). Germ cells were more
abundant in the older patients with some evidence of differentiation to spermatocytes
(Figure 7.1(h)). A healthy adult testis is shown for comparison (Figure 7.1 (i)).
An interesting finding from these studies was the relatively large size of the efferent
ducts in relation to the size of the testis during third trimester development and
infancy (Figure 7.1(a)). This is a new finding of uncertain significance, perhaps
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significant of a larger, as yet undefined role of the epididymis, and warrants further
assessment.
7.3.2. Sertoli cell development (Table 7.1)
Evaluation of Sertoli cell development and maturation was made using
immunoexpression of the protein markers AR, SGP-2, inhibin a and (3B. Nuclear
expression ofAR in certain testicular cell types was evident from 23 weeks gestation
to early puberty, as shown in figure 8.2. However, AR immunoexpression in Sertoli
cells was negative until the onset of puberty (Figure 7.2(a)-(h)). This is in contrast to
the earlier appearance of AR from 'mid childhood' in the marmoset33. A significant
degree of background staining was evident in figure 7.2(c), which reiterated the
difficulties associated with optimising the staining techniques. SGP-2
immunoexpression was not detectable in any of our specimens from 23 weeks
gestation through to 12 years of age. SGP-2 is a marker of Sertoli cell maturation in
the rat and marmoset and these findings reflect the immature state of development in
these subjects, although immunoexpression of SGP-2 was expected in the older
subjects from 9-12 years, if the marmoset model is a true reflection of human
prepubertal testicular development. Inhibin-a was abundantly expressed in Sertoli
cells of all ages and appeared to decrease in intensity with increasing age (Figure
7.3(a)-(i)). Inhibin-a was expressed most intensely in Sertoli cells in the preterm and
neonatal testes (Figure 7.3(a)-(c)). During mid childhood, inhibin-a was only
immunoexpressed at low intensity (Figure 7.3(f) and (g)). Inhibin-(3B was
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immunoexpressed in Sertoli cells in the seminiferous cords during 30-40 weeks of
gestation and was then absent during infancy and early childhood (Figure 7.4(b)-(f)).
Immunoexpression of inhibin (3B was detected in Sertoli cells during mid childhood,
age 6-10 years, and weakly present in the peripubertal testis (Figure 7.4(g) and (h)).
Inhibin (3B was abundantly immunoexpressed in germ cell, Sertoli cells and Leydig
cells of a healthy adult control (Figure 7.4(i)).
7.3.3. Leydig cell development (Table 7.1)
Expression of 3(3-HSD was confined to the cytoplasm of Leydig cells. In the
prepubertal human testis, 3J3-HSD was immunoexpressed intensely and abundantly
during weeks 23-30 of gestation (Figure 7.5a). During the last 10 weeks of foetal life
and infancy immunoexpression remained intense but fewer cells were
immunopositive. There was no 3(3-HSD immunoexpression during childhood (Figure
7.5(e)-(h)). A healthy adult testis illustrates intense 3P-HSD immunoexpression in
the Leydig cells (Figure 7.5(i)). In the marmoset, immunoexpression of 3P-HSD was
relatively intense during the neonatal period and then declined during early to mid
childhood (20-35 weeks) before increasing markedly at puberty through to
adulthood33.
Inhibin a immunoexpression was weakly positive throughout preterm life until six
months of age in the human, and subsequently became negative during childhood,
with very weak expression observed in children of pubertal age (Figure 7.3(a)-(h)).
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Inhibin a immunoexpression in adult human Leydig cells is shown for comparison
(Figure 7.3(i)). In marmosets it was also possible to demonstrate an increase in
Leydig cell number and functional capacity of the cells from mid childhood (35
weeks), through puberty to adulthood33. Based on Leydig cell nuclear volume it was
shown that the number of Leydig cells increased =5-fold, whereas cytoplasmic
volume per testis increased by up to 10-fold between mid childhood and adulthood in
the marmoset33. This sort of evaluation was not possible in our studies as the
testicular volumes were not available.
AR was also immunoexpressed in interstitial cells in the human testis, being maximal
during foetal life and the neonatal period (Figure 7.2(a)-(c)) and subsequently
decreasing during infancy (Figure 7.2(d) and (e)). AR immunoexpression in
peritubular cells remained weakly positive throughout childhood but Leydig cells
remained immunonegative for AR until early puberty in all human specimens studied
(Figure 7.2(e)-(h)).
17a-OH, another cytoplasmic marker of steroidogenic activity in Leydig cells was
intensely expressed in the very preterm infants, born between 23 and 30 weeks of
gestation and was less intensely and abundantly expressed during 30 to 40 weeks of
gestation (Figure 7.6(a) and (b)). Immunoexpression of 17a-OH was absent
throughout childhood and remained undetectable in the peripubertal testis (Figure
7.6(c)-(h)), in contrast to positive immunoexpression in a healthy adult control
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(Figure 7.6(i)). 17a-OH immunoexpression appears to switch off a little earlier than
3|3-HSD, but it is uncertain whether this discrepancy reflects a true pattern of
steroidogenic activity or is indicative of differences in antigen
preservation/detection/sensitivity. It was not possible to compare these findings with
the marmoset during this study.
Inhibin |3B immunoexpression was detected in small numbers of Leydig cells in
some of the samples (Figure 7.3.). Expression was most intense in the preterm
infants, becoming weakly positive to undetectable by the end of the first year of life
and becoming weakly detectable again peripubertally.
ER-a was not immunoexpressed in the Leydig cells in any of our human specimens
studied. ER-a localises to Leydig cells in the rat and may also target some interstitial
cells, though only in the peripubertal period in the marmoset33. In addition, ER-a
immunoexpression localises to efferent duct epithelial cells in marmosets and rats
Positive immunoexpression of ER-a was evident and in the efferent duct epithelial
cells during foetal life and throughout childhood (Figure 7.7(a)-(g)). It was not
possible to stain for ER-a in the peripubertal testis, as the tissue specimen obtained
did not include efferent ducts. ER-a expression was not detected in the rete testis or
epididymis.
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During studies with the germ cell marker c-kit, cytoplasmic immunoexpression of c-
kit in the interstitial cells was also detected (Figure 7.8). C-kit was immunoexpressed
intensely in interstitial cell cytoplasm during 23-30 weeks of gestation (Figure
7.8(a)). There were small numbers of cells stained weakly positive during infancy
(Figure 7.8(d)). Interestingly, in the foetal samples c-kit immunoexpression in
interstitial cells was evident in the cytoplasm and around the perinuclear membrane
in some of the cells (Figure 7.8(a)).
7.3.4. Germ cell development (Table 7.1)
Identification and subsequent quantification of germ cells during testicular
development is hampered by the lack of type-specific germ cell markers. In this
study we used c-kit and MAGE-57B as markers to identify germ cells. C-kit is a
germ cell plasma membrane marker, which is specific for gonocytes and early
spermatocytes in the developing rat. In our studies, c-kit expression was present in
gonocytes during foetal life, most intensely during 30-40 weeks of gestation (Figure
7.8(a) and (b)). Less intense staining was detected up to 6 months of age (Figure
7.8(c) and (d)) but was absent thereafter (Figure 7.8(e)-(h)). In the marmoset, c-kit is
not expressed beyond the first few days of life, in term monkeys, and has not been
studied in premature infants.
Immunoexpression ofMAGE-57B was detected in germ cells from the very preterm
infants through to peripubertal subjects (Figure 7.9(a)-(h)). Intensity of staining was
relatively constant at all ages but there appeared to be more abundant staining during
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foetal life (Figure 7.9(a) and (b)), with fewer cells staining during infancy and early
childhood (Figure 7.9(c)-(e)) and increasing in frequency again from mid childhood
onwards (Figure 7.9(f)-(h)). It was not possible to make an assessment of the
differential expression within the different stages of germ cell development. The
MAGE-57B antigen is expressed in early germ cells, strongly in spermatogonia and
weakly in early spermatocytes in rats, and studies are currently underway to explore
its expression in the marmoset.
7.3.5. Cell proliferation (Table 7.1)
Immunohistochemistry studies using the nuclear marker PCNA were unsuccessful in
our specimens. PCNA immunoexpression occurred in at most only one or two cells
per high-powered field and appeared to immunostain Sertoli cells rather than germ
cells. An example is shown in figure 7.10(a). While this finding may simply indicate
that germ cells were not proliferating at the ages studied, the consistent lack of germ
cell expression of PCNA throughout the range of ages would suggest that this
antigen was not detectable in these tissues for technical reasons, such as poor
preservation of the antigen. A testis from a prepubertal marmoset with widely
expressed PCNA is shown for comparison (Figure 7.10(b)).
A summary of immunoexpression of the various markers used to evaluate
maturational and / or proliferative changes in the main constituent cell types of the
testis is shown in Table 7.1. Positive immunoexpression of a given marker is
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Figure 7.1. Haematoxylin and eosin staining: Panels (a) to (h) demonstrate testis
morphology from 23 weeks gestation through childhood to early puberty.
Seminiferous cords are evident with abundant Sertoli cells and only a few germ cells
during foetal life and early childhood. Seminiferous tubules with luminal
development are demonstrated in the peripubertal testis (h). Panel (a) also illustrates
the relatively large size of the efferent ducts in relation to the size of the testis, which
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Figure 7.2. Androgen receptor immunoexpression: Panels (a) to (h) show AR
immunoexpression during foetal life and childhood. AR expression in Sertoli cells
was negative during foetal life and childhood, (a) to (g), until the onset of puberty
(h). A significant degree of background staining was seen in panel (c). AR
immunoexpression was present in interstitial cells, with a maximum intensity during
weeks 23-30 of foetal gestation and decreasing thereafter. Peritubular cells
immunoexpressed AR during infancy and early childhood, (a) to (g), but
immunoexpression was not detectable in peritubular cells during early puberty (h). A
healthy adult testis is shown for comparison (i). Inset shows the negative control in
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Figure 7.3. Inhibin a immunoexpression: Panels (a) to (h) show inhibin a
immunoexpression in Sertoli cells. Inhibin a was abundantly expressed in Sertoli
cells at all ages and appeared to decrease in intensity during early childhood, (e) and
(f). Some immunostaining for inhibin a was also evident in interstitial cells at some
of the ages, panels (a), (b), (c) and (h). A healthy adult control is shown for
comparison (i) and the inset shows the negative control from which the antibody was
omitted. Scale bar denotes 50 pm.
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Figure 7.4. Inhibin PB immunoexpression: Inhibin PB was immunoexpressed in
Sertoli cells at low intensity in the seminiferous cords during 30-40 weeks gestation
(b) but immunoexpression was not detectable during early childhood, panels (c) to
(f). Inhibin pB was immunoexpressed in both germ cells and Sertoli cells during mid
puberty (g) and was weakly expressed in the peripubertal testis (h). Inhibin PB was
immunoexpressed in interstitial cells during foetal life, panels (a) and (b). For
comparison, a healthy adult testis is shown with abundant immunoexpression of
inhibin pB in Sertoli cells, germ cells and interstitial cells. Inset shows negative
control. Scale bar denotes 50 pm.
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Figure 7.5. 3J3-HSD immunoexpression: Panel (a) shows intense and abundant
immunoexpression 3p-HSD during 23-30 weeks of gestation. Intense but less
abundant 3(3-HSD staining was evident between 30 weeks of gestation and 6 months
of age, panels (b) to (d). 3(3-HSD immunoexpression was not detectable from age 6
months onwards up to puberty, panels (e) to (h). A healthy adult control expressing
3(3-HSD in Leydig cells is shown for comparison with negative inset (i). Scale bar
denotes 50 pm.
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Figure 7.6. 17a-OH immunoexpression: Panels (a) and (b) show intense staining
and abundant immunoexpression of 17a-OH during 23-30 weeks of gestation with
less intense immunoexpression during 30-40 weeks of gestation. Thereafter 17a-OH
immunoexpression was not detectable, even in the prepubertal (h) samples. A healthy
adult exhibiting weak immunoexpression of 17a-OH in Leydig cells is shown for
comparison with negative inset (i). Scale bar denotes 50 |im.
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Figure 7.7. ER-a immunoexpression: Panels (a) to (d) show intense
immunoexpression of ER-a in the efferent duct epithelial cells from 23 weeks
gestation until 6 months of age and thereafter, where immunoexpression was less
intense. There was a notable increase in size of the ducts with increasing age, panels
(a) to (g). Scale bar denotes 50 pm.
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Male fertility in survivors of childhood cancer Chapter 7
Figure 7.8. c-kit immunoexpression: Panels (b), (c) and (d) show
immunoexpression of c-kit on the plasma membrane of the very early germ cells, or
gonocytes, from 23 weeks of gestation until 6 months of age. Immunoexpression of
c-kit on the plasma membrane of the gonocytes is most intense in the specimens aged
30-40 weeks of gestation and 1-6 months of age. Immunoexpression of c-kit is not
detected on the plasma membrane of germ cells from 6 months of age onwards,
panels (e) to (h), reflecting absence of gonocytes from this age onwards. Cytoplasmic
expression of c-kit is evident in Leydig cells at certain ages, panel (a) and (d), 23-30
weeks of gestation and 1 -6 months of age respectively. A healthy adult is shown for
comparison, with no immunoexpression of c-kit detected, and negative inset (i).
Scale bar denotes 50 pm.
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Figure 7.9. MAGE-57B immunoexpression: MAGE-57B immunoexpression was
evident at all ages of development. Immunoexpression of MAGE-57B was most
intense during foetal life, panels (a) and (b), and subsequently decreased in intensity
during infancy and early childhood, panels (c) to (e). MAGE-57B immunoexpression
was intense during mid childhood, panels (f) and (g) and less intense in the
peripubertal specimen, panel (h). Immunoexpression in the peripubertal specimen
also appears to be localized to the spermatogonia and early spermatocytes (h). A
healthy adult control is shown for comparison in which MAGE-57B
immunoexpression was confined to spermatogonia and early spermatocytes, with





















7-12 months 1 -5 years
f
r •< \ *
. >, >
I














^ a fr jSf
# *» » ^ ■?T**









Male fertility in survivors of childhood cancer Chapter 7
Figure 7.10. PCNA immunoexpression: PCNA immunoexpression was almost
negligible in prepubertal human tissues, panel (a), in contrast to the abundant
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7.4. Discussion
This study, to the best of my knowledge, is the first detailed immunohistochemical
study to have investigated the development of the testis in the prepubertal human.
There is growing evidence to suggest that the prepubertal human testis may be
'quietly active' as opposed to truly quiescent33"35'161,183"186. During childhood, there is
Leydig cell development with an increase in absolute number187 and functional
activity, as evidenced by an increase in intratesticular188 and spermatic vein levels of
testosterone189 between 2-4 and 6-8yrs of age, coinciding with night-time activation
of pulsatile LH secretion183"185. Muller and Skakkebaek have shown that testicular
volume increases significantly during childhood, consistent with a 3-fold increase in
germ cell number35. Studies have also shown that the germ cells themselves undergo
a degree of maturation to form spermatocytes, and occasionally spermatids, during
childhood but these germ cells subsequently degenerate due to a lack of maturation
or functional support from the Sertoli and Leydig cells188. These changes are reported
to occur at least 4-5 years before the onset of puberty.
Immunohistochemical studies in marmosets have demonstrated that there is
significant testicular activity detectable during mid childhood33. In the marmoset, the
onset of puberty at around 50-60 weeks of age is associated with a rise in blood
testosterone levels. Evaluation of functional development of Sertoli cells and Leydig
cells, based on immunoexpression of SGP-2 and AR, and 3P-HSD respectively,
demonstrated activity at an age of 35 weeks, when the testis is considered to be
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quiescent, and in advance of the pubertal rise in blood testosterone levels, at 50-60
weeks33. This compelling evidence reinforces the tenet that the testis is not quiescent
during childhood.
The marmoset was chosen as a primate model for the human, because it exhibits a
comparable pattern of testicular development: it descends its testes into the scrotum
by birth, exhibits neonatal proliferation of Sertoli cells and a testosterone surge
followed by infantile 'quiescence'33181. In addition, the adult marmoset testis has been
shown to exhibit an organization of spermatogenesis that approaches that in the
human in contrast to other commonly used primate models such as the rhesus
monkey177. If comparable changes could be demonstrated in the prepubertal human
testis it would validate the use of the marmoset as a model for the human.
Demonstration of cell division and maturation in the relatively 'quiescent' human
testis during childhood, similar to the marmoset, may help us understand the
susceptibility of the prepubertal human testes to damage from cytotoxic
chemotherapy and radiotherapy. Kelnar et al have clearly demonstrated that the
marmoset testis undergoes active development during childhood, considerably in
advance of the clinical onset of puberty33. In an attempt to elucidate the mechanism
of this childhood development, and possibly enhance our understanding of the
susceptibility of the prepubertal testis to cytotoxic therapy, they studied the effect of
treating these animals for a period during early childhood (25-35weeks) with a
GnRH antagonist. The early activation of testicular function observed during mid
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childhood, at 35 weeks, was largely abolished with GnRH antagonist treatment,
indicating that these changes are essentially gonadotrophin dependent. Interestingly,
there was no significant difference in PCNA-labelling index of spermatogonia
between the GnRH antagonist treated and untreated groups, implying that GnRH
antagonist therapy had no impact on germ cell proliferation but did impact on their
survival. This latter observation has important implications when considering GnRH
antagonist intervention therapy as a strategy for preserving testicular function in
children undergoing treatment for childhood cancer. Clearly, furthering our
understanding of the gonadotrophin independent mechanisms of germ cell
proliferation and differentiation is essential. From this it is hoped to be able to
explain why the prepubertal testis is susceptible to damage from cytotoxic cancer
therapy. Moreover, using this primate model to develop methods of protecting
spermatogenesis or preserving germ cells during cancer therapy would have
enormous therapeutic implications for the young boy facing sterilising treatment for
childhood cancer.
The findings in the marmoset studies would imply that functional development of
testicular cells is likely to be initiated at some point during childhood. Based upon
immunoexpression of a number of protein markers of testicular cell development in
the marmoset, these have been applied to human tissue specimens to enable us to
establish whether comparable changes in expression of these markers occur during
human testicular development. Evaluation of Sertoli cell development and
maturation was made using immunoexpression of the protein markers AR, SGP-2,
153
Male fertility in survivors of childhood cancer Chapter 7
inhibin a and |3B. Based upon the absence of immunoexpression of AR, SGP-2,
inhibin pB, essentially throughout childhood, with the exception of weak
immunoexpression of AR in the specimen from a 12yr old patient, this may suggest
that the human testis is relatively quiescent during childhood, in contrast to the
findings of earlier activity reported in the marmoset33. Similarly, lack of functional
activity was observed in Leydig cells during childhood, based upon
immunoexpression of 17a-OH and 3(3-HSD. This is again in conflict with the earlier
functional activity before the onset of puberty suggested by studies in the marmoset
and also in boys33,187"189. Identification of proliferating germ cells with procedures
used in the marmoset proved to be equally challenging. PCNA has been used as a
means of identifying 'non-quiescent' cells in the marmoset during childhood, i.e.
cells in the cell-cycle. In the marmoset, at 35 weeks of age, only germ cells, not
Sertoli cells, are proliferating and therefore immunoexpress PCNA, enabling
quantification of germ cell development. PCNA was not expressed in any of our
specimens from children, in contrast to evidence of abundant proliferation
demonstrated in the marmoset studies33. In this study, germ cells were positively
identified using immunoexpression of the MAGE-57B antigen, throughout all ages
of childhood, although no assessment of the differential expression within the
different stages of germ cell development was made. Quantitative evaluation of the
increasing number of germ cells relative to testicular volume is not possible to
determine in our studies given the lack of available information regarding testicular
volumes. However, studies are currently underway to express the number of germ
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cells relative to the number of Sertoli cells present at any give age. In order to
attempt to make some attempt at quantification of testis cell development studies are
underway using point-counting techniques to express the percentage of germ cells
relative to Sertoli cells. This will be achieved using a double immunohistochemical
staining technique with MAGE-57B and GATA-4 to differentially identify germ
cells and Sertoli cells respectively.
Our preliminary findings of testicular development in the prepubertal human are not
in keeping with the level of activity suggested by studies in the marmoset. A number
of reasons may be proffered to explain these discrepancies. Firstly, it may be
premature to draw conclusions from this study, particularly for the older subjects of
peripubertal age, based upon the paucity of specimens. Secondly, although
immunohistochemistry conditions were optimised for human tissues, and
demonstrated immunoexpression of the various protein markers in the specimens
from the very young patients, the absence of immunoexpression from the older
subjects may reflect inadequate techniques. Perhaps more importantly, the human
testicular specimens were obtained from a tissue archive, which was not specifically
designed to ensure maximum preservation of the tissue specimens, i.e. optimum
antigen preservation, to a standard equal to that of the marmoset or adult human
control specimens. With increasing testicular volumes the significance of the
inadequate fixation procedures may have had a greater adverse impact on
preservation of the antigens under investigation. Fixation issues are particularly of
concern when 'absence of immunoexpression' occurs, as is the case in the present
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series comparing prepubertal human with prepubertal marmoset testes. Absence of
immunoexpression could result from a 'true absence' or from lack of antigen
preservation, with these two opposing explanations being very difficult to
distinguish. There are, however, some indicators from the present studies, for
example, it was clear from inspection of H & E stained slides of the testes sections
from boys aged 8-12 years that more germ cells were present, including some
spermatocytes in the specimens from the oldest boys. Yet none of these samples
exhibited PCNA-staining of the germ cells, even though it is established that most of
these cells should be immunopositive, based on studies of the adult human testis and
of the prepubertal marmoset testis33. This suggests quite strongly that there has been
failure of PCNA preservation. However, this conclusion cannot be generalised, as it
was equally clear that some antigens were still detectable, including the presence
MAGE-57B in germ cells. 17a-OH and 3|3-HSD were used as markers of
steroidogenic activity in Leydig cells. Steroidogenic activity was clearly
demonstrated in the very preterm infants with both 17a-OH and 3(3-HSD staining
immunopositive. During infancy some evidence of functional activity was
demonstrated by positive immunoexpression of 3p-HSD only. The disappearance of
17a-OH may reflect loss of antigen expression or an earlier switching off of this
antigen. Both markers were absent throughout childhood, including the older
specimens of peripubertal age, when we would have expected to see some activity as
demonstrated by inhibin a, again this may reflect lack of antigen preservation. Even
then, if the marmoset model was a true reflection of the human we would have
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expected evidence of functional activity at an earlier age, from mid childhood
onwards. Before definitive conclusions can be drawn from this study about the
applicability ofmarmoset studies as a model for the human a number of steps require
to be taken. Clearly, recruitment of larger number of specimens from the older age
bracket of children is essential and such studies are currently in progress.
Furthermore, we need to explore alternative markers for identifying cells,
particularly functional Leydig cell activity and germ cell proliferation. Unfortunately,
as these specimens are obtained from a tissue archive it will not be possible to
circumvent the problems of inconsistencies and possibly inadequacies, in the fixation
procedures.
It is appreciated that our current studies evaluating the development of the testis in
prepubertal humans is in the preliminary stages and at present it is not yet possible to
definitively conclude whether the marmoset provides an appropriate model for
development of the human testis during childhood. As this work is still in progress,
we are hopeful that we will be able to answer these questions in the near future.
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Chapter 8
Ethical and legal issues
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8. Ethical, legal and practical considerations
Harvesting gonadal tissue and its future use is an exciting new area of gamete
biology which raises a wide range of unresolved ethical and legal issues that must be
addressed before embarking on any clinical programme28,8,190"192. These include issues
relating to the safety of the tissue harvesting, subsequent use and possible
implications for the progeny, together with the legal constraints enforced by the
HFEA relating to gamete storage and manipulation, and the common laws defining
validity of consent in the event of any such procedures becoming available. Each of
these issues is addressed in this chapter and recommendations for future practice are
discussed.
It is undisputable that harvesting and subsequent use of gonadal tissue is still in it's
infancy but as it offers the potential for paternity to vulnerable young individuals,
every effort will be made to pursue such developments. However at present, it
remains undeniably experimental and as such, creates an area of uncertainty and
unprecedented challenges, which must be addressed. The controversial issues arising
from these experimental procedures, or more accurately clinical research, are
twofold; firstly, they involve the use of reproductive, or potential reproductive,
material, and secondly, they relate to children. A number of legal and ethical
constraints govern both any work relating to mature reproductive tissue and research
in children. Unfortunately, the pace of technological advances has outstripped the
laws implemented to protect society from unwanted manipulation of the human
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germline. The potential benefit of these developments to children with cancer could
not have been predicted and consequently such a legacy may inadvertently hamper
progress in this area if current legislation is not revised.
8.1. The legal framework
8.1.1. Consent for storage of human reproductive tissue
The field of assisted reproduction is governed by the statute in the UK and is under
the jurisdiction of the Human Fertilisation and Embryology Authority (HFEA Act,
1990), which dictates strict guidelines on the requirements for informed consent with
respect to the storage of gametes and embryos and their subsequent use'93. The HFEA
grants licences to individuals for certain procedures involving gametes. Proxy
consent is specifically excluded and there is a requirement to provide written and
verbal information and an offer of independent counselling194. The exclusion of
substituted consent may be subject to further consideration under the UK Human
Rights Act 1998, if this proves to be a hindrance in genuine cases of freezing of
genetic material194195. It is the responsibility of the licence holders to ensure that
informed consent is obtained before embarking upon the cryopreservation procedure.
The provider(s) of the gametes or embryos always retains the right to the control of
their genetic material, the fate of which can be altered by a change in the consent at
any time they choose to do so.
A gamete is defined by the HFEA to be 'a reproductive cell, such as an ovum or
spermatozoon, which has a haploid set of chromosomes and which is capable of
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taking part in fertilisation with another of the opposite sex to form a zygote"97.
According to the Tanner classification of pubertal development, boys are capable of
producing 'gametes' from Tanner stage 2 onwards. In practice this would mean that
storage of testicular material from a boy who has reached at least Tanner stage 2
would require consent for storage from the individual, and the centre would require a
licence to store the material. For postpubertal boys the preferred specimen is one
produced by ejaculation using masturbation. However, sperm may be retrieved by
alternative methods as discussed in chapter 7 (Table 7.3). For peripubertal boys, at
least Tanner stage 2, who are deemed to have testicular tissue sufficiently mature to
be considered as capable of producing gametes, the harvesting of tissue remains
entirely experimental but the issues relating to consent for storage of tissue are as for
the older boys. Difficulties of consent arise when boys have reached a stage at which
sperm storage is physically possible but they are not deemed legally competent. In
addition consent for storage of the material cannot be given by proxy, as stated by
the HFEA and this is discussed further in the next section. In contrast, testicular
tissue could be harvested from prepubertal boys provided that the parents give valid
consent and the procedure is in the child's best interests. Until recently, the storage
of immature testicular tissue from prepubertal subjects did not require a licence.
However, recognition of advances in the field of fertility preservation and assisted
reproduction has led to the necessary introduction of changes in the health service. In
particular, the handling and storage of immature gametes now falls under the
Department of Health Code of Practice for Tissue Banks, which came into force in
April 200319U%.
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8.1.2. Consent for harvesting gonadal tissue
Clinical research is regulated by a code of practice, which dictates that the field of
research must be scientifically sound and in the patient's best interest, determined to
be so by stringent ethical review. To enable the research to proceed any further the
patient is then obliged to give informed consent. It is the issue of consent that is
fundamental to the debate. Any research intervention, which may in some
circumstances be potentially harmful must be ethically and legally acceptable and
valid consent obtained. To be valid, consent must be informed, voluntarily obtained,
and given by a competent person. In practice, it may be difficult to satisfy these
criteria, especially in patients with cancer. The information necessary for parents and
children to make an informed choice about fertility preservation is inevitably
complex and its comprehension cannot be guaranteed. Legal competence to consent
requires that the individual giving it is able to understand the information given,
believes that it applies to them, retains it, and uses it to make an informed choice. In
the case of children, consent is proxy, given by the parent or guardian. Legal
competence may be diminished by parental anxieties about their child's illness. Such
issues may also involve consideration of a future, which neither they, nor the child,
can envisage or have discussed. In addition, therapeutic imperatives may limit the
time available for discussion, which in turn imposes constraints on the voluntariness
of the consent. Issues surrounding the safety of the procedures, both with regard to
the harvesting of the tissue and it's storage, raise further concern and, together with
the uncertainty relating to any potential success of future use of the material, makes
obtaining informed consent unrealistic.
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8.1.2.1. Consent - a two-stage process
Some of these practical difficulties may be alleviated if obtaining consent is
considered as a continuum, which can be divided into two stages, with part one
involving harvesting and cryopreservation of the tissue, and part two involving
subsequent use of the tissue. Future use of the tissue also raises a number of issues
for both autotransplantation or in vitro maturation of the tissue. Autotransplantation
carries a potential risk of reintroducing cancer cells into the patient, while in vitro
maturation would involve the development of mature gametes and subsequent use
with ART, and consequently regulation by the HFEA. Clearly, subsequent use of the
tissue would require separate consent from the patient, who would have reached a
stage of sufficient maturity to be able to make decisions relating to his/her fertility.
Issues relating to the use of the tissue in the event of the death of the patient must
also be discussed and, in accordance with the regulations of the HFEA, it would be
likely to take the path of destroying the tissue in the event of the patient's death.
The removal of testicular tissue is an invasive procedure that carries an element of
risk, a risk that is augmented in individuals whose health is already compromised by
their disease. The subsequent reimplantation of stored tissue may carry as yet
unqualified risks with the potential of reactivating disease in individuals in
remission. Given our current lack of knowledge surrounding the issues of safety and
future use, it is questionable whether even competent individuals can give fully
informed consent. Reiteration of the experimental nature of these procedures is
necessary during any discussions with the patient and the family.
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8.1.2.2. Who gives the consent?
The need and the difficulties arising from obtaining informed consent from an adult
have been established but what are the issues for children? Obtaining consent in
young people remains a contentious issue, which is confusing for the patient, the
parent and the medical professionals involved in promoting the child's health and
enabling them to exercise, where possible, their autonomy regarding reproductive
issues. Normally, consent models pertain to treatment but cryopreservation of sperm
or testicular tissue from a mature male is preventative and normally requires no
surgical intervention. In the UK, adolescents over the age of 16 years of age in
Scotland, and 18 years of age in England, may give consent to treatment in
accordance with the Family Law Reform Act 1969 s8, while for younger children,
minors, consent is generally obtained by proxy198199. In exception to this, legally valid
consent from minors can be obtained if their doctor considers that they are competent
to make an informed and wise decision200,201. More recently, in the USA the concept
of assent has been developed. Early adolescents are considered 'to assent' (or, its
converse, dissent) when they have sufficient competence to have some appreciation
of a procedure, but not enough to give fully informed consent. The age of assent is
currently estimated as being 12201"203.
Specifically for adolescents a 'family rule' model of consent has been developed204.
This is a framework for obtaining ethical consent for medical interventions in
children. The rule proposes that informed consent in children can be regarded as
shared between children and their families, the balance being determined by implicit,
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developmentally based negotiations between the child and the parent. Involvement of
the family may help provide support for the adolescent making the decision. It will
provide an opportunity for the family to discuss such delicate matters more openly
and may even serve to bring the family closer together and unite them together to
face something positive during such a devastating time. Providing informed consent
or assent, is a tremendous responsibility for the adolescent who will be facing a
number of complex issues at this difficult time, and involving the parents may allow
open discussion and explanation of complex language to play a guiding role in
helping the adolescent to give informed consent but retaining a degree of autonomy.
In practice there are three scenarios
i. In sexually mature minors, sperm may be produced and consent
obtained in accordance with the Gillick principle and cryopreserved in a
licensed centre.
ii. If the patient, at least Tanner stage 2, is unable to produce a sample by
masturbation, sperm may be surgically retrieved and stored, provided
that the patient is able to give written informed consent.
iii. The patient is pre-pubertal and therefore the testicular tissue does not
contain 'gametes' as defined by HFEA, the legal and practical
considerations falls under the Department of Health Code of Practice
for Human Tissue Banking (enforced since April 2003)196. Under these
circumstances, parental consent is required for the surgical procedure.
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As early as 1970 the World Health Organisation recognised that it was a fundamental
right of every individual to have freedom from organic disorders, disease and
deficiencies that interfere with sexual and reproductive function. Therefore not to
offer storage, by denying choice at a later stage in life, may be an infringement of
this right. Success in animals, however, does not guarantee applicability in humans
and optimisation of the methodology and refining of storage techniques should be
restricted to specialist centres with experience in the cryobiology of reproductive
tissue.
8.2. Recommendations for best code of practice
Harvesting and storage of ovarian cortical tissue from girls and young women before
gonadotoxic chemotherapy has been available in a number of centres since the mid-
1990s and, more recently, a few centres report the storage of testicular tissue205. The
Royal College of Obstetricians and Gynaecologists has provided a report from a
working party on the storage of ovarian and prepubertal testicular tissue. This
provides standards for best practice in the cryopreservation of gonadal tissue,
including the criteria for providing a service, patient identification and selection,
standard operating procedures and requirements for safe storage79.
In December 2002 an international conference was held in Cambridge, the specific
aim of which was to develop an ethically acceptable strategy for the practice and
research related to preserving fertility in children and adolescents being treated for
cancer28. From this meeting a consensus statement was drawn up which made a
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number of recommendations. Integral to these recommendations were the design and
implementation of well constructed research strategies, confined to a finite number
of specialist centres, with centralization of data and rapid dissemination of the
results. In turn, these protocols and results should be subject to rigorous review to
ensure high standards for collection procedures and storage of material. At both a
research and clinical level this would involve multidisciplinary teamwork with
multicentre collaboration, dictating optimum communication to ensure the best
interests of the child are met. It was also recommended that prospective studies be set
up to gather data about the impact of current treatment strategies on fertility
outcomes in prepubertal children treated for cancer to facilitate further our
understanding of the gonadotoxic impact of chemotherapy and radiotherapy in the
hope that future treatment regimens may be modified accordingly. The experimental
nature of this work makes it essential to ensure that clinical and research practice
develops in a phased and co-ordinated manner, as outlined in Table 8.1.
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Table 8.1 Development strategy for research into germ cell harvest and storage.
Phase 1
Develop a consensus regarding treatment-related risks of germ cell damage
Develop a consensus regarding risks to the child associated with germ cell harvest
Phase 2
Develop methods of prospective data collection aimed at registering germ cell
tissues, collection, and conditions of storage
Develop a register of patients at risk of infertility
Phase 3
Monitor success rates of the use of stored germ cell material and the fertility rates of
those registered
Phase 4
Careful follow-up of the offspring of children born following assisted reproduction
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9. Conclusions
As treatment for childhood cancer has become increasingly successful, adverse
effects on reproductive function are assuming greater importance. Treatment of
childhood cancer with chemotherapy and radiotherapy may damage testicular
function resulting in impaired spermatogenesis and temporary or permanent
infertility in adulthood. In this study testicular function and semen quality were
investigated in 33 survivors of childhood cancer. It has been shown that the treatment
of cancer during childhood was associated with a significant risk of subsequently
impaired spermatogenesis, with 30.3% of this population being azoospermic and
18.2% being oligozoospermic. Moreover, in those men who do have surviving
spermatogenesis after treatment, it is commonly compromised, with reductions being
observed in ejaculate volume, sperm concentration, sperm motility and the
proportion of morphologically normal sperm. Only 33.3% of this group of 33 male
childhood cancer survivors had completely normal semen quality by conventional
criteria. However, the sperm produced do not appear to carry a greater burden of
damaged DNA compared with the healthy population, suggesting that assisted
conception treatment is a safe option for these men.
Traditionally, determining the impact of chemotherapy and radiotherapy on gonadal
function has involved clinical assessment of pubertal development and semen
analysis in males. Earlier detection of gonadal damage has been hampered by the
lack of a sensitive marker of gonadal function in prepubertal children. The role of
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inhibin B as a marker of early gonadotoxic effects of chemotherapy in prepubertal
children treated for cancer was investigated. In prepubertal boys, chemotherapy had
little immediate effect on Sertoli cell production of inhibin B, although one boy
showed a delayed deleterious effect. Inhibin B changed earlier and appeared to be a
more sensitive marker of gonadal damage than FSH or LH. It was concluded that
inhibin B may be a useful addition to sensitive measurements of FSH in the
evaluation of early gonadotoxic effects of chemotherapy in prepubertal children.
Further studies are planned, combining inhibin B with FSH, LH and sex hormone
measurements, to assess long-term reversibility and delayed effects, particularly as
the children approach and progress through puberty.
For prepubertal boys, fertility preservation through semen cryopreservation is not an
option and consequently, attention is focusing on the development of techniques that
might preserve or restore fertility potential in boys being subjected to gonadotoxic
cancer therapy. In rats, it has been shown that some germ cells survive cytotoxic
therapy and that the resulting azoospermia is a consequence of the inability of those
spermatogonia that are present to proliferate and differentiate. Suppression of the
hypothalamic-pituitary-gonadal (H-P-G) axis facilitates recovery of spermatogenesis
following such cytotoxic treatment. Investigation of whether suppression of the H-P-
G axis in men rendered azoospermic by treatment for childhood cancer might restore
spermatogenesis was undertaken, using both semen analysis and testicular biopsy as
end points. In men treated with sterilising radiotherapy and chemotherapy for
childhood cancer, effective gonadotrophin suppression with medroxyprogesterone
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acetate for at least 3 months did not result in restoration of spermatogenesis. The
absence of histological evidence of spermatogonial stem cells in testicular biopsies
from these men before and after suppression suggests complete ablation of the
seminiferous epithelium and irreversible infertility.
Understanding the vulnerability of the prepubertal human testis to cytotoxic damage
is compounded by the dearth of data describing normal testicular development in the
prepubertal human. Based on immunohistochemical studies in marmosets, a primate
that exhibits a similar developmental profde to the human male, it has been shown
that significant testicular development occurs during childhood long before the
clinical onset of puberty. If we can establish that cell activity does occur in the
'quiescent' testis in boys and is comparable to changes shown in the marmoset, it
will validate use of the marmoset as a model for the human in this instance and give
encouragement to the possibility of using this primate model to develop a method of
protecting spermatogenesis in boys undergoing cancer therapy prior to puberty.
Preliminary studies to investigate the development of the prepubertal human testis
confirmed testicular cell activity in the foetal and neonatal periods and infancy
comparable to that shown in the marmoset. However, to date development during
mid childhood and early puberty has proved to be somewhat discordant with the
marmoset studies. It is too premature to definitively conclude that marmoset and
human testicular development are dissimilar, as a number of explanations have been
proffered to explain the discrepancies, including suboptimal tissue fixation and/or
antigen preservation in the human tissues.
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9.1. Futureobjectives
It is incumbent upon oncologists to facilitate appropriate counselling of patients at
risk of subfertility as part of their routine care. Preservation of fertility before
treatment must be considered in all young patients at high risk of subfertility.
Limitation of radiation exposure, by shielding of the testes, should be practiced
where possible and sperm banking should be offered to all sexually mature boys at
risk of infertility. Semen can be stored before sterilising chemotherapy and
radiotherapy for use at a later date, thus preserving fertility.
For prepubertal boys, lacking in haploid gametes, there are no options currently
available to preserve fertility and harvesting of testicular germ cells before sterilising
cancer therapy is the most promising option. However, any potential strategies must
be considered entirely experimental. Capitalising on the unique properties of the
spermatogonial stem cell, testicular tissue could be harvested before treatment and
cryopreserved for use at a later date. The functional capacity of the testes appears to
be preserved and autotransplantation of the stem cells in rats has been shown to re¬
initiate spermatogenesis and to permanently restore fertility. Where fears of
reintroducing tumour cells may limit applicability of this approach in humans, in
vitro maturation and use with assisted reproduction techniques is a realistic
alternative.
It is in the area of stem cell biology that our future research will focus. Integral to
this study will be the development of stem cell culture to enable further study of stem
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cell biology and ultimately develop techniques for in vitro proliferation and/or
maturation. Our objective is to optimise stem cell isolation and purification
techniques and to develop safe and efficient germ cell transplantation methods in
mice. If autologous germ cell transplantation is to be considered in oncology
patients, ensuring transplantation of tumour free cells is paramount. Preliminary
steps would involve the development of methods to isolate and cryopreserve
spermatogonial stem cells from mice testes and to establish stem cell purification
procedures. Identification of stem cell markers will be undertaken and stem cell
culture techniques will be developed in mice. Any new understanding from mice
would subsequently be applied to marmosets, and with this in mind, procedures for
germ cell transplantation in the marmoset are in progress and showing some success.
Harvesting gonadal tissue and its future use is an exciting new area of gamete
biology which raises a wide range of unresolved ethical and legal issues that must be
addressed before embarking on any clinical programme. I have explored the inherent
ethical, legal and scientific dilemmas that must be addressed before embarking on
any clinical programme of gonadal tissue harvesting, and I have presented the current
recommendations for considering harvesting of gonadal tissue in boys undergoing
treatment for childhood cancer.
The importance of the late effects of treatment are receiving increasing recognition
and in the UK strategies for long-term follow up are currently being explored .
Consideration of fertility preservation is a quality of life issue at a time of intense
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stress for young patients and their families. Nevertheless, in our experience, open
discussion is embraced and often potentially therapeutic for the vulnerable family
facing treatment for cancer. Discussion of fertility issues at the time of diagnosis
provides the family with the reassurance that they can look forward to long-term
survival for their child, and a future when these issues will become important. It is
also important to be aware of other quality of life issues in this field that are likely to
emerge as the numbers of treated cancer survivors enter old age. In particular, the
age-related decline in testosterone levels in most men (and it's attendant sequelae)
may be advanced or exacerbated in male cancer survivors, based on the evidence that
some men show evidence of compensated Leydig cell failure17"19,53. Long-term
follow-up is essential for these men to enable early recognition of problems and,
where possible, effective therapy instituted to optimise quality of life.
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($> Semen quality and spermatozoal DNA integrity in survivors of
childhood cancer: a case-control study
Angela B Thomson, Alastair J Campbell, D Stewart Irvine, Richard A Anderson, Christopher J H Kelnar, W Hamish B Wallace
Summary
Background Treatment of childhood cancer can result in
impaired spermatogenesis. Intracytoplasmic sperm injection
(ICSI), however, can enable men to achieve fatherhood, and
has focused attention on gamete integrity in men with
oligozoospermia. Our aim was to assess testicular function
in survivors of childhood cancer.
Methods We assessed testicular function in 33 survivors of
childhood cancer and 66 age-matched controls. The median
age at diagnosis and at the start of the trial was
10-0 years (range 2-2-16-9) and 21-9 years (16-5-35-2),
respectively. We assessed pubertal staging, measured
plasma sex steroid hormone concentrations, and analysed
semen quality, including spermatozoal DNA integrity.
Findings Ten (30%) individuals were azoospermic and
six (18%) oligozoospermic (sperm concentration
<20xl06/mL). Sperm concentration was significantly lower in
the non-azoospermic group than in controls (median
37 1X106/mL, IQR 19-7X106 to 89-9X106, vs 90-7xl06/mL,
50-5X106 to 121-5X106; p=0-002). In the non-azoospermic
cancer survivor group, inhibin B concentrations were lower than
in controls (mean 153-3 ng/L, SEM 17-8, vs 223-7 ng/L,
8-8; p<0-001), and FSH concentrations were higher (6-6 U/L,
0-9, vs 3-2 U/L, 0-2; p<0-001). Only 11 (33%) survivors
of childhood cancer had normal semen quality. There was
no significant difference in sperm DNA integrity between
the non-azoospermic and control groups (9%, 5-13, vs 11%,
7-16; p=0-06).
Interpretation Sperm concentration is reduced after
treatment for cancer. However, the sperm produced seems
to carry as much healthy DNA as those produced by the
healthy population, suggesting that assisted conception can
be considered as a treatment option for these men.
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70% of individuals survive childhood cancer, and this
proportion continues to increase. As such, attention is
being focused on the lasting morbidity associated with
radiation and chemotherapy treatment.1 A frequent and
psychologically traumatic late complication of cancer
treatment is infertility. Cytotoxic chemotherapy drugs,
especially alkylating agents, can produce long-lasting
or permanent damage to the germinal epithelium, resulting
in oligozoospermia or azoospermia.2-8 The germinal
epithelium is also sensitive to radiotherapy, and doses as
low as 1 -2 Gy can result in permanent sterility.' Recovery
from surviving germ cells can happen but is unpredictable
and often takes a long time.7,8 Leydig cells, with their slower
rate of turnover, are more resistant to gonadotoxic therapy,
resulting in preservation of androgen production even when
patients are infertile.5
Advances in techniques of assisted reproduction,
especially intracytoplasmic sperm injection (ICSI), have
enabled some men with oligozoospermia to become
fathers.10,11 Concerns have been raised, however, about the
safety of ICSI,12 since whether or not spermatozoa from
men with impaired spermatogenesis carry abnormal genetic
information is unkown.13"15 Data on the health of offspring
bom after ICSI are broadly reassuring," though there are
no data on the health of children bom to fathers whose
deficit in semen quality is a specific consequence of
potentially mutagenic treatment.17 Results of studies in
animals have shown that exposure of the male germ line to
chemotherapy agents can disrupt spermatozoal DNA and
result in deleterious effects on embryo development.18
Awareness of the importance of the integrity of sperm DNA
for accurate transmission of genetic material to the
offspring has necessitated the development of new
techniques to assess sperm characteristics in more detail.19
Our aim was to investigate testicular function and semen
quality in survivors of childhood cancer.
Methods
Patients
We searched the oncology database at the Royal Hospital
for Sick Children, Edinburgh, for all male survivors of
childhood cancer aged older than 16 years, and identified
51 individuals between December, 1999, and June, 2001.
We invited 45 of these men to participate in the study, and
excluded six because they no longer lived in the area (five)
or were on antidepressant medication (one). Six of the
45 men declined and six did not reply to the invitation. The
18 men who did not participate in our study were
comparable for age, diagnoses, age at diagnosis, treatment
regimens, and disease-free survival. 33 men participated in
the study. For each study participant, we recruited two age-
matched controls (n=66). The volunteers were recruited by
means of advertisement in local media and through hospital
out-patient clinics, and selected on the basis of the absence
of any clinical evidence, on history or physical examination,
of reproductive health problems. The Lothian Paediatric
and Reproductive Medicine research ethics subcommittee
approved the study, and all patients provided written
informed consent.
THE LANCET • Vol 360 • August 3, 2002 • www.thelancet.com 361
ARTICLES
Study protocol
We assessed pubertal maturation according to the Tanner
criteria, and measured testicular volume with the Prader
orchidometer.20 We noted the mean volume of the two
testes as the individual's testicular volume. We identified
concentrations of luteinising hormone (LH), follicle
stimulating hormone (FSH), and testosterone in venous
blood samples (20 mL) with an automated immunoassay
analyser (Bayer Immuno 1, Bayer, Newbury, Berkshire,
UK), and measured inhibin B concentrations in serum from
venous blood samples that had been centrifuged at 2000 g
for 10 min and stored at -20°C.21 Semen samples were
collected in a room adjacent to the laboratory,
by masturbation into sterile, wide-mouthed non-toxic
containers, after an abstinence period of at least 48 h. The
samples were analysed for ejaculate volume, sperm
concentration, motility, and normal morphology, according
to WHO protocols.22 Throughout the study, the laboratory
was subject to external quality control.
We measured the extent of DNA fragmentation in
spermatozoa with the terminal deoxyribonucleotidyl
transferase (TdT)-mediated dUTP-biotin nick end-
labelling (TUNEL) technique, according to the general
methodology of Sun and colleagues," modified as follows.
We obtained an unselected population of cells by mixing
an aliquot of each sperm sample with Biggers-
Whitten-Whittingham medium23 containing 20 nmol
N-(2-hydroxyethyl) piperazine-N'-(2-ethan sulfonic acid)
(Invitrogen, Paisley, UK) and 0-3% human serum albumin
solution, and centrifuged at 500 g for 5 min. After decanting
the supernatant, we resuspended the pellet of spermatozoa
in 2 mL of phosphate buffered saline (Sigma-Aldrich,
Gillingham, UK) and centrifuged at 500 g for 5 min. This
step was repeated and the spermatozoa were subsequently
fixed in 1% formaldehyde (Sigma-Aldrich) in phosphate
buffered saline for 60 min at room temperature. The fixed
sperm concentration was adjusted to 20X106cells/mL with
a Neubauer haemocytometer. We centrifuged the sample at
500 g for 5 min and washed it in phosphate buffer saline.
The fixed sperm were resuspended in 100 [jlL prewash
buffer, containing single strength One-Phor-All buffer
(Amersham Pharmacia Biotech, Buckinghamshire, UK)
and 0-1% Triton X-100 (Sigma-Aldrich) for 15 min at
room temperature. We centrifuged out the sperm from the
buffer at 500 g for 30 min and resuspended in 50 pL of
TdT buffer, containing 3 pmol biotin-16-dUTP (Roche
Diagnostics, Lewes, UK), 6 pmol dATP (Amersham
Pharmacia Biotech), and 1 IU/pL of TdT enzyme
(Amersham Pharmacia Biotech), and incubated at 37°C
for 1 h. After washing in phosphate buffer saline, we
resuspended the fixed permeabilised sperm in 100 pL of
staining buffer, consisting of 01% Triton X-100 (in
distilled water) and 1% streptavidin/fluorescin conjugate
(Calbiochem-Novabiochem, Nottingham, UK), and
incubated the sample in the dark at 4°C for 30 min. The
stained cells were spun at 500 g for 5 min and resuspended
in 500 pL phosphate buffer saline to give a concentration of
about 1X106 cells/mL. For negative controls, we omitted
the enzyme terminal transferase from the reaction mixture.
For positive controls, we treated the samples with
0-8 IU/pL DNase I (Roche Diagnostics) for 15 min at room
temperature before incubation with the TdT buffer.
Patient Diagnosis Chlorambucil Procarbazine Vinblastine
total dose total dose total dose
(g/m2) (g/m2) (g/m2)
1 ALL
2 ALL and testis
relapse
3 HD 0-90 (0-67) 16-80 (11-20) 134-00 (96-00)
4 HD 0-50 (0-50) 8-40 (8-40) 79-20 (72-00)
5 HD 0-50 (0-50) 8-40 (8-40) 72-00 (72-00)
6 HD 0-50 (0-50) 10-00 (8-40) 86-40 (72-00)
7 HD 0-34 (0-50) 6-30 (8-40) 54-00 (72-00)




























































































































ALL=acute lymphoblastic leukaemia. HD=Hodgkin's disease. NHL=non-Hodgkin lymphoma.
Table 1: Diagnosis and exposure to potentially gonadotoxic treatment by sperm count of all study patlertfs
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Data are number (%) unless otherwise indicated. *p<0-001 for azoospermic group
compared with other two groups.
Table 2: Testicular function in long-term survivors of childhood
cancer and in controls
We analysed the samples with an Epics XL flow
cytometer (Beckman Coulter Corporation, Bucking¬
hamshire, UK) with a 15 mW argon ion laser operating at
488 nm. We measured green fluorescence with the FL1
detector at 525 nm. The flow rate during analysis was
controlled at 200 events/s, and we analysed 10 000 events
in each sample. Light-scatter and fluorescence data were
obtained at a fixed gain setting in the logarithmic mode.
Debris were gated out on the basis of forward scatter
versus side scatter dot plot, by drawing a region enclosing
the cell population of interest, and 10 000 events were
collected. We processed the data with an IBM compatible
computer installed with System II, version 1.0 (Beckman
Coulter Corporation). We identified the proportion of
labelled sperm in each sample.
Seven of the ten men identified on semen analysis as
being azoospermic had a testicular biopsy done under
general anaesthetic, to exclude a diagnosis of obstructive
azoospermia. We fixed the specimens in Bouins and
stained them with haemotoxylin and eosin. The presence
of spermatogonia! stem cells was assessed.
Statistical analysis
We did statistical analysis with SPSS (version 10.0).
Analysis of variance was done on the endocrine data
(non-parametric) and ejaculate volume (Kruskal-Wallis
test), the data common to all three groups. We did pair-
wise tests to study differences between the groups, if such
differences existed. We did t tests and Mann-Whitney U
tests to compare the differences between patient groups
and controls with respect to endocrine data and semen
data, respectively. For comparisons that involved all three
patient groups, three pair-wise two-sample tests were
done and Bonferroni corrections applied to the p values.
A p value less than 0-05 was judged significant.
Role of the funding source
The sponsors of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report.
Results
The 33 men had a median age of 21-9 years (range
16-5-35-2). Their median age at diagnosis of cancer was
10-0 years (2-2-16-9), and they had a median disease-free
survival time of 11-6 years (0-3-24-4). The underlying
malignancies included acute lymphoblastic leukaemia
(15), Hodgkin's disease (six), Ewing's sarcoma (five),
non-Hodgkin lymphoma (two), brain tumours (two),
Wilms' tumour (one), osteosarcoma (one), and
teratocarcinoma (one). Table 1 shows the patients'
diagnoses and details of the potentially gonadotoxic
chemotherapy and radiotherapy received. Table 2 shows
characteristics ofpatients and controls.
Of the 33 patients, ten were azoospermic. Five of these
individuals had received treatment for Hodgkin's disease
with the alkylating agents chlorambucil, procarbazine,
and vinblastine (table 1), all of which are gonadotoxic.
Two of the azoospermic patients had been treated with
ifosfamide for Ewing's sarcoma, two had received total
body irradiation, and one had received direct testicular
irradiation (table 1). Of the ten azoospermic patients,
seven were prepubertal at diagnosis, providing cogent
evidence that the prepubertal testis is not afforded
protection from cytotoxic insult.
Six (18%) patients were oligozoospermic (sperm
concentration <20X106/mL), with severe oligozoo-
spermia (<2X 10"/mL) in one individual. In controls,
however, oligozoospermia was seen in only three (5%)
individuals. Only one of the six men treated for
Hodgkin's disease with an alkylating agent-based regimen
showed preservation of spermatogenesis (sperm
concentration 4-55X106/mL). Three of the oligo¬
zoospermic patients had been treated with Medical
Research Council Protocols, UKALL II, III, and X,
which consisted of combination chemotherapy, including,
vincristine, prednisolone, 6-mercaptopurine methotrex¬
ate, cytarabine, and cyclophosphamide. Oligozoospermia
was seen in one of the five patients treated for Ewing's
sarcoma, for whom treatment included ifosfamide and
cyclophosphamide. The remaining oligozoospermic
patient (sperm concentration 0-55XlOVmL) did not
receive treatment with agents expected to be gonadotoxic,
and the reason for impaired spermatogenesis remains
unknown.
Sperm concentration in the non-azoospermic group of
individuals treated for cancer was significantly lower than
the sperm concentration of controls (table 3, figure 1).
Nine (29%) of the patients were asthenozoospermic





95% CI azoospermic 95% CI non-azoospermic 95% CI non-azoospermic










1-9 (1-5-2-3) 2-5 (2-1-3-5) 3-4 (2-5-5-1)
0 37-1 (19-7-89-9) 90-7 (50-5-121-5)
-2-7 to -0-7f -1-5 to 0-2 -1-7 to -0-3f
-67 to -15f
56-3 (44-4-64-7) 61-9 (55-5-69-1)
6-5 (3-7-7-6) 9-3 (6-3-11-0)




Data are mean (IQR). *n=64 for TUNEL assay. f= p<0-01. t=p<0-05.
Table 3: Semen quality in long-term survivors of childhood cancer and in controls

























(n=66) long-term survivors of
childhood cancer (n=23)
Figure 1: Sperm concentration in non-azoospermic long-term
survivors of childhood cancer and in controls
Median, IQR, and maximum and minimum values are shown.
(progressive motility <50%) compared with ten (15%)
controls. Median progressive motility for the non-
azoospermic group was significandy less than for the
control group (table 3). The proportion of sperm with
normal morphology was also significantly less in the non-
azoospermic group than in controls (table 3). From our
population of 33 male survivors of childhood cancer only















(n=64) long-term survivors of
chilhood cancer (n=23)
Figure 2: Sperm DNA integrity in long-term survivors of
childhood cancer and in controls
















































Figure 3: Comparison of values for follicle stimulating hormone
(FSH) (A), inhibin B (B), luteinising hormone (LH) (C), and
testosterone (D) in the control group, and in non-azoospermic
and azoospermic cancer survivors
Mean and SEM are shown. Reference ranges for FSH and LH are
1-5-9-0 U/L and for testosterone 10-30 nmol/L. There is no established
reference range for inhibin B.
WHO compared with 55 (83%) in the control group.
There was no correlation between either age at diagnosis
or time out from treatment and sperm concentration in
this group of cancer survivors who were non-azoospermic
(p=0-109 and p=0-516, respectively). There was a
difference in ejaculate volume between the three groups
(p<0-001). Ejaculate volume was significantly reduced in
the azoospermic and non-azoospermic groups compared
with controls (p=0-002 and p=0-006, respectively).
We assessed the integrity of the spermatozoal DNA
with the TUNEL assay and the results are shown in
table 3. There was no significant difference between
DNA fragmentation in the non-azoospermic group and
controls (table 3, figure 2).
Testicular biopsies from seven of the ten men with
azoospermia on semen analysis showed a Sertoli-cell only
picture in all instances, thus excluding obstructive
azoospermia.
Analysis of variance for the endocrine measurements,
FSH, LH, testosterone, and inhibin B, showed a
significant difference for the FSH, LH, and inhibin B
values for the three groups (p<0-001), but no significant
difference was seen between the groups for testosterone
concentrations. Pair-wise tests were subsequently done to
assess the differences between the groups, with
Bonferroni corrections applied.
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Basal serum concentrations of FSH were significantly
higher in the azoospermic group than in the non-
azoospermic (mean difference -16-6, 95% CI -22-0 to
-11-3, p<0-001) and control (-20, -23-1 to -17-1,
p<0-001; figure 3A) groups. The concentrations of FSH
were also significantly greater in the non-azoospermic
group than in the controls (-3-4, -4-8 to -2-1, p<0-001;
figure 3A). Inhibin B concentration was barely detectable
in the azoospermic group, and was significantly lower in
that group than in both the non-azoospermic (129-3, 61-2
to 190-5, p<0-001) and control groups (198-9, 146-6 to
245-9, p<0-001; figure 3B). Inhibin B concentrations
were also significantly lower in the non-azoospermic
group than in the control group (69-6, 34-6 to 106-3,
p<0-001; figure 3B). Serum concentrations of LH were
significantly greater in the non-azoospermic and
azoospermic groups than in the controls (-2-4, -3-5 to
-1-2, and-5-6,-7-1 to-4-2, respectively, p<0-001 in both
instances, figure 3C). Testosterone concentrations were
within normal limits in all three groups, with no
significant differences between the groups (figure 3D).
Discussion
Our results indicate that treatment of childhood cancer is
associated with a high risk of impaired spermatogenesis in
adulthood. Moreover, in men in whom spermatogenesis
continues after treatment, production is generally
compromised, with reductions arising in ejaculate volume,
sperm concentration, sperm motility, and in the
proportion of morphologically normal sperm. Reassur¬
ingly, however, the integrity of the genomic DNA carried
by the gametes of men treated for cancer seems
unaffected. Our findings suggest that the reduction in
sperm number is directly attributable to the cytotoxic
effects of cancer therapy.
Fertility and sexual function are the principal life-style
concerns in more than 80% of men successfully treated
for cancer,24 yet a substantial proportion of survivors
invited refused to take part in our study. Cancer survivors
are less likely to have children for several reasons other
than treatment-induced infertility, including an inability
to form relationships, fear of relapse of their disease, and
the prospect of leaving a child parentless.24
Cytotoxic treatment for childhood cancer should
minimise unwanted side-effects without compromising
survival. Where there is equal efficacy between regimens,
the effect of drugs on reproductive function should be
considered when devising the most appropriate therapy.25
Our data confirm the sterilising effects of treatment for
Hodgkin's disease with a standard regimen, ChlVPP
(chlorambucil, vinblastine, procarbazine and pred¬
nisolone).7-8 The ABVD (adriamycin, bleomycin,
vinblastine and dacarbazine) combination, which does not
contain alkylating agents or procarbazine, is much less
gonadotoxic, resulting in temporary azoospermia in 33%
of patients and oligozoospermia in 21%, with full recovery
after 18 months reported in all patients.26 Consequently,
with the introduction of hybrid regimens, three cycles of
ABVD with three cycles of ChlVPP or MOPP
(mechlorethamine, vincristine, procarbazine, and prednis¬
olone), gonadotoxicity could be greatly reduced.
Three of the sterile men in our study had been treated
with either fractionated total body irradiation or testicular
irradiation. Although recovery has been reported after
several years, the high doses administered in these
treatments make recovery unlikely.' Furthermore, as a
prerequisite of recovery, some stem cells must survive,
and in these three men, as indeed in all seven men
biopsied, stem cells were absent.
Ifosfamide, an analogue of cyclophosphamide,
potentially gonadotoxic. Five of our patients had receive
treatment that included ifosfamide for Ewing's sarcom;
Of these, two had a normal semen analysis, one w;
oligozoospermic, and the remaining two patients wei
azoospermic. The three patients with sperm present i
their ejaculate had been treated more than 11 yea:
previously, compared with the azoospermic patients wh
had completed treatment 4 and 7 months previously. Tf
two sterile patients were sexually mature at the time <
diagnosis and had provided semen samples ft
cryopreservation before commencing cancer therapy, wit
sperm concentrations of 124X106/mL and 128X 107ml
This finding suggests that recovery of testicular functio
with increasing time since treatment is a possibility
Continued, perhaps yearly, reassessment of seme
analysis is warranted in azoospermic patients.
Normal semen quality, as defined by WHO, stipulatt
that sperm concentration must be greater tha
20X106/mL and progressive motility greater than 50%.
According to these criteria, only a third of the survivors <
childhood cancer had a normal semen analysis, compare
with most of the control group. Our results are similar t
those reported by Lopez Andreu and co-workers.27
Oligozoospermia was observed in six (18%) of the lonf
term survivor patients, compared with three (5%) in th
control group. One of the patients, with sevei
oligozoospermia, had been treated with alkylating ageni
for Hodgkin's disease. Three of the oligozoospermi
patients received treatment with standard protocols fc
acute lymphoblastic leukaemia, which included cytarabin
and in one patient cyclophosphamide. The doses c
cytarabine and cyclophosphamide received by these thre
patients were significantly less than previously reported t
be gonadotoxic doses6 and could indicate individui
susceptibility. Lendon and colleagues28 studied th
testicular histology of 44 boys treated for acui
lymphoblastic leukaemia and noted a severely depresse
tubular fertility index, <40%, in 18 individuals, indicativ
of germinal epithelial damage. In a follow-up study b
Wallace and colleagues,4 semen analysis in seven of thes
patients with severe depression of tubular fertility inde>
who had been off treatment for a median of 10-8 yeai
(range 5-5-15-9), reported azoospermia in four c
the patients and full recovery of spermatogenesis i
three (sperm concentration >20xl06/mL)—ie, previoc
chemotherapy treatment with cyclophosphamide an
cytarabine impaired gonadal function, which improve
with increasing time after treatment in some patients.
Inhibin B mediates non-steroidal negative feedbac
from the testes, reflecting the number of spermatozo
produced and regulating FSH secretion.2'-30 Inhibin 1
secretion in the adult requires the presence ofgerm cells.
Inhibin B concentrations were barely detectable in th
azoospermic patients, in whom the germ cells wei
destroyed, despite preservation of Sertoli cells, a
confirmed on testicular biopsy. This finding provide
further evidence for the essential role of the germ cell
Sertoli cell interaction for the production of inhibin E
and confirms the value of inhibin B as a non-invasiv
marker of spermatogenesis after cytotoxic therapy.
The sperm concentration in the non-azoospermic grou
was significantly less than that of the general populatior
Although azoospermia after gonadotoxic chemotherap
has been widely investigated there are few data abot
sperm concentrations in those patients in whor
spermatogenesis is preserved. Rautonen and co-workers
report median sperm concentrations of 67 X106 mL (rang
u-hrx iO-^to t^5A j'07),fri zf"haiieirts"ueaaetr-fof~vtfiTchis'
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childhood haematological and solid cancers. Sperm
concentrations of 20-4X10" mL (3-2X10® to 43X106)
were reported in a small study cohort (four) treated for
acute lymphoblastic leukaemia (one) and non-Hodgkin
lymphoma (three), and 31X10® mL (4-5X10° to
100X10®) in eight long-term survivors of acute
lymphoblastic leukaemia, indicating a general trend
towards a lower sperm concentration.'2,33 In view of the
fact that intact spermatogenesis requires the presence of
stem cells, which are capable of self-renewal in addition to
differentiation, the discrepancy in sperm concentrations
between the non-azoospermic and control groups is
difficult to reconcile. The non-azoospermic group clearly
retains a population of intact stem cells capable of
undergoing normal spermatogenesis, yet the surviving
stem cells do not seem to repopulate the pool to produce
sperm concentrations comparable with the general
population. This deficit could reflect a more complex
picture, emphasising the important role of Sertoli cells in
supporting a finite number of stem cells. If there has been
subtle damage to the germinal epithelium, involving loss
of Sertoli cells, remaining Sertoli cells might already be
functioning to full capacity. This possibility is suggested
by the subnormal inhibin B concentrations and
corresponding rise of serum FSH concentrations in the
non-azoospermic group compared with the control
population. This finding is analogous to data showing a
decline in plasma inhibin B concentrations, directly in
proportion to Sertoli cell numbers, after unilateral
orchidectomy in rhesus monkeys.34 In a physiological
setting, where the negative feedback control system that
regulates the testes is operational, Sertoli cell number is
the primary determinant of circulating inhibin B
concentrations.34
Ejaculate volume was reduced in the non-azoospermic
and azoospermic groups compared with the control
group, a finding which is unlikely to be attributable to
retrograde ejaculation, obstruction, impaired autonomic
innervation, or incomplete specimen collection. Testost¬
erone concentrations were normal in both groups of
patients, making testosterone deficiency an unlikely cause
of decreased ejaculate volume. Damage to the prostate is
unlikely, since only three of the patients had radiotherapy
treatment involving the pelvis. Whether chemotherapy
plays a part is uncertain. In a study" of 55 long-term
survivors treated with chemotherapy or radiotherapy for
various childhood cancers, 18 (33%) were reported to
have a low ejaculate volume.
The mutagenic potential of cancer therapy might confer
a risk to the fetus conceived with gametes produced after
cancer therapy, although current epidemiological data
suggest that offspring of cancer survivors do not have an
increased incidence of congenital abnormalities or cancer
relative to the general population.35 However, an
important concern is that these results are largely based
on offspring arising from natural conception, and the
consequences of circumventing the natural selection
processes of fertilisation involved by means of ICSI, are
unknown.15 There is at least the hypothetical possibility of
injection of abnormal spermatozoa carrying abnormal
genomic DNA with the potential to increase congenital
and other abnormalities among offspring." Techniques to
assess spermatozoal DNA integrity have been
developed, ,4,,° and it has become clear that men from
subfertility clinic populations, with abnormalities of the
conventional criteria of semen quality, also have increased
amounts of damage to the genomic DNA in their
gametes. Even among normal populations, sperm
chromatin damage has been linked with impaired
fecundity.36 Spermatozoal DNA damage does not
preclude pronucleus formation at ICSI,'3 and abnormal
DNA within the male gamete is detectable in the early
embryo.37 Concern thus arises in the case of childhood
cancer survivors, given that the capacity of ionising
radiation and some chemicals to induce transmissible
genetic damage in the germ cells of laboratory mammals
has been clearly shown.38 Thus far, evidence on the safety
of ICSI has been largely based on its use in populations of
men with deficits in spermatogenesis unrelated to
potentially mutagenic cancer treatment. This evidence has
been broadly reassuring with respect to health risks to the
offspring,1®'39 although it is limited by restricted length of
follow-up available. We have shown that although the
conventional criteria of semen quality are frequently
abnormal in long-term survivors of childhood cancer, the
sperm produced do not seem to carry a greater burden of
damaged DNA. This observation goes some way to
providing reassurance about the use of ICSI, which will
circumvent the problems associated with severe
oligozoospermia and asthenozoospermia, and offer cancer
survivors the possibility of paternity in adulthood.
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Investigation of suppression of the hypothalamic-pituitary-
gonadal axis to restore spermatogenesis in azoospermic
men treated for childhood cancer
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BACKGROUND: Does suppression of the hypothalamic-pituitary-gonadal (HPG) axis restore spermatogenesis in
men rendered azoospermic following treatment of childhood cancer? METHODS: Seven men with azoospermia
secondary to treatment for childhood cancer, median age (range), 22.2 (18-25.3) years, aged 10.4 (4.4-13.3) years
at original diagnosis, participated. Each subject underwent semen analysis and testicular biopsy, followed by
treatment with medroxyprogesterone acetate (MPA), 300 mg i.m. repeated after 12 weeks, with 800 mg testosterone
pellets s.c. on day 1 to suppress the HPG axis. Hormone and semen analysis was performed every 6 weeks for 48
weeks. A second testicular biopsy was performed at week 48. RESULTS: Before HPG axis suppression, mean ±
SEM plasma LH was 9.0 ±1.8 U/l, testosterone 17.9 ± 1.5 nmol/1 and FSH 22.4 ± 4.4 U/l. Median (range) venous
plasma and seminal plasma inhibin B levels were 10.0 (7.8-35) and 11.2 (7.8-770) ng/1 respectively. During HPG
suppression, FSH and LH levels were undetectable for >12 weeks followed by a gradual return to pretreatment
concentrations by 48 weeks. All men remained azoospermic at study completion and complete absence of germ
cells on biopsies was demonstrated by immunocytochemistry for all specimens pre- and post-HPG axis suppression.
CONCLUSIONS: HPG axis suppression with MPA-testosterone for >12 weeks did not restore spermatogenesis in
azoospermic men treated with gonadotoxic radiotherapy and chemotherapy for childhood cancer.
Key words: cancer/childhood/hormone suppression/spermatogenesis/testis
Introduction
Advances in the treatment of childhood cancer mean that most
children can realistically hope for long-term survival. With a
70% overall survival rate, the prevalence of long-term survivors
in the young adult population is now estimated to be 1 in
1000 (Wallace, 1997). Of increasing concern among survivors
is the deleterious impact that chemotherapy and radiotherapy
has on future fertility irrespective of pubertal status at the time
of treatment (Heikens et al., 1996; Mackie et al., 1996; Howell
and Shalet, 1998; Waring and Wallace, 2001; Thomson et al.,
2002). For prepubertal boys, fertility preservation through
semen cryopreservation is not an option and consequently,
attention is focusing on the development of techniques that
might preserve or restore fertility potential in boys being
subjected to gonadotoxic cancer therapy.
A number of approaches to this problem have been investi¬
gated, based on the idea that suppression of spermatogenesis
might protect the normally rapidly dividing germ cell popula¬
tion from damage. Suppression of the rat hypothalamic-
pituitary-gonadal (HPG) axis by administration of the GnRH
© European Society of Human Reproduction and Embryology
analogue, goserelin, before and during chemotherapy with
procarbazine, enhanced recovery of spermatogenesis (Ward
et al., 1990). Similarly, protection of spermatogenesis in rats
subjected to treatment with procarbazine, cyclophosphamide
and radiotherapy has been demonstrated using a number of
hormones including testosterone alone (Delic et al., 1986) or
in combination with estrogen (Kurdoglu et al., 1994), GnRH
analogues in combination with testosterone (Pogach et al.,
1988) or the anti-androgen flutamide (Kangasniemi et al.,
1995; Meistrich et al., 1995).
Furthermore, recovery from spermatogenic damage in rats
induced by radiotherapy or procarbazine treatment has been
shown to be enhanced by treatment with GnRH analogues or
testosterone even when administered after the gonadotoxic
agent (Pogach et al., 1988; Meistrich and Kangasniemi 1997;
Meistrich et al., 1999). The mechanisms by which such
hormonal manipulation offers protection or enhancement of
recovery of spermatogenesis are unclear. Hormonal analysis
following irradiation in rats has shown a marked increase in
intratesticular testosterone levels and it has been postulated
1715
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1 ALL _ _ _ 2.76 (2) Cr/TBI 24/14.4 0
2 ALL/testis relapse - - - 2.93 (2) Cr/testis 18/24 0
3 HD 0.9 (0.67) 16.8 (11.2) 134 (96) - None 0
4 HD 0.5 (0.504) 8.4 (8.4) 79.2 (72) - None 0
5 HD 0.5 (0.504) 10 (8.4) 86.4 (72) - Upper mantle 30 0
6 HD 0.34 (0.504) 6.3 (8.4) 54 (72) - Medias/neck 35 0
7 B-cell NHL - - - 2.2 (2) Cr/TBI 6/14.4 0
ALL = acute lymphoblastic leukaemia; HD = Hodgkin's disease; NHL = Non-Hodgkin's lymphoma; TD = total dose; Cr = cranium; TBI = total body
irradiation.
that suppression of the HPG axis promotes multiplication
and differentiation of spermatogonia by lowering testosterone
concentrations within the testis (Meistrich and Kangasniemi,
1997).
While there is significant evidence for the success of
protection/recovery strategies in rats, clinical studies in man
have to date been inconclusive (Johnson et al., 1985; Waxman
et al., 1987; Masala et al., 1997) and there have been no
trials investigating the effects of post-gonadotoxic hormonal
suppression. The present study has investigated whether sup¬
pression of the HPG axis in men rendered azoospermic by
treatment for childhood cancer might restore spermatogenesis,
using both semen analysis and testicular biopsy as endpoints.
Materials and methods
The study was approved by the Lothian Paediatric and Reproductive
Medicine Research Ethics Sub-Committee and all patients gave
written informed consent.
Patients
A review of the oncology database at the Royal Hospital for Sick
Children, Edinburgh for men rendered azoospermic secondary to
treatment for childhood cancer, identified seven men aged 22.2
(18-25.3) [median (range)] years. All men were invited to participate
in the study regardless of the underlying malignancy or cytotoxic
therapy and all seven accepted. The median age at original diagnosis
was 10.4 (4.4-13.3) years with a disease-free survival of 8.4
(3.3-14.7) years. The underlying malignancies were acute lymphoblas¬
tic leukaemia (n = 2), Hodgkin's disease (n = 4) and non-Hodgkin's
lymphoma (n = 1). A summary of the patients' diagnoses with details
of the gonadotoxic chemotherapy and radiotherapy received is given
in Table I.
Clinical assessment and routine haematological and biochemical
assessment was performed on each patient to ensure that there was
no evidence of disease relapse or second primary malignancy, or
other reason likely to impair spermatogenesis. None of the patients
had a family history of impaired spermatogenesis.
Assessment of testicular function
Pubertal maturation was assessed according to the Tanner criteria and
testicular volume (ml) was measured using a Prader orchidometer
(Tanner and Whitehouse, 1976). The mean value of the two testes
was taken to represent the subject's testicular volume. Venous blood
samples were collected (20 ml), and LH, FSH and testosterone
levels determined using an automated immunoassay analyser (Bayer
Immuno 1, Bayer pic., Newbury, Berks, UK). Inhibin B was measured
as previously described (Groome et al., 1996), with the limit of assay
sensitivity being 7.8 pg/ml. Semen samples were collected in a room
adjacent to the laboratory, by masturbation into sterile wide-mouthed
non-toxic containers, following an abstinence period of s®48 h.
Samples were centrifuged at 3000 g for 30 min and the pellet
examined to confirm azoospermia (World Health Organization, 1999).
Seminal plasma was stored at -70°C until assayed for inhibin B
(Anderson et al., 1998). Testicular biopsy under general anaesthetic
was undertaken on all patients at the start of the study to exclude
obstructive azoospermia. The specimens were fixed in Bouin's fixative
and after routine processing and paraffin embedding, sections were
cut at 5 |im and examined. A second biopsy of the same testis was
performed at the end of the study.
HPG axis suppression
All men underwent a period of suppression of the HPG axis,
designed to induce hypogonadotrophic hypogonadism with reduced
intratesticular testosterone levels for a period of -24 weeks, followed
by a recovery period of 24 weeks. Following testicular biopsy,
subjects were administered depot medroxyprogesterone acetate
(DMPA, 300 mg i.m.; Pharmacia and Upjohn, Milton Keynes, UK)
and testosterone pellets (4X200 mg s.c.; NV Organon, Oss, The
Netherlands). Administration of DMPA was repeated 12 weeks later.
Subjects were reviewed at 6 weekly intervals throughout the
48 weeks of the study for clinical assessment, blood sampling and
semen analysis.
Immunohistochemistry of testicular tissue
The objective of the immunohistochemical analysis was to investigate
whether or not any germ cells, in any developmental stage, were
present in the testes of patients before or after HPG suppressive
treatment. This was achieved using immunoexpression of the MAGE-
57B antigen and androgen receptor (AR). The MAGE-57B antigen
is expressed in early germ cells, strongly in the spermatogonia! and
weakly in early spermatocytes (Aubry et al., 2001). AR is expressed
in the nuclei of all Sertoli cells but not in the nuclei of any germ
cells that might be present (Saunders et al., 1996).
Unless otherwise stated, all incubations were undertaken at room
temperature. Sections were deparaffinized in xylene, rehydrated in
graded ethanols and washed in water. A temperature-induced antigen
retrieval step was required for AR only. The sections were pressure-
cooked in 0.01 mol/1 citrate buffer, pH 6.0 for 5 min at full pressure,
allowed to stand for 20 min, cooled in running tap water and washed
twice in (5 min each wash) in Tris-buffered saline [TBS: 0.05 mol
Tris-HCl, pH 7.4,0.85% (w/v) NaCl], Endogenous peroxidase activity
was then blocked by immersing sections in 3% (v/v) H202 in methanol
1716
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Table II. Patient characteristics before hypothalamic-pituitary-gonadal suppression
Patient Tanner Testicular volume FSH LH Testosterone Inhibin B Inhibin B
stage (ml) (U/l) (U/l) (nmol/1) (venous) (semen)
(adult >12 ml) (ref range: 1.5-9) (ref range: 1.5-9) (ref range: 10-30) (ng/1) (ng/1)
1 5 12 18.2 6.6 21.9 35.0 770
2 5 5 45.1 19 17.7 15.5 27.7
3 5 10 23.9 9.3 21.5 <7.8 14.2
4 5 10 23 8 20.5 <7.8 8.2
5 5 5.5 25.2 8.8 10.2 <7.8 <7.8
6 5 8 9.8 6.3 16.6 12.2 N/O
7 5 12 11.6 4.9 17.2 N/O <7.8
Mean (SEM) 11 22.4 (4.4) 9.0 (1.8) 17.9 (1.5)
N/O = values not obtained.
(both from BDH Laboratory Supplies, Poole, UK) for 30 min,
followed by two 5 min washes in TBS. Sections were incubated for
30 min with the appropriate normal serum diluted 1:5 in TBS
containing 5% bovine serum albumin (BSA; Sigma-Aldrich Co. Ltd.,
Poole, Dorset, UK) to block non-specific binding sites. Normal swine
serum (NSS) and normal rabbit serum (NRS) (both from Diagnostics
Scotland, Carluke, UK) were used for AR and MAGE-57B respect¬
ively. Primary antibodies were added to the sections at the appropriate
dilution in either NSS-TBS-BSA (for AR 1:2000: AR N-20, Santa
Cruz Biotechnology SC0816, Santa Cruz, CA, USA) or NRS-TBS-
BSA (for MAGE-57B: 1:50, source of antibody) and incubated
overnight at 4°C in a humidified chamber. The sections were washed
twice in TBS and then incubated for 30 min with anti-rabbit or anti-
mouse horse-radish peroxidase-labelled polymer (EnVision: Dako,
Ely, UK) for AR and MAGE-57B respectively. Sections were washed
twice (5 min each) in TBS and immunostaining was developed using
liquid diaminobenzidine (Dako) until staining was optimal, when the
reaction was stopped by immersing sections in distilled water. The
sections were counterstained with haematoxylin, dehydrated in graded
ethanols, cleared in xylene and cover-slipped using Pertex mounting
medium (CellPath pic, Hemel Hempstead, UK). As negative controls,
slides were processed as above except that the appropriate normal
serum was substituted for the primary antibody.
Immunostained sections were examined and a mean of 132 (range
40-252) tubular cross-sections were counted for each specimen pre-
and post-HPG suppression. The sections were photographed using an
Olympus Provis microscope (Olympus Optical, Honduras Street,
London, UK) fitted with a digital camera (Kodak DCS330: Eastman
Kodak, Rochester, NY, USA). Captured images were stored on a
computer (G4; Apple Computer Inc., Cupertino, CA, USA) and
compiled using Photoshop 5.0 before printing using an Epson Stylus
870 colour printer (Seiko Epson Corp., Nagano, Japan).
Statistical analysis
Statistical analysis was performed by the Statistical Package for
Social Science (SPSS Inc., Chicago, III) version 10.0. For each
individual patient, hormone concentrations at the beginning and end




All seven men were Tanner stage 5 with reduced testicular
volumes of 11 (5-12) ml [mean (range), Table II]. There were
no changes in clinical features during the study and no changes
in testicular volume.
Hl'G axis suppression
MPA-testosterone treatment was well tolerated and there were
no adverse effects. One man reported increased libido during
the first 12 weeks of the study. Pretreatment serum FSH levels
were elevated, 22.4 ± 4.4 U/l (mean ± SEM, reference range:
1.5-9), in keeping with damage to the seminiferous epithelium
(Table II). Serum LH concentrations pretreatment were
9.0 ± 1.8 U/l (reference range: 1.5-9) and testosterone
17.9 ± 1.5 nmol/1 (reference range: 10-30), indicating com¬
pensated Leydig cell dysfunction (Table II). Serum and seminal
plasma inhibin B concentrations were barely detectable in all
but one subject (subject no. 1: 35 and 770 ng/1 respectively;
Table II).
FSH was suppressed to undetectable concentrations during
MPA-testosterone treatment for 12 weeks, and remained par¬
tially suppressed during the subsequent 12 weeks (Figure 1).
Thereafter, there was a gradual rise by weeks 42^-8 to
19.5 ± 3.6 U/l, which was not significantly different from
pretreatment concentrations. LH showed a similar pattern to
FSH, with suppression to undetectable concentrations for
12 weeks, followed by gradual recovery to 8.9 ± 1.6 U/l at
48 weeks (Figure 1). There was no statistically significant
difference between LH concentrations pretreatment and at
48 weeks.
Conversely, testosterone concentrations rose initially follow¬
ing MPA-testosterone administration to a peak of 29.7 ±
1.9 nmol/1 at 6 weeks, close to the upper limit of the normal
range. This was followed by a gradual decline to a nadir of
10.2 ± 0.2 nmol/1 at 30 weeks, with a subsequent slight rise
to 13.8 ± 1.9 nmol/1 at weeks 42^18. The latter was not
significantly different from the pretreatment concentration.
Serum inhibin B concentrations increased from 35 to
60.9 ng/1 at 12 weeks in the subject with the highest inhibin
B pretreatment, and rose from <15 ng/1 to low but detect¬
able concentrations (range 16-35 ng/1) in the five other
subjects (venous serum reference range: mean 257, 95% CI
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Figure 1. Serum concentrations of FSH, LH and testosterone in the
seven patients before (time 0) and during combined treatment with
medroxyprogesterone acetate and testosterone. Values are means ±
SEM. Dashed lines show the limit of assay sensitivity (FSH, LH) or
the upper and lower limits of the normal range (testosterone).
Hormone levels at 42-48 weeks were not significantly different
from pretreatment (week 0) values in each instance.
the end of the study, becoming undetectable in all subjects
other than the individual with the highest pretreatment con¬
centration at weeks 42^-8. This same individual was the
only subject with readily detectable seminal plasma inhibin
B concentration pretreatment (770 versus <20 ng/1 in the
others, seminal plasma reference range: mean 2279, 95% CI
698-3864 ng/1) (Anderson and Sharpe, 2000). Seminal plasma
inhibin B was not determined during MPA-testosterone treat¬
ment as the volume of the ejaculate was insufficient. In
all subjects, seminal plasma inhibin B concentrations were
undetectable at the end of the study.
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Figure 2. Haemotoxylin and eosin staining: (a) and (b) show testis
morphology pre- and post-hypothalamic-pituitary-gonadal axis
suppression respectively, and demonstrate complete absence of all
germ cell types, in contrast to the abundant germ cells in the
normal seminiferous epithelium of a healthy adult man (c). Scale
bars = 50 pm.
Semen analysis
All men remained azoospermic throughout the study.
Hormone restoration of spermatogenesis
Testicular tissue
Light microscopy
Examination of testicular tissue pre- (Figure 2a) and post-
(Figure 2b) HPG axis suppression indicated complete absence
of all germ cells, in contrast to the abundant different germ
cell types in the normal seminiferous epithelium of a healthy




The nuclei of all cells within the seminiferous epithelium of
all patients immunoexpressed AR (Figure 3a, brown staining),
and this was comparable before MPA-testosterone treatment
and at the end of the study (Figure 3b), in contrast to AR
negative cells evident in the testis of a healthy adult man
(Figure 3c). This finding suggested that only Sertoli cells were
present within the tubules of the cancer patients. Using the
methodology applied in the current study, all Sertoli cells in
the human testis immunostain for AR with similar intensity
(Saunders et al., 1996), although application of modified
methods can reveal differences in staining intensity between
different Sertoli cells in the normal adult testis (Suarez-Quian
et al., 1999).
MAGE-57B antigen
Immunoexpression of MAGE-57B was negative in all speci¬
mens, pre- and post-HPG axis suppression, in contrast to the
abundant immunopositive germ cells seen in the healthy
adult control (Figure 3d-f). This confirms the absence of
spermatogonia in the cancer patients.
Discussion
This study demonstrates that suppression of the HPG axis for
3=3 months, in men rendered azoospermic by gonadotoxic
chemotherapy or radiotherapy for childhood cancer, did not
result in restoration of spermatogenesis, assessed by both
semen analysis and testicular biopsy. In rats, it has been shown
that some germ cells survive cytotoxic therapy and that the
resulting azoospermia is a consequence of the inability of those
spermatogonia that are present to proliferate and differentiate
(Kangasniemi et al., 1995). Suppression of the HPG axis
facilitates recovery of spermatogenesis following such treat¬
ment, and it has been hypothesized that this is the result of
a reduction in intratesticular testosterone concentrations
(Meistrich and Kangasniemi, 1997). This can be achieved by
administration of steroid hormones, or GnRH agonists or
antagonists with or without testosterone before, during or after
chemotherapy or radiotherapy and such regimens have been
demonstrated to enhance recovery of spermatogenesis in rats
(Ward et al., 1990; Delic et al., 1986; Pogach et al., 1988;
Kangasniemi et al., 1995; Meistrich et al., 1995; Meistrich,
1998). Application of this approach to humans makes the
important assumption that the mechanism of cytotoxic chemo¬
therapy or radiotherapy-induced testicular damage is similar
in both species, and it has been assumed that like the rat, men
might retain a population of spermatogonia! stem cells from
which spermatogenesis could be regenerated. The mechanism
and permanency of impaired spermatogenesis induced by some
forms of chemotherapy/radiotherapy in the human may differ
more substantially from the rat than was previously appreciated.
The success of hormonal treatment to aid recovery of
spermatogenesis in rats subjected to chemotherapy is believed
to be based on lowering intratesticular testosterone levels.
While the prepubertal testis is relatively quiescent, there is a
steady turnover of early germ cells, which undergo spontaneous
degeneration before maturation is reached (Muller and
Skakkebaek, 1983). This relatively low activity, compared
with the adult, does not protect the prepubertal testis from the
deleterious impact of cytotoxic therapy, as the present data
confirm. The slow turnover of germ cells and their subsequent
degeneration in the prepubertal testis may be partly due to
low levels of intratesticular testosterone, which is required to
complete the end-stages of spermatogenesis (Chemes, 2001).
The lack of protection afforded to the prepubertal testis, at a
time when testosterone levels are low, would suggest that
additional environmental factors play a role in the successful
recovery of spermatogenesis in rats and the vulnerability of
the prepubertal human testis to cytotoxic therapy. In this
regard, our studies with the marmoset, a primate surrogate for
man, have demonstrated that activation of testicular cell
function occurs well before puberty and is largely gonadotro-
phin-dependent, but that spermatogonia! replication appears to
be independent of gonadotrophin stimulation (Kelnar et al.,
2002).
In one study in which cyclophosphamide was administered
as immunosuppressive therapy for nephrotic syndrome in adult
men, preservation of fertility was achieved via supraphysio-
logical testosterone therapy (Masala et al., 1997). Of 15 men
treated with cyclophosphamide, five received testosterone to
suppress testicular function before and during the 8 month
cycle of chemotherapy. All men were azoospermic or severely
oligozoospermic within 6 months of commencing cyclophos¬
phamide. Nine of the 10 men who received cyclophosphamide
alone remained azoospermic 6 months after the end of immuno¬
suppressive therapy, whereas sperm concentrations returned to
normal in all five of the men who received testosterone therapy.
High dose cyclophosphamide is known to be associated with
impaired spermatogenesis, which is often temporary, and it is
probable that in this study the simultaneous administration of
testosterone with cyclophosphamide provided some protection
or hastened the recovery of spermatogenesis. It would be
interesting to have long-term follow-up data on the 10 patients
who received cyclophosphamide-only treatment to enable a
direct comparison with the natural history of recovery of sperm
production. In contrast, other studies have failed to show
similar benefits in humans. For example, suppression of
testicular function with a GnRH agonist, alone or in combina¬
tion with testosterone during gonadotoxic chemotherapy treat¬
ment for lymphoma, did not confer any protective benefit or
enhance recovery of spermatogenesis (Johnson et al., 1985;
Waxman et al., 1987). A number of reasons may be considered
for the lack of successful outcome in the aforementioned
studies. The number of patients and controls studied was small
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Figure 3. Androgen receptor (AR) staining: (a) and (b) show AR immunoexpression pre- and post-hypothalamic-pituitary-gonadal axissuppression respectively, and demonstrate that all cell nuclei within the seminiferous tubules are AR immunopositive (brown staining),
thus excluding the presence of AR negative germ cells, as evident in the testis of a healthy adult man (c). Inset shows negative control in
which the primary antibody was omitted. Scale bars = 50 pm. MAGE-57B staining: (d) and (e) show no evidence of expression of the
MAGE-57B antigen (all cells stained blue), both pre-and post-HPG axis suppression, in contrast to the abundant germ cells immunopositive
(brown staining) for MAGE-57B demonstrated in the healthy adult control (f). Insert shows negative control in which the primary antibody
was omitted. Scale bars = 50 pm.
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with cyclophosphamide for a non-malignant condition. Treat¬
ment regimens may not have been sufficiently gonadotoxic to
cause sterility, so no recovery effect could be seen or, con¬
versely, the agents were so gonadotoxic that permanent ablation
of all germ cells was induced. Waxman et al. studied the
protective effects of a GnRH agonist during the treatment of
20 men with cytotoxic chemotherapy for advanced Hodgkin's
disease (Waxman et al., 1987). Following administration of
the GnRH agonist, standard GnRH testing demonstrated
adequate suppression of LH, but not of FSH, throughout the
chemotherapy treatment. Follow-up assessment of the men
after a 3 year interval showed that all remained severely
oligozoospermic (Waxman et al., 1987). In another study, the
effect of GnRH agonist administration during combination
chemotherapy for advanced lymphoma was evaluated in six
patients (Johnson et al., 1985). By 6 years post treatment, only
one patient demonstrated any evidence of spermatogenesis.
While the present study explored the delayed suppression
aspect of this hypothesis, no human studies have combined
pre-chemotherapy suppression with continued suppression for
a significant length of time following chemotherapy.
A number of steroid hormone combinations have been used
to suppress the HPG axis in rats and successfully restore
spermatogenesis after chemotherapy, including MPA in com¬
bination with testosterone (Velez de la Calle et al., 1990; Jegou
et al., 1991). Low dose testosterone, MPA or GnRH analogues
alone have been shown to stimulate recovery of spermato¬
genesis in rats following sterilization with radiotherapy. How¬
ever, the addition of testosterone to GnRH analogues may
reduce the effectiveness of GnRH analogues (Shetty et al.,
2000). The combination of testosterone with MPA may also
have a reduced effect compared with either agent alone,
although this combination results in a profound reduction in
intratesticular testosterone concentrations in men (McLachlan
et al., 2002). Although further study is warranted, the appro¬
priate choice of hormone suppression will require careful
consideration. Long-acting gonadotrophin analogues, such as
goserelin, have been shown to be ineffective at suppressing
FSH long term in normal men, with recovery of FSH and
resumption of spermatogenesis occurring within 2-3 months
(Behre et al., 1992; Bhasin et al., 1994).
Inhibin B mediates non-steroidal negative feedback from
the testes, reflecting the number of sperm produced and
regulating FSH secretion (Andersson et al., 1999; Peterson
et al., 1999; Anderson and Sharpe, 2000; Kolb et al., 2000).
Inhibin B secretion in the adult requires the presence of germ
cells (Andersson et al., 1999). Inhibin B concentrations were
barely detectable in the azoospermic patients, despite the
preservation of Sertoli cells. This provides further evidence
for an essential role of the germ cell-Sertoli cell interaction
in the production of inhibin B and confirms the value of
inhibin B as a non-invasive marker of spermatogenesis follow¬
ing cytotoxic therapy. Inhibin B was also undetectable in
seminal plasma in most subjects, as previously found in men
with azoospermia of other aetiologies (Anderson et al., 1998).
Although the gonadotoxic effect of chemotherapy depends
upon dosage and drugs administered, and radiotherapy-induced
damage upon field of irradiation and dose received, it is
difficult to reliably predict the extent of testicular damage and
which azoospermic patients may show recovery of spermato¬
genesis. Our study population comprised an unselected group
of seven men rendered azoospermic secondary to treatment
for childhood cancer. Testicular biopsies from all seven patients
demonstrated complete absence of spermatogonia, yet survival
of stem cells is a prerequisite for endocrine restoration of
spermatogenesis. It was felt to be unethical to exclude men
from the trial on the basis of Sertoli cell-only biopsy specimens
for several reasons. Testicular volume in these men was
markedly reduced and thus it was justified to take only a small
piece of testicular tissue, to eliminate any impact which a
reduction in testicular tissue may have on Leydig cell numbers.
Small islands of spermatogonia may be present but in our
study were absent from the biopsied tissue. Survival of germ
cells following apparently sterilizing chemotherapy is evident
from a number of studies. Temporary azoospermia and late
recovery of spermatogenesis following chemotherapy have
been reported, indicating the survival of stem cells (Viviani
et al., 1985; Wallace et al., 1991; Pryzant et al., 1993),
although permanent azoospermia tends to follow procarbazine
and alkylating agent-based regimens, typical of treatment for
Hodgkin's disease (Whitehead et al., 1982; da Cuhna et al.,
1984; Bramswig et al., 1990). Similar histological findings
have been reported in other studies following treatment
for Hodgkin's disease with procarbazine-based regimens
(Chapman et al., 1979; Charak et a!., 1990). With advances in
assisted reproduction techniques, the development of testicular
sperm extraction (TESE) combined with ICSI offers potential
for paternity in these young men. Chan and co-workers report
the use of TESE-ICSI to retrieve sperm from men with long¬
standing azoospermia and achieve a pregnancy (Chan et al
2001). Seventeen men, median age (range) 37.4 (28-54) years,
had undergone sterilizing chemotherapy treatment 16.3 (6-34)
years previously. Of the 17 men, 13 demonstrated Sertoli cell-
only on biopsy and the remaining four were described as
having hypospermatogenesis. Using microdissection TESE
techniques, sperm retrieval was achieved in seven subjects,
three (43%) of whom demonstrated Sertoli cell-only on testicu¬
lar histology and four (57%) with hypospermatogenesis. The
seven subjects underwent nine TESE combined with ICSI
procedures resulting in a clinical pregnancy in three (33%)
and a live birth in two (22%). These encouraging results
suggest that microscopic visualization of the seminiferous
tubules may enable identification of areas of continued
spermatogenesis within the testis and sperm retrieval using
microdissection techniques. This reiterates the importance of
not excluding men from hormone restoration clinical trials or
from assisted reproduction techniques on the basis of a Sertoli
cell-only testicular biopsy.
Although small islands of germ cell spermatogonia may
exist in the sections of testes that were not biopsied, it is likely
that in our patients, the severity of the cytotoxic-induced germ
cell loss is such that recovery of spermatogenesis is simply
impossible. This does not exclude the possibility that earlier
intervention and HPG axis suppression might have been
beneficial. However, it seems more probable that HPG axis
suppression to restore spermatogenesis may be more successful
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in patients in whom the testicular insult is less severe and in
whom there is some preservation of spermatogonial stem cells.
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The successful treatment of childhood cancer can be associated with impaired gonadal function in
adulthood. Chemotherapy and radiotherapy may damage germ-cell spermatogonia, resulting in
impaired spermatogenesis or sterility in the male, or may hasten oocyte depletion with truncated
fecundity and premature menopause in the female. The only established option in current clinical
practice for preserving male fertility is cryopreservation of spermatozoa. The only strategy
currently available for preserving female fertility is cryopreservation of embryos. Harvesting and
storage of ovarian cortical tissue from girls and young women before potentially gonadotoxic
chemotherapy has been available in a number ofcentres but there have been no live births and the
procedure remains experimental. Standards for best practice in the cryopreservation of gonadal
tissue, including the criteria for providing a service, patient identification and selection, standard
operating procedures and requirements for safe storage, remain to be defined. Recent advances
in assisted reproduction may circumvent natural conception barriers and the implications of
impaired DNA integrity may be manifest as an increased risk of congenital abnormalities and
chromosomal disorders in the offspring. In this chapter we consider the late reproductive
sequelae following treatment for childhood cancer and options for fertility preservation.
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Continuing therapeutic advances in the management of childhood malignancies mean
that the majority of children can realistically hope for long-term survival. With survival
rates in excess of 70% it is estimated that by the year 2010 one in 250 of the young
adult population will be a long-term survivor of childhood cancer.1-2 The successful
treatment of childhood cancer with chemotherapy and or radiotherapy is associated
with significant morbidity in later life.3 The major challenge faced by paediatric
oncologists today is to sustain the excellent survival rates while striving to achieve
optimal quality of life.
One of the most frequently encountered and psychologically traumatic late
complications of radiotherapy and chemotherapy for childhood cancer is infertility.
Consequently, attention is focusing on developing techniques to preserve fertility.
Advances in assisted reproduction techniques have focused attention on preserving
gonadal tissue for future use.4-7 For pre-pubertal boys for whom fertility preservation
through cryopreservation of semen is not possible, testicular germ cell harvesting
provides a technique by which germ cells can be removed and stored during cytotoxic
therapy. At a later date, following recovery, the stored tissue could be auto-
transplanted or these stored cells could be matured in vitro until they reach a stage
sufficiently mature to procure fertilization with assisted reproduction.7-" Preservation
of female fertility is equally challenging. Embryo cryopreservation is restricted by time
constraints, sexual maturity and the presence of a stable partner. Cryopreservation of
immature ovarian tissue is the most promising option, with restoration of natural
fertility following autotransplantation, or maturation of oocytes in vitro in com¬
bination with assisted reproduction.1213 Harvesting, and the potential future use of
gonadal tissue, is an exciting area of gamete biology which opens up new and
uncharted territory for paediatric oncologists managing children with cancer. These
techniques are still in the realms of experimental development. A number of ethical
and legal issues must be addressed to ensure that their clinical application conforms to
a voluntary code of practice, which offers realistic and safe prospects of fertility
preservation for young children with cancer.14
GONAOAL DAMAGE
Cytotoxic chemotherapy and radiotherapy may damage gonadal tissue and result in
long-lasting or permanent sterility. Cancer therapy may damage the developing gonad
in children. However, the full impact of the deleterious effects generally remains latent




The testis is highly susceptible to the toxic effects of radiation and chemotherapy at all
ages of life. Although the exact mechanism is uncertain it appears to involve a
combination of destruction of the proliferating germ cell pool and, where germ cells
survive, inhibition of further differentiation.23 Spermatogenesis is a process, beginning
at puberty and continuing throughout adult life, whereby totipotential stem cell
spermatogonia undergo continual self-renewal and differentiation into mature
spermatozoa.24 In the relatively quiescent pre-pubertal testis there is a steady
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turnover of early germ cells which undergo spontaneous degeneration before the
haploid stage is reached; nevertheless, it is likely that it is this steady state that
renders the pre-pubertal testis vulnerable to the deleterious impact of cytotoxic
therapy.25-27
Chemotherapy. Cytotoxic chemotherapy agents may produce long-lasting or perma¬
nent damage to the germinal epithelium resulting in oligozoospermia or azoosper¬
mia. I5-18'28"34 The extent of the damage is dependent upon the agent administered and
the dose received. However, as most treatment is delivered as multi-agent regimens
with often synergistic toxicity, it can be difficult to determine the specific contribution
of each individual agent. A number have been identified as being gonadotoxic, including
alkylating agents (such as chlorambucil and cyclophosphamide), procarbazine, cis-platin
and vinblastine (Table |),|6d 7,28-34 Combination chemotherapy treatment of Hodgkin's
disease with established regimens (mechlorethamine, vincristine, procarbazine and
prednisolone (MOPP) or chlorambucil, vinblastine, procarbazine and prednisolone
(ChlVPP) or cyclophosphamide, vincristine, procarbazine and prednisolone (COPP))
have been reported in a number of studies to result in permanent azoospermia in more
than 90% of recipients. The gonadotoxic agents in these regimens are mechlorethamine
and procarbazine in MOPP, chlorambucil and procarbazine in ChlVPP and procarbazine
and cyclophosphamide in COPP.16-33 The ABVD combination (adriamycin, bleomycin,
vinblastine and dacarbazine), which contains neither an alkylating agent nor pro¬
carbazine, has been shown to be significantly less gonadotoxic, resulting in temporary
azoospermia in 33% of patients and oligozoospermia in 21%, with 'full' recovery after 18
months reported in most, if not all, patients.33
'Hybrid' regimens (e.g. alternate cycles of ABVD with cycles of ChlVPP or MOPP)
are likely to be less gonadotoxic. Fertility seems to be preserved in approximately 50%
of men following three cycles of MOPP/ABVD, in contrast to almost universal
azoospermia following six cycles of MOPP.33
Cyclophosphamide, either alone or in combination with other agents, is known to
damage the germinal epithelium but the threshold for sterility, as with most
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gonadotoxic agents, is difficult to determine. Follow-up of 30 men for a mean of 12.8
years following treatment with cyclophosphamide (total dose 560-840 mg/kg) for
childhood nephrotic syndrome, reported azoospermia in 13%, oligozoospermia in 30%
and normal semen analysis in the remaining 57% of the men.31 The threshold for
impaired spermatogenesis was a total dose of 10 g. However, when used for the
treatment of solid tumours in combination with doxorubicin and dacarbazine or
vincristine, which have not been shown to be gonadotoxic, azoospermia was
permanent in 90% of men treated with cyclophosphamide doses >7.5 g/m2.35
Management of childhood leukaemia, which is the commonest childhood malignancy,
is continually evolving and often includes cyclophosphamide or cytarabine. A study of
testicular histology in 44 boys treated for acute lymphoblastic leukemia (ALL)
demonstrated a 50% reduction in tubular fertility index (TFI) (percentage of tubules
containing identifiable spermatozoa), with severe impairment (TFI <40%) in 18
patients. The severity of the damage was influenced by previous chemotherapy
treatment with cyclophosphamide and cytarabine (> I g/m2), whereas the tubular
fertility index improved with increasing time from treatment.36 'Full' recovery of
spermatogenesis was observed in three of seven of the patients with severe depression
of TFI followed up for median (range), 10.8 (5.5-15.9) years of treatment.29 Germinal
epithelial damage has also been described following successful treatment for childhood
ALL with a modified LSA2L2 protocol, which includes treatment with cyclopho¬
sphamide and cytarabine.37 In contrast, normal testicular function was reported in 14
boys successfully treated for ALL with treatment which did not include either
cyclophosphamide or cytarabine.38 Current treatment of ALL in the UK includes
cytarabine (total dose: 2 g/m2 or 4 g/m2) and cyclophosphamide (total dose: 1.2 g/m2
or 2.4 g/m2). Although this is unlikely to be sterilizing, long-term follow-up is
necessary.
Ifosfamide, an analogue of cyclophosphamide, is another potentially gonadotoxic
agent, although limited data describing its effect on testicular function are available. In
one study that included five patients treated for Ewing's sarcoma with an ifosfamide-
based regimen (total dose: 84—126 g/m2) only two men had a normal semen analysis,
one was oligozoopermic and the remaining two patients were azoospermic.39
Radiotherapy. The degree and permanency of radiotherapy-induced testicular damage
depends on the treatment field, total dose and fractionation schedule.I5,19,20 Doses as
low as 0.1 — 1.2 Gy damage dividing spermatogonia and disrupt cell morphology,
resulting in oligozoospermia.40'41 Following low-dose, single-fraction irradiation,
complete recovery of spermatogenesis was observed 9-18 months following irradiation
with I Gy, by 30 months following doses of 2—3 Gy and at 5 years or more in those
treated with 4 Gy.40'41 The germinal epithelium appears to be more susceptible to
fractionation of radiotherapy, with doses greater than 1.2 Gy fractionated resulting in
permanent azoospermia.20 Leydig cells are more resistant to damage from radiotherapy
than is the germinal epithelium and progression through puberty with normal potency
is common despite severe impairment of spermatogenesis. Testicular irradiation with
doses greater than 20 Gy is associated with Leydig cell dysfunction in pre-pubertal boys
while Leydig cell function is usually preserved up to 30 Gy in sexually mature males
(Table 2).42
In practice, radiotherapy treatment with fractionated total body irradiation (TBI)
with 14.4 Gy is liable to render men permanently sterile. Administration of higher
doses, for example, 24 Gy for testicular relapse of ALL, is likely to result in sterility
and impaired androgen production.
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Table 2. Radiotherapy-induced damage to the reproductive tract.
Gender Site Effect




>1.2 Gy — azoospermia
0.1—I.I Gy — oligoozspermia
Leydig cells
> 20 Gy - prepubertal
>30 Gy - post-pubertal
Females Cranial/total body irradiation Endocrine axis disruption
TBI/abdomen/pelvic Ovarian failure (LD^ < 4 Gy)
Older women > 5 Gy




Investigation of testicular function. Assessment of testicular maturation and function
involves pubertal staging, plasma hormone analysis and semen analysis (Table 3).
Pubertal staging provides important clinical information about both Leydig cell
function and spermatogenesis.43 The development of normal secondary sexual
characteristics would imply intact Leydig cell function with normal steroidogenesis.
Reduced testicular volume (< 15 ml), determined using the Prader Orchidometer,
is strongly suggestive of impaired spermatogenesis. Hormone analysis requires
measurement of basal plasma follicle-stimulating hormone (FSH), luteinizing hormone
(LH), testosterone and inhibin B if available.44 In pre-pubertal children hormone
analysis is an unreliable predictor of gonadal damage because the hypothalamic-
pituitary-testicular axis is quiescent. In post-pubertal boys, elevated LH and diminished
testosterone levels would indicate Leydig cell dysfunction, while elevated FSH and
diminished inhibin B, despite normal plasma testosterone level, would support germ
cell failure (Table 2). Semen analysis remains the definitive measure of spermatogen¬
esis.
Inhibin B mediates non-steroidal negative feedback from the testes, reflecting the
number of spermatozoa produced and regulating FSH secretion.45 Inhibin B secretion
in the adult requires the presence of germ cells. This provides further evidence for the
essential role of the germ cell-Sertoli cell interaction for the production of inhibin B




Female fertility may be impaired following chemotherapy or radiotherapy treatment
for childhood cancer. In contrast to the situation in males, the female gamete pool is
fixed at birth, with approximately two million primordial follicles present. This non¬
renewable pool begins an exponential decline by atresia throughout childhood to
adulthood until the number of primordial follicles falls below approximately 1000 at an
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average age of 50 years when the menopause occurs. The fertile 'window' in females is
characterized by roughly 400 monthly ovulations of a mature oocyte.46,47 Ovarian
failure and a premature menopause will arise from any cytotoxic insult which either
depletes the oocyte pool or hastens its decline.48
Chemotherapy. Females are generally less susceptible than males to the deleterious
effects of chemotherapy on the gonad. Nevertheless, ovarian dysfunction is well
recognized following combination chemotherapy. Ovarian damage is drug- and dose-
dependent and is related to age at time of treatment, with progressively smaller doses
required to produce ovarian failure with increasing age 49-52 The gonadotoxic agents
are similar for males and females (Table I).
Treatment of Hodgkin's disease with mechlorethamine, vinblastine, procarbazine
and prednisolone (MVPP), MOPP or ChlVPP results in ovarian failure in 19-63%.16,49-52
Amenorrhoea is much more commonly encountered in women over 30 years
(50-89%) than in younger women where ovarian function appears to be preserved in
48-100%.1 49-52 Long-term follow-up will be necessary as a number of these young
women may subsequently progress to a premature menopause.48
Treatment for childhood ALL appears to be associated with preservation of ovarian
function in the majority of cases.53-55 In a UK study of 40 girls treated for childhood
ALL, all achieved adult pubertal development and 37 had regular menses. There were
14 live births in nine long-term survivors with no serious congenital abnormalities and
no reported cases of malignant disease in their offspring.56 A recent study has shown
decreased LH excretion and short luteal phase in young women treated for ALL in
childhood. This subtle ovulation disorder is probably related to low-dose cranial
irradiation.57
Ovarian failure following high-dose chemotherapy treatment as conditioning for
bone marrow transplantation appears to be temporary. In a study of 43 women with
aplastic anaemia, cyclophosphamide conditioning (200 mg/kg) resulted in amenorrhoea
in all women, with 36 showing recovery of normal ovarian function 3-42 months after
transplantation.58 Ovarian function was normal in 95% of females treated pre¬
pubertal^ with cyclophosphamide (200 mg/kg) as conditioning therapy for bone
marrow transplantation. However, doses in excess of 200 mg/kg may result in
Table 3. Assessment of gonadal function.
Testicular dysfunction













Ovarian failure during or post-puberty
Endocrine profile Elevated FSH
Reduced oestradiol
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premature ovarian failure.59 Studies are currently underway to evaluate the impact of
ifosfamide, an analogue of cyclophosphamide, on ovarian function. Patients receiving
combination chemotherapy within continually evolving protocols require vigilant long-
term follow-up to monitor the risk of late effects.3
Radiotherapy. Total body, abdominal or pelvic irradiation may cause ovarian and
uterine damage. The degree of impairment is related to radiation dose, fractionation
schedule and age at time of treatment.21,22,56,59 The number of primordial follicles
present at the time of treatment and dose of radiotherapy will determine the fertile
'window' and dictate the age at menopause. This means that the younger the child at
the time of radiotherapy the larger the oocyte pool and hence the later the
menopause. The human oocyte is sensitive to radiation, with an estimated LD50 of less
than 4 Gy.22 A permanent menopause may be induced in women over 40 years
following treatment with 6 Gy while significantly higher doses are required to destroy
the oocyte pool completely and to induce ovarian failure in younger women and
children.19,21
Ovarian failure has been observed in 97% (37 of 38) of females following whole
abdominal irradiation in childhood (20-30 Gy). Of the 37 women, primary amenor-
rhoea was reported in 71% and premature menopause (median age 23.5 years) in the
remainder.21
Total body irradiation (TBI), either alone or in combination with cyclophosphamide
(as conditioning for bone marrow transplantation), is associated with infertility. All
women conditioned with total body irradiation (9.2—15.75 Gy) and cyclophosphamide
(120 mg/kg) before bone marrow transplantation for leukaemia develop amenorrhoea,
with recovery seen in only nine of 144. TBI was found to be the only factor significantly
influencing ovarian failure - the younger the age of the patient at the time of treatment
the greater the probability of recovery of ovarian function.58 In a long-term follow-up of
708 women, median 3 (range: 1-17) years, after bone marrow transplantation, 532 had
received TBI (10-15.75 Gy, single exposure or fractionated) and 176 were treated with
cyclophosphamide (200 mg/kg), alone or with busulphan (16 mg/kg), as conditioning
therapy. Ovarian failure was observed in 90% of patients following TBI and 68% following
Table 4. Clinical and experimental strategies for the preservation of reproductive










Cryoperservation of immature Cryopreservation of oocytes
spermatogenic cells
Gonadotrophs suppression
Gonadotrophin suppression Inhibition of follicle apoptosis
Cryopreservation of testicular tissue Cryopreservation of ovarian tissue
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chemotherapy among an additional 82 patients treated pre-pubertally with the same
regimens, ovarian failure was reported in 72%.60
Investigation of ovarian function. Clinical manifestations of ovarian damage depend
upon the age of the child at the time of treatment (Table 3). Cytotoxic damage
sustained pre-pubertally may result in failure to develop secondary sexual
characteristics. If the child is peri-pubertal at the time of treatment there may be
arrest of pubertal development with subsequent primary amenorrhoea. In post¬
puberal females ovarian failure will manifest as secondary amenorrhoea, often with
symptoms of oestrogen deficiency. Biochemically, ovarian failure is detected as
elevated gonadotrophins, and undetectable oestradiol. Prediction of a premature
menopause is difficult, although early follicular phase assay of follicle-stimulating
hormone (FSH), oestradiol and inhibin B and ovarian ultrasound are potential tools for
assessing ovarian reserve. Elevated early follicular phase FSH with preservation of
oestradiol production is characteristic of the peri-menopause, the length of which may
vary.61,62 Ovarian failure will require oestrogen replacement for puberal induction
and cyclical hormone replacement to relieve the symptoms of oestrogen deficiency
(vaginal dryness, hot flushes and irritability), provide cardiovascular protection and
optimize bone density.
Uterus
Radiotherapy and chemotherapy. Recent data demonstrate that uterine function may be
compromised following radiotherapy. Reduced uterine volume and decreased elasticity
of uterine musculature, possibly as a consequence of impaired vascularization, are found
in girls receiving pelvic, abdominal and total body irradiation pre-pubertally.63,64
Disruption of uterine characteristics may compromise implantation and continuation
of pregnancy. Although successful pregnancies following radiotherapy are reported, the
incidence of spontaneous miscarriage, premature delivery and intrauterine growth
retardation is significantly increased.21,60,65-67 Following whole abdominal irradiation
(20—30 Gy) in childhood, all pregnancies occurring in women with preserved ovarian
function resulted in mid-trimester miscarriage.21 In studies exploring the role of
exogenous sex steroids, women with premature ovarian failure following TBI for
childhood leukaemia, treated with physiological sex steroid replacement therapy, have
shown an increase in uterine volume and endometrial thickness.64,68 This is encouraging
for future fertility prospects and may be a useful way of improving uterine function
when assessing these women for assisted reproductive techniques.
Chemotherapy does not appear to have any significant lasting adverse effect on
uterine function. Successful pregnancy, with no increased risk of miscarriage, and
healthy offspring are reported following treatment with multi-agent chemotherapy
regimens.37,69,70
Investigation of uterine function. Normal uterine shape, length and volume for pre-,
peri- and post-puberty are well documented.71 Ultrasound scanning is a reliable non¬
invasive technique for assessing uterine size and shape, blood supply and endometrial
thickness. Uterine artery blood flow may be assessed by Doppler scanning and
resistance to flow expressed as the pulsatility index. Endometrial biopsy enables
assessment of endometrial function using histological and immunocytochemistry
techniques.72,73
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FERTILITY PRESERVATION
Advances in assisted reproduction and increasing interest in gamete extraction and
maturation have focused attention on preserving gonadal tissue from children before
sterilizing chemotherapy or radiotherapy, with the realistic expectation that future
technologies will be able to utilize their immature gametes. The impetus for pre¬
serving gonadal tissue follows on the heels of pioneering experiments in ewes,74
together with media interest in the report of a successful autologous ovarian graft in a
previously oophorectomized female. In addition, live human births have been reported
resulting from the transfer of embryos fertilized with immature spermatogenic
cells.75-80 Such issues have inevitably raised questions from parents and oncologists
about their possible application in children undergoing cancer therapies.14,81
Males
Potential strategies for preservation of male fertility are dependent upon the sexual
maturity of the patient (Table 4). Spermatogenesis is a highly organized and complex
process in which undifferentiated diploid stem cell spermatogonia undergo a series of
proliferation, differentiation and maturation into mature haploid spermatozoa. This
highly efficient process begins in puberty, although a number of immature sper¬
matogenic cells are described in the pre-pubertal testis.24 Spermarche is a mid-
pubertal event, preceding the ability to produce an ejaculate, which occurs at a median
age (range) of 13.4 (11.7-15.2) years when median testicular volume is 11.5
(4.7-19.6) ml.82
Established practice
Cryopreservation of gametes. The only established current clinical option for
preservation of male fertility is cryopreservation of spermatozoa. Spermatozoa are
usually obtained from the ejaculate by masturbation but may be obtained using rectal
electrostimulation techniques under anaesthetic. When it is not possible to obtain an
ejaculate, sperm can be retrieved by epididymal aspiration or testicular biopsy in
sexually mature men. Not infrequently, sperm produced by cancer patients at the
time of diagnosis is of poor quality. With advances in assisted reproduction
techniques, in particular intracytoplasmic sperm injection (ICSI), which involves the
injection of a single spermatozoan directly into an ooctye, the problems of low
numbers and poor motility sperm may be cirvcumvented.5"7 More recently a small
number of pregnancies have been achieved with ICSI using immature spermatids and
secondary spermatocytes extracted from testicular tissue in men with spermatogenic
arrest.75"80
Experimental strategies
Gonadotrophin suppression. Azoospermia following cytotoxic cancer therapy was
believed to be a consequence of destruction of the rapidly proliferating spermatogonia!
stem cells. In man this would result in azoospermia within 12 weeks, the time taken
from differentiation of stem cell to mature spermatozoa, yet spontaneous recovery of
spermatogenesis is reported after many years of azoospermia.40,41 Furthermore, the
relatively quiescent pre-pubertal testis is not afforded any protection from cytotoxic
therapy. To address these incongruities, studies in rats have shown that some stem
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cells survive cytotoxic therapy arid that ensuing infertility is a consequence of the
inability of spermatogonia! stem cells to differentiate.23 Failure of spermatogonia! stem
cells to differentiate is likely to result from loss of appropriate environmental
endocrine or paracrine growth factors. Studies have shown that administration of
gonadotrophin-releasing hormone (GnRH) agonists or antagonist to rats, either
immediately or after a delay following treatment with sterilizing irradiation or
chemotherapy, restores the ability of spermatogonia to differentiate and resume
normal spermatogenesis. Similar results have been achieved using testosterone, alone
or in combination with oestradiol or progestin. Despite the attractiveness of this
theory studies in humans have failed to demonstrate any convincing evidence of clinical
benefit.83,84 In men treated with sterilizing radiotherapy and chemotherapy for
childhood cancer, effective gonadotrophin suppression with medroxyprogesterone
acetate for at least 3 months did not result in restoration of spermatogenesis.85 Studies
in the marmoset, a primate animal model, have demonstrated that the pre-pubertal
testis is not quiescent and that both GnRH-dependent and -independent activity
occurs in pre-puberty.27 Survival of stem cells is a prerequisite for endocrine
enhancement of recovery of spermatogenesis. The absence of histological evidence of
spermatogonia! stem cells in testicular biopsies from these men demonstrated that
there may have been complete ablation of the germinal epithelium and infertility was
likely to be irreversible. Endocrine manipulation to enhance recovery of spermatogen¬
esis may be successful in patients in whom the testicular insult is less severe and there
is some preservation of spermatogonia! stem cells.
Harvesting testicular tissue. For pre-pubertal boys, lacking in haploid gametes, there
are no options currently available to preserve fertility and any potential strategies
must be considered entirely experimental. In theory, testicular tissue could be
removed before the start of treatment and cryopreserved either as a segment of tissue
or as isolated germ cells. Following cure from his malignancy the frozen thawed
testicular tissue could be auto-grafted to the testes or undergo enzymatic digestion to
isolate the germ cells. Frozen thawed germ cells could be re-implanted back into his
own testes, or these cells could be matured in vitro until they reach a stage sufficiently
mature to achieve fertilization with intra-cytoplasmic sperm injection (ICSI).
The concept of testicular germ cell transplantation was pioneered by Brinster and
collegues in I994.9 Testicular germ cells isolated from mouse testis and transplanted
into the testis of genetically or experimentally sterile mice initiated and sustained
normal donor spermatogenesis, restoring fertility and producing healthy offspring.85
Successful transplantation has also been shown in mouse recipients rendered sterile
with the chemotherapeutic agent busulfan. Interestingly, these experiments also
demonstrated both endogenous and donor spermatogenesis simultaneously, indicating
that busulfan did not kill all the endogenous stem cells.9 Subsequent studies have shown
that testicular germ cell transplantation can occur through autologous, heterologous
(mouse-to-mouse, rat-to-rat) or xenologous (hamster, dog, rabbit or rat to mouse)
transfer of cells. The site can be heterotopic, as graft to a non-gonadal site in the
recipient, or homotopic, when the cells are re-introduced into the testis.9"11,86"88 In
order to develop autologous germ cell transplantation in humans techniques have to
be developed by which human testicular germ cells can be isolated, stored and re¬
introduced into the testis.
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Cryopreservation of whole tissue. Testicular tissue obtained by testicular biopsy has
been successfully cryopreserved with subsequent isolation of spermatozoa from the
thawed tissue and successfully used in ICSI.89,90 These studies have only utilized
spermatozoa or immature spermatogenic cells retrieved from tissue post-thaw and it
may be that survival of spermatogonia! germ cells post-thaw is poor. Furthermore, as
there is a more than theoretical risk of transplanting tumour cells, it is likely that
clinical practice will involve enzymatic digestion and isolation of germ cells before
cryopreservation rather than autografting testicular tissue.
Germ cell isolation and storage. Transplantation in rodent models has involved only
semi-purified cell populations of germ cells and somatic cells but for human application
purified stem cell populations would be necessary to ensure that no malignant cells
were transferred. The term 'stem cell' is a functional description, given that there are
no morphological, antigenic or biochemical criteria by which to identify these cells in
vivo or in vitro. Spermatogonia! transplantation is the only method at present by
which stem cell presence can be authenticated. In mice LacZ encodes the enzyme
P-galactosidase which can be demonstrated histochemically as an intracellular blue
reaction product. Effective purification will demand the development of specific
antibody probes to differentiate stem cells from other cells. Studies have shown that a
number of cell surface antigens are expressed on stem cells, including alpha-6, beta-1
integrin and c-kit, which may enable enrichment using magnetic cell sorting.91 The
major limitation for human application is that these antigens are shared with other
progenitor cells, including haematopoietic cells, creating inherent problems in cancer
patients.
Germ cell enrichment. The highly efficient process of spermatogenesis begins in
puberty, although a number of immature spermatogenic cells are described in the pre¬
pubertal testis. It is believed that I04 germ cells contain as few as two stem cell
spermatogonia capable of self-renewal.26 With the average number of germ cells in the
testis estimated to range between 13 and 83 x I06 during childhood, the relatively small
numbers of stem cell spermatogonia available pose a challenge for the process of stem
cell isolation.25 Consequently, there is a need to develop an in vitro culture system to
augment stem cell numbers following harvesting and isolation. The feasibility of
enrichment has been shown by Nagano et al who have maintained mouse stem cells in
culture for up to 4 months and the cultured cells initiated successful spermatogenesis
following transplantation.92
Cryopreservaton of spermatogoniaI stem cells. Cryopreservation of spermatozoa and
fertilization following thawing are well established. Application of this approach to
stem cell spermatogonia will require modification and optimization of freezing
procedures, taking into consideration the inherent biological differences between the
immature diploid stem cells and mature gametes.93 There is thus a need for studies to
devise cryopreservation regimens that are applicable to stem cells from the pre¬
pubertal testis.
Future use of germ cells. The future use of testicular germ cells is likely to involve
either maturation of the germ cells in vitro for use with ICSI or transplantation.
Ideally, transplantation would involve injecting preparations of purified germ cells into
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the testis with restoration of natural fertility. In vitro maturation techniques, although
still very much in their infancy, would have the advantage of eliminating any risk of
transplanting harvested malignant cells back into the patient.
In vitro maturation. Creating an environment in vitro to simulate germ cell matu¬
ration and differentiation into spermatozoa may be the only option for a number of
patients where cancer therapy damage has been so extensive that the supporting
Sertoli cells would be unable to support spermatogenesis. Attempts to cultivate male
germ cells in vitro have shown that germ cells can survive several months in culture
and are likely to be undergoing cell division.92 Tesarik reported in vitro sper¬
matogenesis and healthy offspring using ICSI. However, the maturation process
involved in vitro maturation of late stages of spermatogenesis rather than development
from germ cells.94,95
Germ cell transplantation. A number of studies have concentrated on developing the
most efficient technique for infusing the stem cells into the testis. The simplest and
most effective method of filling the seminiferous tubules in vitro proved to be by
injection into the rete testis of bull, monkey and man, under ultrasound guidance 96
These experiments involved injection into partially involuted or pre-pubertal testes.
This eliminates the problems associated with back pressure of fluid in fully active
testes, which would otherwise block the infusion of the cell suspension into the
tubules. Successful in vivo rete injections have been performed on cynomologus
monkeys treated with GnRH antagonist. The advantage of injecting the cells into the
rete allows a much larger volume to be infused in contrast to the micro-injections
involved in re-infusing directly into the seminiferous tubules.96 Further work is
required to perfect this technique for human application.
Xenogeneic grafting of testicular tissue. Immature testicular tissue has been shown to
grow and differentiate when grafted into another species.10 This provides an additional
strategy for conserving the male germ line and circumvents the risk of re-introducing
malignant cells. Clearly, this technique is unlikely to be ethically acceptable and is
compromised by the risk of interspecies transfer of potentially pathogenic micro¬
organisms.
Females
As with males, the options available are dependent upon the sexual maturation of the
patient, although in contrast to males, the gamete pool is fixed at birth and collection
is technically more difficult. A number of strategies for protecting the ovaries and
preserving fertility during cancer therapy have been attempted with limited success
(Table 4). Limitation of radiation dose to the ovary is practised but is not very effective.
In young, sexually mature females with partners, collection of mature oocytes for
storage or fertilization and subsequent embryo cryopreservation is possible. For pre¬
pubertal girls, and the majority of young women, preservation of fertility remains
experimental and harvesting and storage of gonadal tissue before commencing cancer
therapy is the most promising option.
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Established practices
Surgical translocation. Reducing the radiation dose to the ovary by shielding or
removing the ovaries from the field of radiation (oophoropexy) may preserve ovarian
function.96-99 Oophoropexy involves laparoscopic transposition of the ovaries (with
blood supply intact) to a position behind the uterus, which acts as a shield, or to
the paracolic gutters, away from the field of radiation to minimize exposure.
Experimentally, heterotopic ovarian autotransplantation has involved grafting the
ovary to a distant site in the body and anastomosing blood vessels.98 The ovarian dose
received during pelvic nodal irradiation for Hodgkin's disease can be limited by
midline oophoropexy from 44 Gy to between 0.22 and 0.55 Gy, and in women who
are less than 25 years of age at the time of treatment, ovarian failure is infrequent.97
However, even where ovarian function is preserved oocyte retrieval with assisted
reproduction and surrogacy may be required to achieve a pregnancy as the uterus may
also have been damaged by the radiation therapy. This will compromise to ability of
the women to carry a pregnancy to term.
Storage of embryos or mature oocytes. The only strategy currently available for
preservation of female fertility is cryopreservation of embryos. Embryo cryopreserva-
tion and in vitro fertilization (IVF) may be offered to women before treatment for
cancer. Embryo banking has the advantage that it allows a number of embryos to be
stored without a need for further IVF cycles; however, this requires the patient to
have a partner or to use donor sperm. On average 10 oocytes are collected per cycle,
limiting the number of embryos available for cryopreservation. The overall live birth
rate from a single cycle of treatment is 11 %.100 Cryopreservation of oocytes is an
alternative possibility for women without a partner but is much less successful, with
fewer than one baby born per 100 oocytes stored and as such remains experimental.101
The main disadvantage of embryo or oocyte storage is requirement for superovulation
with gonadotrophins which will inevitably delay the commencement of cancer
therapy.
Experimental strategies
Gonadotrophin suppression. The mechanism of cytotoxic chemotherapy and radiotherapy-
induced gonadal damage is uncertain and may differ in males and females, between
different modalities of therapy and individual drugs. In contrast to males, females appear
to be less susceptible to the cytotoxic effects of chemotherapy. Consequently it was
hypothesized that inducing a pre-pubertal milieu during chemotherapy would decrease
the risk of premature ovarian failure. Gonadotrophin analogues (GnRH-a) prevent
follicular growth and mitosis by blocking gonadotrophin induction. Although the exact
mechanism is uncertain it may involve direct suppression of GnRH receptors in the
ovary, with subsequent inhibition of recruitment of small follicles into the proliferating
pool as well as atresia of the already developed follicles. A number of studies have
demonstrated that GnRH-a inhibit chemotherapy-induced ovarian follicular depletion in
rodents, although there remains uncertainty about applicability in the human,
particularly as the human ovary has significantly fewer numbers of GnRH receptors in
the ovary.102-104 Ataya et al demonstrated that GnRH-a co-treatment protected the
Rhesus monkey from cyclophosphamide induced ovarian damage by significantly
reducing follicular decline compared with cyclophosphamide alone.103 These findings
are supported by clinical studies which demonstrated that co-treatment of GnRH-a
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with chemotherapy resulted in premature ovarian failure (POF) in one out of 28 (3.6%)
compared with 26 out of 40 (65%) in the group treated with chemotherapy alone.104
Adjuvant treatment with GnRH-a to limit the gonadal toxic effects of otherwise
successful treatment regimens is potentially attractive. However, this must be
viewed with some caution as although GnRH-a provided some protection against
cyclophosphamide no advantage was conferred against irradiation-induced damage.
This may be in part explained by the different mechanism of gonadal damage induced
by radiotherapy, namely, the destruction of primordial follicles which are not under
the influence of gonadotropins.105 The judicious use of GnRH-a may play a role in
the appropriate patient group, such as young women and children subjected to
alkylating-agent-based chemotherapy for Hodgkin's disease.
Prevention of follicle atresia. Oocyte loss induced by anticancer therapy has been
shown to occur by apoptosis; consequently, inhibition of the apoptotic pathway has
been explored as a mechanism for preventing ovarian failure. Although the exact
pathway remains to be elucidated, accumulating data support the role of ceramide in
signalling somatic cell death. Ceramide is a sphingolipid second messenger derived
from sphingomyelinase-catalysed hydrolysis, in addition to de novo synthesis. In turn,
ceramide is metabolized and phosphorylated to give sphingosine-1-phosphate (SIP)
which is believed to inhibit apoptosis in somatic cells. The role of the sphingomyelin
pathway has also been studied in germ cells. Disruption of the gene encoding acid
sphingomyelinase or treatment with sphingosine-1-phosphate attenuates apoptosis
of primordial fetal oocytes with increased oocyte numbers present at birth.
Treatment of mice ooctyes with sphingosine-1-phosphate prevents chemotherapy-
induced apoptosis in vitro. In vivo administration of sphingosine-1-phosphate confers
resistance to radiation-induced apoptosis in mice, with pregnancy rates of 100%.106
While SIP may herald promise of a new approach to preservation of ovarian
function, further studies are necessary to explore the detrimental effects of such
treatment on normal neurological function as deletion of sphingomyelinase during
normal fetal life leads to the development of Niemann—Pick-disease-like symptoms in
post-fetal life.106
Harvesting ovarian tissue. Oocyte maturation and storage is possible in post-pubertal
girls but is associated with limited success.100 The only option potentially available for
pre-pubertal children and the majority of young women is the cryopreservation of
ovarian tissue. Harvesting ovarian tissue may take the form of cryopreservation of slices
of ovarian cortex, which are rich in primordial follicles, or cryopreservation of
immature oocytes. Good survival rates and viability post-thawing is similar whether
primordial follicles are stored as slices or in isolation, in contrast to immature oocytes,
where survival is poor and increased rates of chromosomal abnormalities and spindle
malformation are reported.12107
Future use of ovarian tissue
Ovarian tissue transplantation. The harvesting of ovarian tissue, either whole ovary or
cortical strips, can readily be achieved laparoscopically before potentially sterilizing
cytotoxic therapy. The tissue can be safely cryopreserved until required for future use.
A potential scenario would be to replant the ovarian tissue with the hope of restoring
natural fertility and also maintaining sex steroid production. Autologous transplan¬
tation of fresh and frozen-thawed primordial follicles to the ovaries of sterile recipients
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has restored fertility, resulting in live healthy offspring in mice and sheep.74108-110
Human primordial follicles survive cryopreservation, and the return of ovarian
hormonal activity has been achieved with re-implantation. However, no pregnancies
have yet been reported and this procedure must be considered experimental."1'"2 It
is likely that ovarian grafts will have a limited life span, in which case transplantation
should be delayed until fertility is desired.
In vitro culture. Alternative strategies are required because of concerns that the re-
implanted ovarian tissue may transmit the original malignant disease. This is of
particular concern for haematological malignancies. Fresh and frozen-thawed ovarian
tissue from diseased mice transmitted lymphoma when transplanted into healthy
recipients."3 This highlights the risk of potential transmission of cancer cells and
emphasizes the need to ensure that adequate procedures are developed to enable
storage of tumour-free tissue and the careful selection of the appropriate patients from
whom to harvest tissue. In view of the potential risk of transplanting tumour cells a
number of alternative strategies are being investigated.
The risk of transplanting tumour cells can be eliminated by maturing the ovarian
follicles in vitro followed by assisted reproduction."1"4 In vitro culture of secondary
pre-antral follicles to antral stages using FSH stimulation has been successful in a
number of species, including mouse, hamster, pig and humans."5-120 Maturation of
secondary mouse follicles in vitro with fertilization of the oocytes has produced
healthy offspring."6 Despite this, secondary follicles are few in number in human
ovaries and development into early antral stages is associated with a very high rate of
oocyte loss."9 Consequently, successful and realistic in vitro maturation of human
tissues dictates the development of techniques to mature the much more abundant,
primordial follicle.120,12' At present this is limited by our current lack of knowledge
of the signals involved in inducing primordial follicle growth into secondary follicles,
although it is presumably mediated by interaction with surrounding stromal cells."9
Culture of primordial follicles may be approached by culture of ovarian cortical slices,
which would maintain the structural integrity and enable interaction between
follicles and surrounding stromal cells. Alternatively, primordial follicles could be
isolated and cultured, which would have the advantage of allowing direct monitoring
of follicular development. Culture of primary and primordial follicles to pre¬
ovulatory and pre-antral stages, respectively, has been achieved in mice, with
subsequent isolation and maturation of the secondary follicles and a live offspring
produced following IVF in one case.122 Cultures from enzymatically isolated primary
and primordial follicles from mice, rats and pigs have yielded similar degrees of
development.122-125 Isolated fresh and frozen-thawed human primordial follicles have
been successfully maintained in culture for up to 5 days but no evidence of growth
was observed.12
Xenogeneic transplantation. Heterotopic xenogeneic transplantation is one alternative.
Studies have shown that the renal capsule of immunodeficient mice can successfully
serve as a site for transplantation of ovarian slices from various species.126,127 Ovarian
cortical slices from sheep, cats and marmosets have been transplanted to immu¬
nodeficient mice and developed to late antral stages, providing a model and a host for
follicular development.128,129 Similar studies transplanting human ovarian slices to SCID
mice have produced similar results following administration of follicle-stimulating
hormone.130
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Clinical practice for harvesting gonadal tissue
Harvesting and storage of ovarian cortical tissue from girls and young women before
gonadotoxic chemotherapy has been available in a number of centres since the mid-
1990s and, more recently, a few centres have reported the storage of testicular
tissue.131 The Royal College of Obstetricians and Gynaecologists has provided a report
from a working party on the storage of ovarian and pre-pubertal testicular tissue. This
provides standards for best practice in the cryopreservation of gonadal tissue, including
the criteria for providing a service, patient identification and selection, standard
operating procedures and requirements for safe storage.132
PROGENY
Overall, there are reassuring reports that there is no increased incidence of either
congenital abnormalities or childhood malignancy in children born to long-term
survivors of childhood cancer.133 '34 However, these successful pregnancies result
mostly from normally achieved conception. We do not know the consequences of
circumventing the natural selection processes of normal sexual reproduction using
assisted reproduction techniques (ART), nor the effects of ART on the complex
cascade of precisely timed molecular interactions of early embryonic development.
Continued surveillance of the progeny of survivors of childhood cancer remains
essential.135
Paternal risk to the offspring
The mutagenic potential of cancer therapy may confer a risk to the fetus conceived
using gametes produced after cancer therapy, although current epidemiological data
suggest that offspring of cancer survivors do not have an increased incidence of
congenital abnormalities or cancer relative to the general population.133135 However,
an important concern is that these results are based largely on offspring arising from
natural conception and the consequences of circumventing the natural selection
processes of fertilization involved by means of ICSI are unknown.135 There is at least
the hypothetical possibility of injection of abnormal spermatozoa or immature
spermatogenic cells carrying abnormal genomic DNA with the potential to increase
congenital and other abnormalities among offspring.136 Studies in animals have shown
that exposure of the male germ line to chemotherapy agents may disrupt
spermatozoal DNA and result in deleterious effects on embryo development.137-139
Awareness of the importance of sperm DNA integrity for accurate transmission of
genetic material to the offspring has necessitated the development of new techniques
to assess sperm characteristics in more detail.137 It has become clear that men from
subfertility clinic populations, with abnormalities of the conventional criteria of semen
quality, also demonstrate elevated levels of damage to the genomic DNA in their
gametes. Even among normal populations, sperm chromatin damage has been linked
with impaired fecundity.140 It has been shown that sperm DNA damage does not
preclude pronucleus formation at ICSI, and that abnormal DNA within the male
gamete is detectable in the early embryo.141 Thus far, evidence on the safety of ICSI
has been based largely upon its use in populations of men with deficits in sper¬
matogenesis unrelated to potentially mutagenic cancer treatment. This evidence has
been broadly reassuring concerning health risks to the offspring, although it is limited
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by the restricted length of follow-up currently available.142 Studies have shown that
although, by conventional criteria, semen quality is frequently abnormal in long-term
survivors of childhood cancer, the sperm produced do not appear to carry a greater
burden of damaged DNA.39 This observation goes some way to providing reassurance
about the use of ICSI, which will circumvent the problems associated with severe
oligozoospermia and asthenozoospermia, and offer cancer survivors the possibility of
paternity in adulthood.
As assisted reproduction techniques advance, successful pregnancies are achieved
with immature spermatogenic cells, adding a further unquantified risk to the fetus.
Fertilization of oocytes with immature spermatogenic cells, such as round cells and
elongated spermatids, which have not yet completed spermatogenesis, must be
pursued with caution. The mechanism by which sperm precursor cells activate the
oocyte at fertilization is uncertain but it is speculated that suboptimal oocyte
activation may confer poor fertilization, implantation and high early abortion
rates.143 Spermatid transition into spermatozoa is characterized by salient changes
in nuclear protein composition; the significance of circumventing these changes
is uncertain.144 Genetic imprinting is reported to play an important role in
embryogenesis and in processes leading to the development of paediatric cancers,
including Wilms' tumour and embryonal rhabdomyosarcoma, and other human
diseases.145 Although the mechanism involved in genetic imprinting is uncertain it is
likely to involve differences in DNA methylation and requires careful consideration
when embarking on germ-cell maturation. Children born following assisted
conception using spermatozoa and immature spermatogenic cells require long-
term careful monitoring.
Maternal risk to the offspring
As with males there is the theoretical risk that exposure to chemotherapeutic agents
or irradiation may cause mutations and DNA changes to the oocyte. Animal studies
have demonstrated high abortion and malformation rates related to different stages
of oocyte maturation at the time of exposure to chemotherapy.60,70,146 This has
raised concerns regarding the use of assisted reproduction techniques and embryo
cryopreservation in patients previously exposed to cancer therapy. Reassuringly,
studies of pregnancy outcome in cancer survivors have not substantiated these
concerns. There is no increased incidence of chromosomal or congenital abnormalities
in offspring born to women exposed to cancer therapy.60,70,146
CONCLUSIONS
As treatment for childhood cancer has become increasingly successful, adverse effects on
reproductive function are assuming greater importance. Preservation of fertility before
treatment must be considered in all young patients at high risk of subfertility. Limitation
of radiation exposure by shielding of the testes and ovaries should be practised where
possible and sperm banking should be offered to all sexually mature boys at risk of
infertility. The rapidly advancing experimental techniques for harvesting of gonadal
tissue must be considered and embarked upon without unrealistic expectations,
although future utilization of the tissue is likely to be realized in the next decade.
Semen can be stored before sterilizing chemotherapy and radiotherapy for use at a
later date, thus preserving fertility. Attempts to restore spermatogenesis in azoospermic
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men, using hormone manipulation, have so far been unsuccessful. However, capitalizing
on the unique properties of the spermatogonia! stem cell, testicular tissue could be
harvested before treatment and cryopreserved, for use at a later date. The functional
capacity of the testes appears to be preserved and autotransplantation of the stem cells in
rats has been shown to re-initiate spermatogenesis and permanently restore fertility.
Where fears of re-introducing tumour cells may limit applicability of this approach in
humans, in vitro maturation and use with assisted reproduction techniques is a realistic
alternative.
Girls undergoing treatment for childhood cancer face limited options for
preservation of fertility. Harvesting ovarian tissue and cryopreservation of cortical
slices are practised in a number of centres although these procedures remain
experimental and future utilization of stored tissue is uncertain. Ultimately,
autografting and restoration of natural fertility is the aim of cryopreservation of
ovarian tissue but techniques need to be developed to ensure that malignant cells are
not transferred in the tissue. Isolation of follicles and in vitro maturation for assisted
reproduction is likely to be the best option and may be the only option when the
uterus has also been damaged. It is likely that these techniques will be developed in
the not too distant future and preservation of fertility will be a realistic expectation for
girls treated with gonadotoxic therapy.
It is incumbent upon oncologists that appropriate counselling of patients at risk of
subfertility be part of their routine care. The importance of the late effects of
treatment are receiving increasing recognition and in the UK strategies for long-term
follow-up are currently being explored.3
Practice points
• successful treatment of childhood cancer may be associated with impaired gonadal
function in adulthood
• the testis is highly susceptible to the toxic effects of radiation and chemotherapy
at all ages of life
• assessment of testicular maturation and function involves pubertal staging, plasma
hormone analysis and semen analysis
• females are generally less susceptible than males to the deleterious effects of
chemotherapy
• total body, abdominal or pelvic irradiation may cause ovarian and uterine damage
and the degree of impairment is related to the radiation dose, fractionation
schedule and age at time of treatment
• apart from cryopreservation of spermatozoa in the male and embryos for the
female, all alternative strategies remain experimental
• human primordial follicles survive cryopreservation, and return of ovarian
hormonal activity has been achieved with re-implantation; however, no
pregnancies have yet been reported and this procedure must be considered
experimental
• best practice in the cryopreservation of gonadal tissue, including the criteria for
providing a service, patient identification and selection, standard operating
procedures and requirements for safe storage need to be established
• concerns that the offspring of patients successfully treated for cancer might have
an increased risk of congenital abnormalities and childhood cancer have not been
substantiated
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Research agenda
Males
• isolation, identification and storage of stem spermatogonia
• in vitro maturation of stem spermatogonia
• in vivo transplantation of testicular tissue
Females
• harvesting of ovarian tissue
• in vitro maturation of primordial follicles
• autologous transplantation of ovarian tissue
• prevention of follicle atresia by novel stategies
General
• a voluntary code of practice for collection of gonadal material
• safe cryopreservation techniques need to be developed
• epidemiological surveillance of offspring of survivors of childhood cancer after
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Summary
background and objective Chemotherapy treat¬
ment of childhood cancer may impair gonadal func¬
tion, which may be manifested only in adulthood as
permanent sterility. Detection of gonadal dysfunction
in prepubertal children has been hampered by the
absence of a sensitive marker. Inhibin B is secreted by
small antral follicles and Sertoli cells in females and
males, respectively, and may be a marker of gonadal
function in prepubertal children. The aim of this pilot
study was to evaluate inhibin B in relation to sensitive
measurements of gonadotrophins as markers of the
early gonadotoxic effects of chemotherapy in prepu¬
bertal children treated for cancer.
study design and subjects Twenty-five prepu¬
bertal children (9 females), median age 4-5 years
(range 1-2-12-8 years) with cancer (16 solid tumours,
nine acute lymphoblastic leukaemia, ALL) were
studied longitudinally. Blood samples were collected
before and during chemotherapy (solid tumours) or
immediately following induction and first intensifica¬
tion (ALL). Post-treatment (1-6 months) samples were
collected in 12 of the patients (5 females).
measurements Dimeric inhibin B was measured by
double antibody enzyme-linked immunosorbent assay
(ELISA). FSH and LH were measured by sensitive time-
resolved immunofluorescence.
Correspondence: Dr P. M. Crofton, Department of Paediatric
Biochemistry, Royal Hospital for Sick Children, Sciennes Road,
Edinburgh EH9 1LF, UK. Tel.: 0131 536 0403; Fax: 0131 536 0410;
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results Girls: Pretreatment inhibin B was slightly
high in one girl but normal for age and sex in all others:
median 16-1 (range 9-4-186-2) ng/l, median SD score
+0-2 (-1-3 to +2-6). Inhibin B decreased to undetect¬
able levels (< 8 ng/l) in 8/9 girls during treatment
(P= 0-03), with no accompanying rise in FSH or LH.
Post-treatment recovery of inhibin B was variable:
median 16-1 (range < 8-0-44-2) ng/l, median SD score
+0-1 (range <-2-4 to +1-8). Sustained undetectable
inhibin B levels were observed in 2/5 girls with corre¬
spondingly elevated FSH concentrations (11-8 and
10-9 U/l).
Boys: Inhibin B was normal for age and sex in all boys
before treatment with no significant change during or
after treatment (medians 93 ng/l, 85 ng/l and 94 ng/l,
SD scores -0-3, -0-6 and -0-2, respectively). Inhibin
B decreased to undetectable levels in one boy post-
treatment with no accompanying increase in FSH or LH.
conclusions In prepubertal girls with cancer, chem¬
otherapy is associated with suppression of inhibin B,
usually transient, which may indicate arrest of follicle
development. Sustained suppression of inhibin B
following treatment may be indicative of permanent
ovarian damage. In prepubertal boys, chemotherapy
had little immediate effect on Sertoli cell production of
inhibin B, although one boy showed a delayed effect.
Inhibin B, together with sensitive measurements of
FSH, may be a potential marker of the gonadotoxic
effects of chemotherapy in prepubertal children with
cancer.
The successful treatment of childhood cancer may be associated
with gonadal dysfunction and infertility in adulthood (Waring &
Wallace, 2000; Thomson etal., 2002). Chemotherapy and radi¬
otherapy may damage testicular germinal epithelium resulting in
temporary or permanent azoospermia in the male, or hasten
oocyte depletion with truncated fecundity and a premature men¬
opause in the female. Although chemotherapy may damage the
gonads in both sexes throughout life, females appear to be less
susceptible to the deleterious effects ofchemotherapy than males.
The extent of chemotherapy-induced damage is dependent upon
the agent administered and dose received. However, it can be dif¬
ficult to determine the relative contribution of each individual
296 © 2003 Blackwell Publishing Ltd
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drug as most treatments are administered asmultiagent regimens.
A number of agents have been identified as being gonadotoxic,
including cisplatin, melphalan and the alkylating agents, such as
cyclophosphamide.
Traditionally, determining the impact of chemotherapy and
radiotherapy on gonadal function has involved clinical assess¬
ment of pubertal development, menstrual history in females and
semen analysis in males. Earlier detection ofgonadal damage has
been hampered by the lack of a sensitive marker ofgonadal func¬
tion in prepubertal children. In these children gonadotrophins
may be unreliable predictors of gonadal damage because the
hypothalamic-pituitary-gonadal axis is relatively quiescent.
Inhibin B is a dimeric glycoprotein produced by the gonads,
secreted from Sertoli cells in males and developing antral folli¬
cles in females (Roberts et al., 1993; Anderson & Sharpe, 2000).
In the adult male inhibin B plays an important role in sperma¬
togenesis, while in the adult female it plays an integral role in
folliculogenesis, oocyte maturation and corpus luteal function,
mediated in part by inhibition ofFSH secretion. There is increas¬
ing evidence reporting that the prepubertal gonads are not
entirely quiescent but have a low level of activity (Wu et al.,
1996; Kelnar et al., 2002). We investigate the role of inhibin B,
together with sensitive gonadotrophin measurements, as markers
of early gonadotoxic effects of chemotherapy in prepubertal
children treated for cancer.
Patients and methods
Patients
Stored plasma was analysed from blood samples collected for
previous prospective, longitudinal studies exploring the effects
of chemotherapy on growth and bone turnover (Crofton et al.,
1998; Bath et al., in press). The original studies and their exten¬
sion to this study were approved by the Lothian Paediatric and
Reproductive Medicine Research Ethics Sub-Committee. The
previous studies involved sequential recruitment of 47 children
(18 females), median age 4-5 years (range T2-15-3 years), pre¬
senting with a variety of haematological and solid malig¬
nancies over a 2-year period (Crofton et al., 1998; Bath et al., in
press). From this cohort we excluded postpubertal patients
(n = 7), germ cell tumours (n = 1) and patients for whom there
was insufficient plasma stored before or during treatment
(n = 14). The study group consisted of 25 clinically prepubertal
children (nine girls). The median age (range) at diagnosis was
4-5 (1-2—12-8) years and underlying malignancies included acute
lymphoblastic leukaemia (ALL, n = 9, females 3), neuroblast¬
oma (n = 5, females 1), non-Hodgkin's lymphoma (« = 3,
females 0), rhabdomyosarcoma (n = 3, females 2), osteosarcoma
(n = 2, females 1), Ewing's sarcoma (n = 1, females 1), medullo-
blastoma (n = 1, females 1) and Wilms (n = 1, females 0).
Children with solid tumours (n = 16) were treated with multiagent
chemotherapy regimens in accordance with United Kingdom
Childrens Cancer Study Group (UKCCSG) protocols. One
female also received lumbar radiotherapy for Ewing's sarcoma
(L3). Children with ALL (n = 9) were treated with the MRC
UKALL XI protocol. We collected blood samples from patients
with solid malignancies (n= 16) before and during chemother¬
apy (median number of cycles 7, range 4-14) and from patients
with ALL (n = 9) pretreatment and at the end of week 6 (after
completion of induction and first intensification). In 12 of the
25 children treated for cancer, follow-up blood samples were
collected between 1 and 6 months after completion of
chemotherapy.
Methods
Blood samples were separated immediately after collection and
plasma stored at -70°C until analysis. Dimeric inhibin B
was measured in duplicate by a double antibody enzyme-linked
immunosorbent assay (ELISA), using a monoclonal antibody
raised against a synthetic peptide from the (3B subunit, combined
with an antibody to an inhibin a subunit sequence, as described
(Groome et al., 1996; Crofton et al., 2002a). The assay detection
limit was 8 ng/1. Within- and between-assay coefficients of
variation (CVs) were 9-6% and 13-0% at 19 ng/1,7-4% and 10-6%
at 88 ng/1, and 8-4% and 10-2% at 233 ng/1, respectively. FSH
and LH were measured in duplicate by Delfia time-resolved
immunofluorescence assays (Wallac, Milton Keynes, UK),
standardized against the second International Reference Pre¬
parations of pituitary FSH and LH, coded 78/549 and 80/552,
respectively. Assay detection limits were 0-3 U/l for FSH and
0-2 U/l for LH. Between-assay CVs for FSH were 6-5% at 5-2 U/
1, 3-5% at 10-4 U/l and 3-6% at 35-3 U/l, and for LH were 5-9%
at 6-4 U/l, 5-5% at 11-3 U/l and 4-4% at 18-7 U/l.
Data analysis
Inhibin B varies with age and sex. Data are presented both
as absolute concentrations (ng/1) and as SD scores calculated for
age and sex following log-transformation, based on our own pub¬
lished data (Crofton et al., 2002a,b). Group results are presented
as medians and ranges. Within-individual changes through time
were evaluated by Wilcoxon matched pairs.
Results
Girls
Inhibin B, FSH and LH results in the children before, during and
after chemotherapy are shown in Table 1. Pretreatment inhibin
B levels were comparable to the normal age- and sex-matched
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"Total number of children with cancer (number with solid tumours),
fP < 0-05 compared with pretreatment levels.
JNot reported because 8/9 girls had undetectable inhibin B during chemotherapy (see text).
SDS, SD score according to age and sex.
Table 1 Median (range) of inhibin B, FSH and LH
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population in eight of the nine girls. One clinically prepubertal
girl, aged 10-5 years, had a high inhibin B level for age (SD score
+2-6) but prepubertal gonadotrophin levels (FSH 1-9 U/l,
LH 0-2 U/l). All other girls had pretreatment inhibin B levels
within their respective age- and sex-specific reference ranges and
appropriate for prepubertal girls (Crofton et al., 2002a). FSH
and LH concentrations were prepubertal in all nine girls.
During treatment, inhibin B decreased to undetectable levels
in eight of the nine girls (P = 0-03 compared with pretreatment
samples) (Fig. la) with no accompanying rise in FSH or LH
(Table 1). The only girl in whom inhibin B was not suppressed
was treated with low doses of potentially gonadotoxic agents
(cyclophosphamide 1-5 g/m2, cisplatin 80 mg/m and carboplatin
1-0 g/m2).
Samples were available from five girls after completion of
treatment. Analysis of post-treatment samples demonstrated
variable recovery of inhibin B, with levels remaining below the
assay detection limit in two girls (Fig. la). FSH (but not LH)
increased in all girls post-treatment compared with their pretreat¬
ment levels (P =0-06, Table 1). The two girls (aged 2-6 and
10-5 years, respectively) in whom inhibin B remained undetectable
post-treatment had the highest post-treatment levels of FSH
(11-8 and 10-9 U/l, respectively).
Boys
Inhibin B levels were appropriate for age with no significant
changes before, during and after treatment in all but one boy
(Table 1). FSH and LH levels remained prepubertal in all patients
pre-, during and post-treatment (Table 1). Following completion
of treatment, six of the seven boys showed little change
in inhibin B (Fig. lb). In one patient (aged 2 years), inhibin B
levels decreased to undetectable levels following completion of
treatment with alkylating agent-based gonadotoxic chemo¬
therapy (cyclophosphamide, 4-4 g/m2, cisplatin 320 mg/m2 and
melphalan 200 mg/m2) with no post-treatment increase in
gonadotrophins (FSH 0-8 U/l, LH < 0-2 U/l).
Discussion
Girls
Chemotherapy treatment of childhood cancer is associated with
suppression of inhibin B during treatment, which may indicate
arrest of follicular development. Recovery of ovarian function
following completion of chemotherapy treatment is variable and
is likely to reflect the severity of the gonadotoxic insult. Some
of the girls treated with known gonadotoxic agents demonstrated
sustained suppression of inhibin B levels and continued assess¬
ment will be necessary to observe if this is transient or associated
with impaired ovarian function and development of a premature
menopause.
At diagnosis, prepubertal girls' inhibin B levels were appro¬
priate for age and sex, indicating that they continued to maintain
normal ovarian follicular development, at least to the small antral
stage. During treatment with a variety of combination chemo¬
therapy regimens, inhibin B was suppressed in all but one girl,
indicating arrest of follicular development from the primordial
pool. The exception was a girl in whom chemotherapy had been
curtailed owing to lack of tumour response and who had therefore
been exposed to relatively low doses of potentially gonadotoxic
chemotherapy. There was no accompanying increase in FSH
levels in the girls with suppressed inhibin B, consistent with
hypothalamic-pituitary quiescence during chemotherapy in
these prepubertal girls. Although all three girls with ALL had
undetectable inhibin B at the end of first intensification (which
© 2003 Blackwell Publishing Ltd, Clinical Endocrinology, 58, 296-301
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Stage of treatment Stage of treatment
Fig-1 Inhibin B levels in individual children with cancer before, during and after treatment: (a) girls; (b) boys. Inhibin B is plotted on a log scale. The
dotted line represents the detection limit of the inhibin B assay. Results below the assay detection limit are plotted at the detection limit. *P < 0-05
compared with pretreatment levels (Wilcoxon matched pairs). See text for details.
includes cytarabine, a potentially gonadotoxic agent), inhibin
B returned to normal, detectable levels 2-4 weeks later and
remained normal in all three girls during the second year of
continuing chemotherapy (data not shown). These results suggest
that arrest of folliculogenesis in girls treated for ALL is likely to
be transient. This is consistent with retrospective studies of
survivors of childhood ALL that have reported relatively normal
ovarian function and reproductive pattern in females treated with
chemotherapy (Nygaard et al., 1991; Wallace et al., 1993).
After completion of treatment, there was variable recovery of
inhibin B. Two girls in whom inhibin B remained undetectable
had elevated post-treatment levels of FSH, suggesting resump¬
tion of pituitary activity with loss of feedback suppression on
FSH production. One of these girls was aged 10-5 years at the
start of treatment and 11-3 years old at the time of follow-up,
6 months after completion of treatment, an age at which there is
normally active follicular development to the small antral stage
with detectable inhibin B in all girls (Crofton et al., 2002a). This
girl therefore appeared to have persistent defective folliculogen¬
esis following gonadotoxic chemotherapy (cisplatin 600 mg/m2).
Cisplatin doses of this magnitude have been shown to be
associated with long-term ovarian damage in survivors (Wallace
et al., 1989). Post-treatment inhibin B was also undetectable in
a 2-year-old patient treated for neuroblastoma with combination
chemotherapy including the gonadotoxic agents cisplatin
(320 mg/m2), cyclophosphamide (4-2 g/m ), and melphalan
(200 mg/m2) as preconditioning therapy for autologous bone
marrow transplantation. At this age inhibin B may be undetect¬
able on random sampling in up to 35% of normal girls (Crofton
et al., 2002a). However, her FSH increased from 0-7 U/l pretreat¬
ment to 11-8 U/l post-treatment. The combination of undetect¬
able inhibin B and increased FSH is suggestive of ovarian damage.
Although the numbers in our study are small, the data suggest
that the arrest of follicular development associated with poten¬
tially gonadotoxic chemotherapy may persist in some girls during
the early post-treatment period. In other girls, inhibin B and FSH
levels were normal after completion of treatment, with a positive
relationship between the two hormones, as observed in normal
prepubertal girls (Crofton et al., 2002a). This is consistent with
resumption of follicular development under the influence of
FSH. Long-term follow-up ofall patients is warranted to monitor
for the development of premature ovarian failure.
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Boys
Inhibin B, produced from Sertoli cells, mediates nonsteroidal
negative feedback from the testes, reflecting the number of
spermatozoa produced and regulating FSH secretion (Pierik et al.,
1998). Inhibin B secretion in the adult requires the presence of
germ cells and in the prepubertal boy may reflect continuous
Sertoli cell proliferation and functional activity together with
maturation ofearly germ cells and spontaneous degradation. Men
with complete absence ofgerm cells (Sertoli cell only syndrome,
SCOS), severe hypospermatogenesis and spermatogonia! and/or
spermacytic arrest have lower inhibin B levels and higher FSH
levels than normozoospermic controls (Mahmoud et al., 1998;
Bohring & Krause, 1999; Foresta et al., 1999). Gonadotoxic chemo¬
therapy in men is associated with a decrease in circulating
inhibin B during treatment (Wallace et al., 1997). We have recently
demonstrated reduced sperm concentration, reduced inhibin B
and increased FSH levels in male survivors of childhood cancer
(Thomson et al., 2002). Chemotherapy has been implicated as
the cause of these endocrine abnormalities in adult survivors of
childhood cancer (Lahteenmaki et al., 1999; Schmiegelow et al.,
2001). However, a longitudinal study of prepubertal boys with
acquired SCUS caused by irradiation/chemotherapy tor ALL has
demonstrated that reductions in inhibin B levels are generally
delayed until postpuberty (Andersson et al., 1998).
In our study, boys with cancer had normal inhibin B levels
before treatment started and these changed little during and after
chemotherapy except for one boy with neuroblastoma treated
with relatively high doses of known gonadotoxic agents, cyclo¬
phosphamide, cisplatin and melphalan (Watson et al., 1985; Jaffe
et al., 1988; Aubier et al., 1989; Wallace et al., 1989; Chatteijee
et al., 1994; Waring & Wallace, 2000) in whom inhibin B became
undetectable following completion of treatment, suggestive of
Sertoli cell damage. This may reflect damage to the germinal
epithelium and long-term follow-up and monitoring of testicular
function will be essential. Our results show that inhibin B levels
were normal in boys with ALL throughout treatment, including
year 2 of continuing chemotherapy (data not shown), consistent
with reports of normal testicular function and normal sperma¬
togenesis in most male survivors of childhood ALL (Blatt et al.,
1981; Wallace et al., 1991). FSH and LH remained low or un¬
detectable in all prepubertal boys with cancer before, during
and after treatment, illustrating their insensitivity as markers of
gonadal damage before the onset of puberty. In the boy who
developed undetectable inhibin B, there was no accompanying
increase in FSH, consistent with previous evidence that inhibin
B and FSH secretion are independent in prepubertal boys, in
contrast to the inverse relationship that develops later during
puberty (Crofton et al., 2002b).
In summary, prepubertal girls treated with chemotherapy
developed suppressed inhibin B levels indicating arrest of follic¬
ular development, with variable short-term recovery of follicu-
logenesis after completion of treatment. In prepubertal boys,
chemotherapy had little immediate effect on Sertoli cell produc¬
tion of inhibin B, although one boy showed a delayed deleterious
effect. This pilot study has not addressed the long-term implica¬
tions for future fertility. Further studies are planned, combining
inhibin B with FSH, LH and sex hormone measurements, to
assess longer term reversibility and delayed effects, particularly
as the children approach and progress through puberty.
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Preservation of fertility in children treated for cancer
W H B Wallace, A B Thomson
As treatment for childhood cancer has become
increasingly successful, adverse effects on reproductive
function are assuming greater importance. Preservation
of fertility before treatment must be considered in all
young patients at high risk of infertility, and provision of
such services requires collaboration between oncology
centres and assisted conception units. The UK Children's
Cancer Study Group is planning to audit current
management of preservation of reproductive function in
young patients with cancer, and the British Fertility
Society is preparing a voluntary code of best practice to
guide and inform clinicians and scientists. Limitation of
radiation exposure by shielding of the testes and ovaries
should be practiced where possible and sperm banking
should be offered to all sexually mature boys at risk of
infertility. The rapidly advancing experimental
techniques for harvesting of gonadal tissue must be
considered and embarked on without unrealistic
expectations, although future utilisation of the tissue is
unlikely to be realised until the next decade.
Improvements in the diagnosis, management,and treatment of childhood cancers have madethe prospect of survival into adulthood a realis¬
tic expectation for the majority of children. How¬
ever, it is a recognised complication that certain
forms of treatment may compromise fertility.12
Consideration of fertility preservation is a quality
of life issue at a time of intense stress for young
patients and their families. Nevertheless, in our
experience, open discussion is embraced and
often potentially therapeutic for the vulnerable
family facing treatment for cancer. Discussion of
fertility issues at the time of diagnosis provides
the family with the reassurance that the oncology
team believe in a future when these issues will
become important.
Treatment of childhood cancer with chemo¬
therapy and radiotherapy may damage gonadal
tissue and result in permanent sterility in both
males and females.'"18
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The nature of radiotherapy induced gonadal
damage depends on the field of treatment, total
dose, and fractionation schedule.3"5 In males,
doses as low as 0.1-1.2 Gy can damage dividing
spermatogonia and disrupt cell morphology,
resulting in oligozoospermia.'4 Permanent
azoospermia has been reported following single
Arch Dis Child 2003;88:493-496
fraction irradiation with 4 Gy or 1.2 Gy
fractionated.3 4 Leydig cells are more resistant to
damage from radiotherapy than the germinal
epithelium, and progression through puberty
with normal potency is frequent, despite severe
impairment of spermatogenesis. Testicular irra¬
diation with doses of greater than 20 Gy is associ¬
ated with Leydig cell dysfunction in prepubertal
boys, while Leydig cell function is usually
preserved up to 30 Gy in sexually mature males.5
Total body, abdominal, or pelvic irradiationmay
cause ovarian and uterine damage.1"9 The human
oocyte is sensitive to radiation, with an estimated
LDS0 of less than 2 Gy.6 The younger the child at
the time of radiotherapy the larger the number of
primordial follicles present, hence for a given
radiation exposure the longer the "window" of
fertility before a premature menopause ensues.
Ovarian failure will require oestrogen replace¬
ment for pubertal induction and cyclical hormone
replacement to relieve the symptoms of oestrogen
deficiency (vaginal dryness, hot flushes, and irri¬
tability), provide cardiovascular protection, and
optimise bone density. However, even where ovar¬
ian function is preserved, this does not guarantee
fecundity as radiation damage to the uterus may
have occurred. Uterine irradiation in childhood
increases the incidence of nulliparity, spontane¬
ous miscarriage, and intrauterine growth
retardation.8 9 The mechanism underlying these
findings remains unclear, but reduced elasticity of
the uterine musculature and uterine vascular
damage have been suggested.8 9
CHEMOTHERAPY INDUCED GONADAL
DAMAGE
The impact of combination cytotoxic chemo¬
therapy on gonadal function is dependent on
gender and age of the child undergoing treat¬
ment, and the nature and dosage of the drugs
received.9"18 Drugs known to cause gonadal
damage include procarbazine, cytosine arabino-
side, and the alkylating agents, particularly cyclo¬
phosphamide, chlorambucil, mustine, melphalan,
busulphan, and the nitrosoureas.9"18 Treatment for
Hodgkin's disease in the UK with "ChlVPP"
(chlorambucil, vinblastine, procarbazine, pred¬
nisolone) is known to cause gonadal damage,
particularly in the male, and the agents impli¬
cated are chlorambucil and procarbazine. In a
recent long term follow up study, 89% of the
males treated before puberty had evidence of
Abbreviations: GnRH, gonadotrophs releasing
hormone; HFEA, Human Fertilisation and Embryology




severe damage to the germinal epithelium and recovery of
spermatogenesis would be unlikely." Around 50% of girls
treated for Hodgkin's disease prepubertally with six or more
courses of ChlVPP had raised plasma gonadotrophin concen¬
trations, but longer follow up is needed to determine whether
these women have recovery of function or go on to develop a
premature menopause." The use of ABVD (Adriamycin, bleo¬
mycin, vinblastine, dacarbazine), which does not contain
alkylating agents or procarbazine, is significantly less
gonadotoxic." Current regimens with hybrid protocols are
likely to preserve fertility inwomen and in approximately 50%
of men.
Chemotherapy does not appear to have any significant last¬
ing adverse effect on uterine function. Successful pregnancy,
with no increased risk of miscarriage, and healthy offspring




Potential strategies for preservation of fertility are dependent
on the sexual maturity of the patient. The only established
option for preservation of male fertility is cryopreservation of
spermatozoa." Spermatozoa are usually obtained from the
ejaculate by masturbation. When it is not possible to obtain an
ejaculate, sperm can be retrieved by epididymal aspiration or
testicular biopsy in sexually mature males. Not infrequently,
sperm produced by cancer patients at the time of diagnosis is
of poor quality. However, with advances in assisted reproduc¬
tion techniques, in particular intracytoplasmic sperm injec¬
tion (ICSI), which involves the injection of a single spermato¬
zoon directly into an oocyte, the problems of low numbers and
poor motility sperm may be circumvented.20 In our view any
spermatozoa retrieved, either from the ejaculate or surgically,
should be cryopreserved irrespective of the perceived quality
of the material. Data on the health of offspring born after ICSI
are broadly reassuring.21 A recent study showed that although
the conventional criteria of semen quality are frequently
abnormal in long term survivors of childhood cancer, the
sperm produced do not appear to carry a greater burden of
damaged DNA. This observation goes some way to providing
reassurance about the use of ICSI, which will circumvent the
problems associated with severe oligozoospermia and offer
cancer survivors the possibility of paternity in adulthood.22
A number of strategies to protect the ovaries and preserve
fertility during cancer therapy have been attempted with lim¬
ited success. In contrast to males, the gamete pool in females
is fixed at birth and collection is technically more difficult. In
young sexually mature females with partners, collection of
mature oocytes for fertilisation and subsequent embryo cryo¬
preservation is possible.2' Cryopreservation of oocytes is an
alternative possibility for women without a partner but is less
successful. On average 5-10 oocytes may be harvested per
patient with fewer than one baby born per 100 oocytes
stored.24 The main disadvantage of embryo or oocyte storage is
the requirement for superovulation with gonadotrophins,
which will inevitably delay the commencement of cancer
therapy. Limitation of radiation dose to the ovary is sometimes
practiced in adult women, but in children is technically
difficult."
Experimental strategies
For prepubertal children, lacking in haploid gametes, there are
no options currently available to preserve fertility, and any
potential strategies must be considered entirely experimental.
One approach to preserving fertile potential was based on the
original idea that the prepubertal gonads are quiescent and
therefore protected from the cytotoxic effects of chemo¬
therapy and radiotherapy which destroy rapidly dividing cells.
It was hypothesised that suppression of the hypothalamic -
pituitary-gonadal axis by administration of gonadotrophin
releasing hormone (GnRH) analogues would render the
gonads less susceptible. While it has since become clear that
the prepubertal gonads are susceptible to the deleterious
effects of cytotoxic therapy, there is significant evidence for
the success of protection/recovery strategies in rats. However,
clinical studies in man have to date been inconclusive.2''27 In
men treated with sterilising radiotherapy and chemotherapy
for childhood cancer, effective gonadotrophin suppression
with medroxyprogesterone acetate for at least three months
did not result in restoration of spermatogenesis.27 A number of
studies have shown that GnRH analogues inhibit chemo¬
therapy induced ovarian follicular depletion in rodents by
blocking gonadotrophin induction." These findings are
supported by clinical studies which showed that co-treatment
of GnRH analogues and chemotherapy resulted in primary
ovarian failure in 1 of 44 (2.3%) compared with 26 of 45 (58%)
in the group treated with chemotherapy (with or without
mantle field irradiation) only.28 The judicious use of GnRH
analogues may play a role in the appropriate patient group,
such as young women and children subjected to alkylating
agent based chemotherapy for Hodgkin's disease.
Oocyte loss induced by cytotoxic therapy has been shown to
occur by apoptosis; consequently inhibition of the apoptotic
pathway has been explored as a mechanism for preventing
ovarian failure. Sphingosine-1 -phosphate (SIP), a metabolite
of ceramide, is believed to inhibit apoptosis in somatic cells.
Treatment of mice ooctyes with SIP prevents chemotherapy
induced apoptosis in vitro. In vivo administration of SIP con¬
fers resistance to radiation induced apoptosis in mice, with
pregnancy rates of 100%.29 While SIP may herald promise of a
new approach to preservation of ovarian function, further
studies are necessary to explore the detrimental effects of such
treatment on normal neurological function, as deletion of
sphingomyelinase during normal fetal life leads to the devel¬
opment of Neimann-Pick disease-like symptoms in post-fetal
life.
Advances in assisted reproduction and increasing interest
in gamete extraction and maturation have focused attention
on preserving gonadal tissue from children before sterilising
chemotherapy or radiotherapy, with the realistic expectation
that future technologies will be able to utilise their immature
gametes. The impetus for preserving gonadal tissue follows on
the heels of pioneering experiments in ewes,'0 together with
media interest in the report of an autologous ovarian graft in
a previously oophorectomised female with return of, albeit
short lived, menstrual cycle." In addition, live human births
resulting from the transfer of embryos fertilised with
immature spermatogenic cells have been reported.'2 Such
issues have inevitably raised questions from parents and
oncologists about their possible application in children under¬
going treatment for cancer." 14
In theory gonadal tissue could be removed before the start
of treatment and cryopreserved, either as a segment of tissue
or as isolated germ cells. Following cure from his/her
malignancy the frozen thawed gonadal tissue could be used in
a number of ways. In males, the isolated germ cells could be
autotransplanted to the testis or matured in vitro until they
reach a stage sufficiently mature to achieve fertilisation with
ICSI. Immature testicular tissue has been shown to grow and
differentiate when grafted into another species." This provides
an additional strategy for conserving the male germ line and
circumvents the risk of reintroducing malignant cells. Clearly
this technique is unlikely to be ethically acceptable and is
compromised by the risk of interspecies transfer of potentially
pathogenic microorganisms. In females, one potential strategy
for the future use of the stored material would be to replant
the ovarian tissue, with the hope of restoring natural fertility
and also maintaining sex steroid production.
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Autologous transplantation of fresh and frozen thawed pri¬
mordial follicles to the ovaries of sterile recipients has restored
fertility, resulting in live healthy offspring in mice and
sheep.'6 Human primordial follicles survive cryopreservation,
and return of ovarian hormonal activity has been achieved
with reimplantation.'7 However, no pregnancies have yet been
reported and this procedure must be considered experimental.
It is likely that ovarian grafts will have a limited life span, in
which case transplantation should be delayed until fertility is
desired. In females, harvesting ovarian tissue and cryopreser¬
vation of cortical slices are practiced in a number of centres,
although these procedures remain experimental and future
utilisation of stored tissue is uncertain. As with males, in view
of the potential risk of transplanting tumour cells, a number of
alternative strategies are being investigated. Isolation of folli¬
cles and in vitro maturation for assisted reproduction is likely
to be the best option and may be the only option when the
uterus has been damaged by radiotherapy.
There is a dearth of data reported on the experience of
human ovarian tissue cryopreservation. In a study of 51
women, aged 17.9 (2.7-34) years, at risk of infertility second¬
ary to treatment for cancer, ovarian tissue was harvested in 31
patients, 71% of whom had previously received
chemotherapy.'8 In 77% of subjects the whole ovary was
removed, while in the remainder half of the ovary was
removed, either laparoscopically (n = 29) or at laparotomy
(n = 2). Evaluation of the number of primordial follicles in
the ovarian cortex showed a mean of 20/mm2 in girls less than
7 years (n = 6), 4/mm2 in girls aged 10-15 years (n = 8),
diminishing to 1.6/mm2 in girls greater than 15 years old. Of
the 31 patients, 11 died, while follow up of the remainder was
limited. Eight patients were lost to follow up and of the
remaining 12 patients, no data were available on ovarian
function. Although this study showed the feasibility of ovarian
tissue cryopreservation, clearly structured prospective studies
are required.'8
ETHICAL ISSUES
Harvesting gonadal tissue and its future use is an exciting new
area of gamete biology which raises a wide range of ethical
and legal dilemmas that must be addressed before embarking
on any clinical programme." " '9"41 These include the safety of
the tissue harvesting, subsequent use, and possible implica¬
tions for the progeny, as well as the legal constraints enforced
by the Human Fertilisation and Embryology Authority
(HFEA), and the common laws defining validity of consent.
For clinical research involving potentially harmful interven¬
tions, valid consent is necessary. To be valid, consent must be
informed, voluntarily obtained, and given by a competent per¬
son. Legal competence to consent requires that the individual
giving it is able to understand the information given, believes
that it applies to them, retains it, and uses it to make an
informed choice. The complex issues of fertility preservation
and limited time for discussion imposed by therapeutic
imperatives, further fuelled by parental and patient anxieties,
will inevitably diminish the validity of such consent. Some of
these practical difficulties may be alleviated if obtaining con¬
sent could be divided into two stages, with part one involving
harvesting and cryopreservation of the tissue and part two
involving subsequent use of the tissue. Issues relating to the
use of the tissue in the event of the death of the patient must
also be discussed.'4"
The legal framework defines who is eligible to give the con¬
sent. Adolescents over the age of 16 years in Scotland, and 18
years in England, may give consent to treatment in accordance
with the Family Law Reform Act 1969 s8, while for younger
children, "minors", consent is generally obtained by proxy. In
exception to this, legally valid consent from "minors" can be
obtained if their doctor considers that they are competent to
make an informed decision (Gillick competence).12 However,
the field of assisted reproduction is governed by the statute in
the UK and is under the jurisdiction of the HFEA (HFEA Act,
1990), which dictates strict guidelines on the requirements for
informed consent with respect to the storage of gametes and
embryos and their subsequent use.4' The HFEA grants licences
to individuals for certain procedures involving gametes. Proxy
consent is specifically excluded and there is a requirement to
provide written and verbal information and an offer of
independent counselling. A gamete is defined by the HFEA to
be "a reproductive cell, such as an ovum or spermatozoon,
which has a haploid set of chromosomes and which is capable
of taking part in fertilisation with another of the opposite sex
to form a zygote".44 In practice this would mean that
non-gametes, or immature germ cells, could be harvested
from children, with parental consent, and stored in, at present,
unlicensed premises. If this immature material should ever be
matured to form gametes, the requirements for storage of
such material would then fall under the jurisdiction of the
HFEA. In sexually mature boys, sperm may be produced or
retrieved surgically, and written consent obtained in accord¬
ancewith the Gillick principle and cryopreserved in a licensed
centre.
Harvesting and storage of ovarian cortical tissue from girls
and young women before gonadotoxic chemotherapy has
been available in a number of centres since the mid-1990s and
more recently, a few centres have reported the storage of tes¬
ticular tissue.'8 48 The Royal College of Obstetricians and
Gynaecologists has provided a report from a working party on
the storage of ovarian and prepubertal testicular tissue. This
provides standards for best practice in the cryopreservation of
gonadal tissue, including the criteria for providing a service,
patient identification and selection, standard operating proce¬
dures, and requirements for safe storage.40
In December 1999 an international conference was held in
Cambridge, to develop an ethically acceptable strategy for the
practice and research related to preserving fertility in children
and adolescents being treated for cancer. From this meeting a
consensus statement was drawn up which made a number of
recommendations." Integral to these recommendations were
the design and implementation of well constructed research
strategies, confined to a finite number of specialist centres,
with centralisation of data and rapid dissemination of the
results. In turn, these protocols and results should be subject
to rigorous review to ensure high standards for collection pro¬
cedures and storage of material. This would involve multidis-
ciplinary teamwork with multicentre collaboration, to ensure
that the best interests of the child are met. It was also recom¬
mended that prospective studies be set up to gather data on
the impact of current treatment strategies on fertility
outcomes in prepubertal children treated for cancer. The
experimental nature of this work makes it essential to ensure
that clinical and research practice develops in a phased and
coordinated manner.
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Summary
background and objective Chemotherapy treat¬
ment of childhood cancer may impair gonadal func¬
tion, which may be manifested only in adulthood as
permanent sterility. Detection of gonadal dysfunction
in prepubertal children has been hampered by the
absence of a sensitive marker. Inhibin B is secreted by
small antral follicles and Sertoli cells in females and
males, respectively, and may be a marker of gonadal
function in prepubertal children. The aim of this pilot
study was to evaluate inhibin B in relation to sensitive
measurements of gonadotrophins as markers of the
early gonadotoxic effects of chemotherapy in prepu¬
bertal children treated for cancer.
study design and subjects Twenty-five prepu¬
bertal children (9 females), median age 4-5 years
(range 1-2-12-8 years) with cancer (16 solid tumours,
nine acute lymphoblastic leukaemia, ALL) were
studied longitudinally. Blood samples were collected
before and during chemotherapy (solid tumours) or
immediately following induction and first intensifica¬
tion (ALL). Post-treatment (1-6 months) samples were
collected in 12 of the patients (5 females).
measurements Dimeric inhibin B was measured by
double antibody enzyme-linked immunosorbent assay
(ELISA). FSH and LH were measured by sensitive time-
resolved immunofluorescence.
Correspondence: Dr P. M. Crofton, Department of Paediatric
Biochemistry, Royal Hospital for Sick Children, Sciennes Road,
Edinburgh EH9 1LF, UK. Tel.: 0131 536 0403; Fax: 0131 536 0410;
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results Girls: Pretreatment inhibin B was slightly
high in one girl but normal for age and sex in all others:
median 16-1 (range 9-4-186-2) ng/l, median SD score
+0-2 (-1-3 to +2-6). Inhibin B decreased to undetect¬
able levels (< 8 ng/l) in 8/9 girls during treatment
(P= 0-03), with no accompanying rise in FSH or LH.
Post-treatment recovery of inhibin B was variable:
median 16-1 (range < 8-0-44-2) ng/l, median SD score
+0-1 (range <-2-4 to +1-8). Sustained undetectable
inhibin B levels were observed in 2/5 girls with corre¬
spondingly elevated FSH concentrations (11-8 and
10-9 U/l).
Boys: Inhibin B was normal for age and sex in all boys
before treatment with no significant change during or
after treatment (medians 93 ng/l, 85 ng/l and 94 ng/l,
SD scores -0-3, -0-6 and -0-2, respectively). Inhibin
B decreased to undetectable levels in one boy post-
treatment with no accompanying increase in FSH or LH.
conclusions In prepubertal girls with cancer, chem¬
otherapy is associated with suppression of inhibin B,
usually transient, which may indicate arrest of follicle
development. Sustained suppression of inhibin B
following treatment may be indicative of permanent
ovarian damage. In prepubertal boys, chemotherapy
had little immediate effect on Sertoli cell production of
inhibin B, although one boy showed a delayed effect.
Inhibin B, together with sensitive measurements of
FSH, may be a potential marker of the gonadotoxic
effects of chemotherapy in prepubertal children with
cancer.
The successful treatment of childhood cancer may be associated
with gonadal dysfunction and infertility in adulthood (Waring &
Wallace, 2000; Thomson et al., 2002). Chemotherapy and radi¬
otherapy may damage testicular germinal epithelium resulting in
temporary or permanent azoospermia in the male, or hasten
oocyte depletion with truncated fecundity and a premature men¬
opause in the female. Although chemotherapy may damage the
gonads in both sexes throughout life, females appear to be less
susceptible to the deleterious effects ofchemotherapy than males.
The extent of chemotherapy-induced damage is dependent upon
the agent administered and dose received. However, it can be dif¬
ficult to determine the relative contribution of each individual
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drug as most treatments are administered asmultiagent regimens.
A number of agents have been identified as being gonadotoxic,
including cisplatin, melphalan and the alkylating agents, such as
cyclophosphamide.
Traditionally, determining the impact of chemotherapy and
radiotherapy on gonadal function has involved clinical assess¬
ment of pubertal development, menstrual history in females and
semen analysis in males. Earlier detection ofgonadal damage has
been hampered by the lack of a sensitive marker ofgonadal func¬
tion in prepubertal children. In these children gonadotrophins
may be unreliable predictors of gonadal damage because the
hypothalamic-pituitary-gonadal axis is relatively quiescent.
Inhibin B is a dimeric glycoprotein produced by the gonads,
secreted from Sertoli cells in males and developing antral folli¬
cles in females (Roberts et al., 1993; Anderson & Sharpe, 2000).
In the adult male inhibin B plays an important role in sperma¬
togenesis, while in the adult female it plays an integral role in
folliculogenesis, oocyte maturation and corpus luteal function,
mediated in part by inhibition of FSH secretion. There is increas¬
ing evidence reporting that the prepubertal gonads are not
entirely quiescent but have a low level of activity (Wu et al.,
1996; Kelnar et al., 2002). We investigate the role of inhibin B,
together with sensitive gonadotrophin measurements, as markers
of early gonadotoxic effects of chemotherapy in prepubertal
children treated for cancer.
Patients and methods
Patients
Stored plasma was analysed from blood samples collected for
previous prospective, longitudinal studies exploring the effects
of chemotherapy on growth and bone turnover (Crofton et al.,
1998; Bath et al., in press). The original studies and their exten¬
sion to this study were approved by the Lothian Paediatric and
Reproductive Medicine Research Ethics Sub-Committee. The
previous studies involved sequential recruitment of 47 children
(18 females), median age 4-5 years (range 1 -2—15-3 years), pre¬
senting with a variety of haematological and solid malig¬
nancies over a 2-year period (Crofton et al., 1998; Bath et al., in
press). From this cohort we excluded postpubertal patients
in = 7), germ cell tumours (n = 1) and patients for whom there
was insufficient plasma stored before or during treatment
(h = 14). The study group consisted of 25 clinically prepubertal
children (nine girls). The median age (range) at diagnosis was
4-5 (1 -2—12-8) years and underlying malignancies included acute
lymphoblastic leukaemia (ALL, n = 9, females 3), neuroblast¬
oma (n = 5, females 1), non-Hodgkin's lymphoma (n = 3,
females 0), rhabdomyosarcoma (n = 3, females 2), osteosarcoma
(n = 2, females 1), Ewing's sarcoma (n- 1, females 1), medullo-
biastoma (n = 1, females 1) and Wilms (n = 1, females 0).
Children with solid tumours (n = 16) were treated with multiagent
chemotherapy regimens in accordance with United Kingdom
Childrens Cancer Study Group (UKCCSG) protocols. One
female also received lumbar radiotherapy for Ewing's sarcoma
(L3). Children with ALL (n = 9) were treated with the MRC
UKALL XI protocol. We collected blood samples from patients
with solid malignancies {n = 16) before and during chemother¬
apy (median number of cycles 7, range 4-14) and from patients
with ALL (« = 9) pretreatment and at the end of week 6 (after
completion of induction and first intensification). In 12 of the
25 children treated for cancer, follow-up blood samples were
collected between 1 and 6 months after completion of
chemotherapy.
Methods
Blood samples were separated immediately after collection and
plasma stored at -70°C until analysis. Dimeric inhibin B
was measured in duplicate by a double antibody enzyme-linked
immunosorbent assay (ELISA), using a monoclonal antibody
raised against a synthetic peptide from the PB subunit, combined
with an antibody to an inhibin a subunit sequence, as described
(Groome et al., 1996; Crofton et al., 2002a). The assay detection
limit was 8 ng/1. Within- and between-assay coefficients of
variation (CVs) were 9-6% and 13-0% at 19 ng/1,7-4% and 10-6%
at 88 ng/1, and 8-4% and 10-2% at 233 ng/1, respectively. FSH
and LH were measured in duplicate by Delfia time-resolved
immunofluorescence assays (Wallac, Milton Keynes, UK),
standardized against the second International Reference Pre¬
parations of pituitary FSH and LH, coded 78/549 and 80/552,
respectively. Assay detection limits were 0-3 U/l for FSH and
0-2 U/l for LH. Between-assay CVs for FSH were 6-5% at 5-2 U/
1, 3-5% at 10-4 U/l and 3-6% at 35-3 U/l, and for LH were 5-9%
at 6-4 U/l, 5-5% at 11-3 U/l and 4-4% at 18-7 U/l.
Data analysis
Inhibin B varies with age and sex. Data are presented both
as absolute concentrations (ng/1) and as SD scores calculated for
age and sex following log-transformation, based on our own pub¬
lished data (Crofton et al., 2002a,b). Group results are presented
as medians and ranges. Within-individual changes through time
were evaluated by Wilcoxon matched pairs.
Results
Girls
Inhibin B, FSH and LH results in the children before, during and
after chemotherapy are shown in Table 1. Pretreatment inhibin
B levels were comparable to the normal age- and sex-matched
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Before During After
Girls
N* 9(6) 9(6) 5(5)
Inhibin B (ng/1) 16-1 (9-4, 186-2) < 8-0 (< 8-0, 20-8)+ 16-1 (<8-0,44-2)
Inhibin B (SDS) +0-2 (-1-3, +2-6) ++ + 0-1 (<-2-4, +1-8)
FSH (U/l) 0-7 (<0-3, 1-9) 1-0 (<0-3, 3-0) 6-0(1-4, 11-8)
LH (U/l) < 0-2 (< 0-2, 0-2) < 0-2 (< 0-2, < 0-2) <0-2 (<0-2, 1-1)
Boys
N* 16 (10) 16(10) 7(6)
Inhibin B (ng/1) 93 (77, 244) 85 (58, 261) 94 (< 8, 170)
Inhibin B (SDS) -0-3 (- 1-9, +1-8) -0-62 (-1-8, +1-8) -0-18 (<-7-0,+1-4)
FSH (U/l) <0-3 (<0-3, 1-2) <0-3 (<0-3, 0-8) 0-4 (< 0-3, 2-6)
LH (U/l) < 0-2 (< 0-2, 0-3) < 0-2 (< 0-2, < 0-2) <0-2 (<0-2, 0-3)
*Total number of children with cancer (number with solid tumours).
fP< 0-05 compared with pretreatment levels.
JNot reported because 8/9 girls had undetectable inhibin B during chemotherapy (see text).
SDS, SD score according to age and sex.
Table 1 Median (range) of inhibin B, FSH and LH
levels in children before, during and after
chemotherapy
population in eight of the nine girls. One clinically prepubertal
girl, aged 10-5 years, had a high inhibin B level for age (SD score
+2-6) but prepubertal gonadotrophin levels (FSH 1-9 U/l,
LH 0-2 U/l). All other girls had pretreatment inhibin B levels
within their respective age- and sex-specific reference ranges and
appropriate for prepubertal girls (Crofton et at., 2002a). FSH
and LH concentrations were prepubertal in all nine girls.
During treatment, inhibin B decreased to undetectable levels
in eight of the nine girls (P = 0-03 compared with pretreatment
samples) (Fig. la) with no accompanying rise in FSH or LH
(Table 1). The only girl in whom inhibin B was not suppressed
was treated with low doses of potentially gonadotoxic agents
(cyclophosphamide 1-5 g/nT, cisplatin 80 mg/m" and carboplatin
1-0 g/m2).
Samples were available from five girls after completion of
treatment. Analysis of post-treatment samples demonstrated
variable recovery of inhibin B, with levels remaining below the
assay detection limit in two girls (Fig. la). FSH (but not LH)
increased in all girls post-treatment compared with their pretreat¬
ment levels (P = 0-06, Table 1). The two girls (aged 2-6 and
10-5 years, respectively) in whom inhibin B remained undetectable
post-treatment had the highest post-treatment levels of FSH
(11-8 and 10-9 U/l, respectively).
Boys
Inhibin B levels were appropriate for age with no significant
changes before, during and after treatment in all but one boy
(Table 1). FSH and LH levels remained prepubertal in all patients
pre-, during and post-treatment (Table 1). Following completion
of treatment, six of the seven boys showed little change
in inhibin B (Fig. lb). In one patient (aged 2 years), inhibin B
levels decreased to undetectable levels following completion of
treatment with alkylating agent-based gonadotoxic chemo¬
therapy (cyclophosphamide, 4-4 g/m2, cisplatin 320 mg/m" and
melphalan 200 mg/m2) with no post-treatment increase in
gonadotrophins (FSH 0-8 U/l, LH < 0-2 U/l).
Discussion
Girls
Chemotherapy treatment of childhood cancer is associated with
suppression of inhibin B during treatment, which may indicate
arrest of follicular development. Recovery of ovarian function
following completion of chemotherapy treatment is variable and
is likely to reflect the severity of the gonadotoxic insult. Some
of the girls treated with known gonadotoxic agents demonstrated
sustained suppression of inhibin B levels and continued assess¬
mentwill be necessary to observe if this is transient or associated
with impaired ovarian function and development of a premature
menopause.
At diagnosis, prepubertal girls' inhibin B levels were appro¬
priate for age and sex, indicating that they continued to maintain
normal ovarian follicular development, at least to the small antral
stage. During treatment with a variety of combination chemo¬
therapy regimens, inhibin B was suppressed in all but one girl,
indicating arrest of follicular development from the primordial
pool. The exception was a girl in whom chemotherapy had been
curtailed owing to lack of tumour response and who had therefore
been exposed to relatively low doses of potentially gonadotoxic
chemotherapy. There was no accompanying increase in FSH
levels in the girls with suppressed inhibin B, consistent with
hypothalamic-pituitary quiescence during chemotherapy in
these prepubertal girls. Although all three girls with ALL had
undetectable inhibin B at the end of first intensification (which
© 2003 Blackwell Publishing Ltd, Clinical Endocrinology, 58, 296-301
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Stage of treatment Stage of treatment
Fig-1 Inhibin B levels in individual children with cancer before, during and after treatment: (a) girls; (b) boys. Inhibin B is plotted on a log scale. The
dotted line represents the detection limit of the inhibin B assay. Results below the assay detection limit are plotted at the detection limit. *P < 0-05
compared with pretreatment levels (Wilcoxon matched pairs). See text for details.
includes cytarabine, a potentially gonadotoxic agent), inhibin
B returned to normal, detectable levels 2-4 weeks later and
remained normal in all three girls during the second year of
continuing chemotherapy (data not shown). These results suggest
that arrest of folliculogenesis in girls treated forALL is likely to
be transient. This is consistent with retrospective studies of
survivors of childhood ALL that have reported relatively normal
ovarian function and reproductive pattern in females treated with
chemotherapy (Nygaard et al., 1991; Wallace et al., 1993).
After completion of treatment, there was variable recovery of
inhibin B. Two girls in whom inhibin B remained undetectable
had elevated post-treatment levels of FSH, suggesting resump¬
tion of pituitary activity with loss of feedback suppression on
FSH production. One of these girls was aged 10-5 years at the
start of treatment and 11 -3 years old at the time of follow-up,
6 months after completion of treatment, an age at which there is
normally active follicular development to the small antral stage
with detectable inhibin B in all girls (Crofton et al., 2002a). This
girl therefore appeared to have persistent defective folliculogen¬
esis following gonadotoxic chemotherapy (cisplatin 600 mg/m2).
Cisplatin doses of this magnitude have been shown to be
associated with long-term ovarian damage in survivors (Wallace
et al., 1989). Post-treatment inhibin B was also undetectable in
a 2-year-old patient treated for neuroblastoma with combination
chemotherapy including the gonadotoxic agents cisplatin
(320 mg/m2), cyclophosphamide (4-2 g/m2), and melphalan
(200 mg/m2) as preconditioning therapy for autologous bone
marrow transplantation. At this age inhibin B may be undetect¬
able on random sampling in up to 35% of normal girls (Crofton
et al., 2002a). However, her FSH increased from 0-7 U/l pretreat¬
ment to 11-8 U/l post-treatment. The combination of undetect¬
able inhibin B and increased FSH is suggestive ofovarian damage.
Although the numbers in our study are small, the data suggest
that the arrest of follicular development associated with poten¬
tially gonadotoxic chemotherapy may persist in some girls during
the early post-treatment period. In other girls, inhibin B and FSH
levels were normal after completion of treatment, with a positive
relationship between the two hormones, as observed in normal
prepubertal girls (Crofton et al., 2002a). This is consistent with
resumption of follicular development under the influence of
FSH. Long-term follow-up ofall patients is warranted to monitor
for the development of premature ovarian failure.
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Boys
Inhibin B, produced from Sertoli cells, mediates nonsteroidal
negative feedback from the testes, reflecting the number of
spermatozoa produced and regulating FSH secretion (Pierik et al.,
1998). Inhibin B secretion in the adult requires the presence of
germ cells and in the prepubertal boy may reflect continuous
Sertoli cell proliferation and functional activity together with
maturation ofearly germ cells and spontaneous degradation. Men
with complete absence ofgerm cells (Sertoli cell only syndrome,
SCOS), severe hypospermatogenesis and spermatogonial and/or
spermacytic arrest have lower inhibin B levels and higher FSH
levels than normozoospermic controls (Mahmoud et al., 1998;
Bohring & Krause, 1999; Foresta et al., 1999). Gonadotoxic chemo¬
therapy in men is associated with a decrease in circulating
inhibin B during treatment (Wallace et al., 1997). We have recently
demonstrated reduced sperm concentration, reduced inhibin B
and increased FSH levels in male survivors of childhood cancer
(Thomson et al., 2002). Chemotherapy has been implicated as
the cause of these endocrine abnormalities in adult survivors of
childhood cancer (Lahteenmaki et al., 1999; Schmiegelow et al.,
2001). However, a longitudinal study of prepubertal boys with
acquired SCOS caused by irradiation/chemotherapy forALL has
demonstrated that reductions in inhibin B levels are generally
delayed until postpuberty (Andersson et al., 1998).
In our study, boys with cancer had normal inhibin B levels
before treatment started and these changed little during and after
chemotherapy except for one boy with neuroblastoma treated
with relatively high doses of known gonadotoxic agents, cyclo¬
phosphamide, cisplatin and melphalan (Watson et al., 1985; Jaffe
et al., 1988; Aubieref a/., 1989; Wallace et al., 1989; Chatterjee
et al., 1994;Waring &Wallace, 2000) in whom inhibin B became
undetectable following completion of treatment, suggestive of
Sertoli cell damage. Ihis may reflect damage to the germinal
epithelium and long-term follow-up and monitoring of testicular
function will be essential. Our results show that inhibin B levels
were normal in boys with ALL throughout treatment, including
year 2 of continuing chemotherapy (data not shown), consistent
with reports of normal testicular function and normal sperma¬
togenesis in most male survivors of childhood ALL (Blatt et al.,
1981; Wallace et al., 1991). FSH and LH remained low or un¬
detectable in all prepubertal boys with cancer before, during
and after treatment, illustrating their insensitivity as markers of
gonadal damage before the onset of puberty. In the boy who
developed undetectable inhibin B, there was no accompanying
increase in FSH, consistent with previous evidence that inhibin
B and FSH secretion are independent in prepubertal boys, in
contrast to the inverse relationship that develops later during
puberty (Crofton et al., 2002b).
In summary, prepubertal girls treated with chemotherapy
developed suppressed inhibin B levels indicating arrest of follic¬
ular development, with variable short-term recovery of follicu-
logenesis after completion of treatment. In prepubertal boys,
chemotherapy had little immediate effect on Sertoli cell produc¬
tion of inhibin B, although one boy showed a delayed deleterious
effect. This pilot study has not addressed the long-term implica¬
tions for future fertility. Further studies are planned, combining
inhibin B with FSH, LH and sex hormone measurements, to
assess longer term reversibility and delayed effects, particularly
as the children approach and progress through puberty.
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ARTICLES
<£> Semen quality and spermatozoal DNA integrity in survivors of
childhood cancer: a case-control study
Angela B Thomson, Alastair J Campbell, D Stewart Irvine, Richard A Anderson, Christopher J H Kelnar, W Hamish B Wallace
Summary
Background Treatment of childhood cancer can result in
impaired spermatogenesis. Intracytoplasmic sperm injection
(ICSI), however, can enable men to achieve fatherhood, and
has focused attention on gamete integrity in men with
oligozoospermia. Our aim was to assess testicular function
in survivors of childhood cancer.
Methods We assessed testicular function in 33 survivors of
childhood cancer and 66 age-matched controls. The median
age at diagnosis and at the start of the trial was
10-0 years (range 2-2-16-9) and 21-9 years (16-5-35-2),
respectively. We assessed pubertal staging, measured
plasma sex steroid hormone concentrations, and analysed
semen quality, including spermatozoa! DNA integrity.
Findings Ten (30%) individuals were azoospermic and
six (18%) oligozoospermic (sperm concentration
<20xi06/mL). Sperm concentration was significantly lower in
the non-azoospermic group than in controls (median
37-lxl06/mL, IQR 19-7xl06to 89-9X106, vs 90-7xl06/mL,
50-5X106 to 121-5X106; p=0-002). In the non-azoospermic
cancer survivor group, inhibin B concentrations were lower than
in controls (mean 153-3 ng/L, SEM 17-8, vs 223-7 ng/L,
8-8; p<0-001), and FSH concentrations were higher (6-6 U/L,
0-9, vs 3-2 U/L, 0-2; p<0-001). Only 11 (33%) survivors
of childhood cancer had normal semen quality. There was
no significant difference in sperm DNA integrity between
the non-azoospermic and control groups (9%, 5-13, vs 11%,
7-16; p=0-06).
Interpretation Sperm concentration is reduced after
treatment for cancer. However, the sperm produced seems
to carry as much healthy DNA as those produced by the
healthy population, suggesting that assisted conception can
be considered as a treatment option for these men.
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70% of individuals survive childhood cancer, and this
proportion continues to increase. As such, attention is
being focused on the lasting morbidity associated with
radiation and chemotherapy treatment.' A frequent and
psychologically traumatic late complication of cancer
treatment is infertility. Cytotoxic chemotherapy drugs,
especially alkylating agents, can produce long-lasting
or permanent damage to the germinal epithelium, resulting
in oligozoospermia or azoospermia.2"8 The germinal
epithelium is also sensitive to radiotherapy, and doses as
low as 1-2 Gy can result in permanent sterility.® Recovery
from surviving germ cells can happen but is unpredictable
and often takes a long time.7,8 Leydig cells, with their slower
rate of turnover, are more resistant to gonadotoxic therapy,
resulting in preservation of androgen production even when
patients are infertile.5
Advances in techniques of assisted reproduction,
especially intracytoplasmic sperm injection (ICSI), have
enabled some men with oligozoospermia to become
fathers.10,11 Concerns have been raised, however, about the
safety of ICSI,12 since whether or not spermatozoa from
men with impaired spermatogenesis carry abnormal genetic
information is unkown.13-15 Data on the health of offspring
born after ICSI are broadly reassuring,16 though there are
no data on the health of children bom to fathers whose
deficit in semen quality is a specific consequence of
potentially mutagenic treatment.17 Results of studies in
animals have shown that exposure of the male germ line to
chemotherapy agents can disrupt spermatozoal DNA and
result in deleterious effects on embryo development.18
Awareness of the importance of the integrity of sperm DNA
for accurate transmission of genetic material to the
offspring has necessitated the development of new
techniques to assess sperm characteristics in more detail."
Our aim was to investigate testicular function and semen
quality in survivors of childhood cancer.
Methods
Patients
We searched the oncology database at the Royal Hospital
for Sick Children, Edinburgh, for all male survivors of
childhood cancer aged older than 16 years, and identified
51 individuals between December, 1999, and June, 2001.
We invited 45 of these men to participate in the study, and
excluded six because they no longer lived in the area (five)
or were on antidepressant medication (one). Six of the
45 men declined and six did not reply to the invitation. The
18 men who did not participate in our study were
comparable for age, diagnoses, age at diagnosis, treatment
regimens, and disease-free survival. 33 men participated in
the study. For each study participant, we recruited two age-
matched controls (n=66). The volunteers were recruited by
means of advertisement in local media and through hospital
out-patient clinics, and selected on the basis of the absence
of any clinical evidence, on history or physical examination,
of reproductive health problems. The Lothian Paediatric
and Reproductive Medicine research ethics subcommittee
approved the study, and all patients provided written
informed consent.
THE LANCET • Vol 360 • August 3, 2002 • www.thelancet.com 361
For personal use. Only reproduce with permission from The Lancet Publishing Group.
